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Protein-protein interactions (PPIs) are an important class of therapeutic target, 
however due to their large interaction interface they are considered difficult to 
inhibit. The two PPIs of interest in this thesis are the HIF-1α (hypoxia inducible 
factor-1α)/p300 and eIF4E (eukaryotic initiation factor 4E)/eIF4G interactions, both 
of which have been shown to be involved in many different cancers and are 
hypothesised to be good targets for targeted therapy. A rational design approach is 
favoured for PPIs, however for this to be possible a detailed understanding of the 
binding interface is required.  
 
Biophysical assessment of the HIF-1α CTAD/p300 CH1 interface has revealed a key 
binding “hot-spot” of p300 where the helix three region of HIF-1α binds to p300, 
this area has subsequently been targeted using oligoamide α-helix mimetics to 
disrupt the interaction. This binding site was found by two approaches, used to 
probe the HIF-1α binding surface on p300, first, by analysis of the binding of shorter 
HIF-1α peptide fragments; and second, by phage display experiments. The HIF-1α 
fragment study demonstrated that HIF-1α helix 3 region binds to p300 with a higher 
affinity than any of the short (<20 amino acids) peptide regions of HIF-1α and a 
peptide containing helices 2 and 3 binds with a higher affinity than a peptide 
containing helices 1 and 2, this importance of the helix 3 binding site was validated 
using mutagenesis. The phage display experiment found 12mer peptides that bind to 
p300 with a higher affinity than any short peptide region of HIF-1α. Structural 
techniques and mutagenesis were the used to verify that this binding site was similar 
to that of HIF-1α helix 3. The rationally designed mimetics of HIF-1α helix 3 were 
able to disrupt the interaction with low micromolar affinity.  A second phage display 
experiment found Adhirons which bound with low nanomolar affinity and were able 
to disrupt the interaction with low micromolar affinity, docking of the crystal 
structure of this Adhiron indicated that it may be acting at a different site to the HIF-
1α helix 3 region. 
 
This is a proof of principle that a detailed understanding of an interaction, using both 
biophysical and structural techniques, can directly lead to the development of 
inhibitors of challenging and therapeutically relevant PPIs. 
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Chapter 1 : Introduction 
 
Protein–protein interactions (PPIs) control many physiological processes, from 
intercellular signaling to programmed cell death in both healthy and diseased states, 
and therefore represent a large and important class of targets for development of 
molecular therapies1, 2. However, despite the clear importance of PPI modulation, 
progress in the development of PPI modulators has been hampered by the historic 
view that PPIs are “undruggable”. This view has been shown to be unfounded, as 
success has been achieved, with several PPI modulators currently in clinical 
development1, 3-6 (Table 11). However, despite such progress, PPI modulation 
remains a challenge of drug discovery. The challenge arises for numerous reasons, 
most prominently the general lack of small-molecule starting points for drug design 
and the large size of the PPI interface2. 
This thesis will address the challenges involved in inhibiting α-helix mediated PPIs, 
using HIF-1α/p300 and eIF4E/eIF4G as model systems. Also demonstrate that 
structural and biophysical information about the PPI can be utilized in the drug 
design process, principally for rational and structure based drug design. 
 
1.1 Protein-Protein Interactions General Observations 
 
Traditionally, drug discovery has focused on enzymes as drug targets, as enzymes 
tend to have well defined pocket-like binding sites, amenable to competitive 
inhibition by small molecule ligands7, 8. In contrast, the interacting surfaces involved 
in PPIs are larger (1500-3000 Å2) and often lack a clearly defined pocket, making 
potent and selective inhibition more challenging9, 10 (Figure 1), as a conventional 
small molecule11 could not cover the whole interacting interface. Furthermore, 
transition-state analogues are available to inform enzyme inhibitor design7,  allowing 
for a lock and key principle of design. Such analogues are not available as starting 





















Figure 1 - The difference in binding sites and inhibition of enzymes and PPIs. A) An 
interaction between two proteins, illustrating an inhibitor displacing one of the binding 
partners. B) An enzyme substrate complex, showing an inhibitor fitting in to the enzyme 
cleft using the lock and key principle. 
 
 
1.1.1 Hot spots 
 
Although the binding interface of a PPI is large, Clackson and Wells demonstrated 
that a small subset of resides involved, contribute most of the free energy of binding, 
they termed such residues “hot-spots”12. Mutational studies indicate that many 
protein–protein interfaces contain compact, centralized regions of residues that are 
crucial for the affinity of the interaction2, 12-14. These hotspots, are generally found on 
both protein partners and constitute less than half of the contact surface of the 
proteins involved in the interaction5. Therefore if we consider the binding interface 
of only the hot-spots and not the full interface, then the challenge of designing a 
small molecule to cover the interface becomes less daunting. Proteins involved in 
PPIs can be ‘promiscuous’, binding to several targets using the same hotspot region5, 
15. Structural studies show that these contact surfaces are adaptable, so one protein 
can interact with a range of structurally diverse partners; presenting the same 
residues in different structural contexts5, 15-18. Structural changes in the hot-spot are 
observed through side-chain rotations and in the protein backbone; usually in loops 
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and hinge regions between protein domains2. It has been observed that despite having 
different structures and functions, many PPIs have similar properties at their binding 
interface; hot-spots tend to be hydrophobic and contain a protruding component19. 
Consequently, although the whole PPI interface is large, there is often a concentrated 
region to focus small molecule design upon.  
 
A detailed analysis of binding hot-spots has been carried out20. Examination of the 
PDB showed that multi-protein complexes constitute 15% of the databank, of these 
multi-protein complexes 62% feature an α-helix at the interface, highlighting the role 
of α-helices in PPIs. However, this does not necessarily mean the whole helix is 
critical for binding. Computational alanine scanning mutagenesis (using Rosetta) was 
performed to evaluate the energetic contribution of each residue within a helix to 
complex formation21. After normalization for natural abundance, it was found that 
aromatic residues and arginine, as well as leucine (the most abundant residue in 
proteins), are overrepresented as key binding residues at helical interfaces in 
comparison to polar residues. Hydrophobic and aromatic residues represent the 
majority of hot spot residues; however, polar and charged residues also contribute 
significantly22. This analysis supports the common perception that PPIs are generally 
hydrophobic but feature key salt bridges and other polar interactions that influence 
the binding energy23.  
 
1.1.2 Previous misconceptions with targeting PPIs 
 
The limited success in targeting PPIs with small molecules has lead to many 
misconceptions as to the nature of PPIs and the reasoning for the limited number of 
modulators. The more common misconceptions are outlined below. 
 
Historically PPIs were reported to have large, flat and rigid interfaces, therefore not 
presenting cavities for small molecules to bind. However, most contact surfaces 
show some adaptability and flexibility in terms of small loop perturbations and side 
chain motion5. In addition, most interacting surfaces do present cavities available for 
small molecule binding, although sometimes these cavities are not clear in the 
structure of either protein when free in solution or bound to one another. For this 
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reason it should not be assumed that the best binding site for a small molecule is 
always observed in static structures of either the free protein target or even the 
protein–protein complex. Molecular dynamic simulations can be used to search for 
such cavities, for example Bcl-xL appears to have a flat surface in its static apo state, 
however simulations reveal small transient cavities; although these cavities are only 
observed for nanoseconds they still provide potential sites for small molecule 
modulation24. 
 
Conventional high-throughput screening (HTS) methods have been deemed 
unsuitable for PPIs5. However, the vast majority of PPI drug development programs 
still start with empirical screening, either fragment screening or traditional HTS 
involving small-molecule libraries5, and this approach has yielded some success. For 
example Nutlin, an inhibitor of the interaction between Mdm2 and tumour 
suppressor p53, was discovered through a high throughput screen25. The Mdm2/p53 
interaction is an attractive therapeutic target in oncology, as p53 tumour-suppressor 
activity can be stimulated to eradicate tumour cells.  Mdm2 activity is dysregulated 
in many cancers, exerting its oncogenic effects predominantly by inhibiting p53, 
therefore inhibiting its tumour suppressor activity. It is hoped that inhibiting the 
Mdm2/p53 interaction with synthetic molecules will lead to p53-mediated cell-cycle 
arrest or apoptosis in p53-positive stressed cell26, 27. One reason why HTS may 
appear more successful for more traditional drug targets (e.g. enzymes) than for 
PPIs, is due to the relative ease of enzyme assays, which have a more measureable 
end point. In addition, current libraries are informed by historical medicinal-
chemistry efforts within pharmaceutical companies. These ‘chemical phenotypes’ 
(chemotypes) are dominated by past drug-discovery research which have focused on 
more traditional drug targets such as G-protein-coupled receptors and enzymes. As 
PPIs are a new target and have different types of interface, a different type of 
chemotype will most likely be required. Indeed analysis comparing high affinity PPI 
modulators to compounds targeting more traditional targets using a compound 
similarity ensemble approach showed very little similarity28. It is therefore likely that 
the current HTS libraries are not suitable for PPIs, rather than the screening approach 
itself being the problem. Moreover, it should not be assumed that there will be a few 
‘privileged’ scaffolds that will unlock this entire target class, as was the case for 
protein kinases and G-protein-coupled receptors. Except for close homologues, each 
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protein–protein interface is different, so the chemotypes of their inhibitors are likely 
to be more diverse in chemical space5. As fragment libraries allow for a greater 
search of chemical space, it is possible that fragment libraries will yield more success 
than traditional HTS libraries28, 29. 
 
Small molecules identified to be PPI inhibitors have been criticised as they were 
deemed too large to be drugs. It is widely believed that for good oral absorption (and 
bioavailability), drugs must be less than 500 Da11, 30. However, this principle, which 
is derived from a small subset of known agents, has notable exceptions relating to 
PPIs. For example ABT-737 (a Bcl-2 inhibitor) is 813 Da and has a reasonable 
(70%) bioavailability in rodents31, and a derivative of ABT-737 of similar size is 
currently in clinical trials. Bcl-2 inhibitors are an anti-cancer strategy as Bcl-2 is a 
member of a family of anti-apoptotic proteins responsible for dysregulation of 
apoptosis and prevention of death in cancer cells32. Further examples of agents, 
which have made clinical development despite not lying within Lipinski rule of 511, 
can be seen in Table 1. Still, in terms of pharmacokinetic properties, toxicity and 
solubility it is usually the case that the smaller the drug candidate the better the 
properties, however there must always be a trade-off between compound binding 















Table 1 -Table summarising resent example of PPI modulators in the clinic 
Target PPI Inhibitor Molecular weight (Da) clogP 
Mdm2/p5333 RG7112 728 10 
β-catenin–/CREB- binding 
protein34 
ICG-001 549 6.1 
IAP family/SMAC35 TL32711 807 2.8 
Tubulin/α-tubulin-β36, 37  Vinflunine 
ditartrate/PM391 
817 5.4 
Tubulin/α-tubulin-β 38, 39 Eribulin mesylate/E7389 730 1.2 
Tubulin/α-tubulin-β40 Ixabepilone 507 3.1 
IAP/family SMAC41 LCL161 501 3.6 
BCL-2/BAX and BAK BH3 
domain42  
ABT-263  975 12.4 
mTOR/FKBP1243  Temsirolimus 1030 7.5 
BCL-2/family-BH3 domain; 
BCL/2-beclin 1; BCL-xL/beclin 144, 
45 
(-)-gossypol 519 6.1 
Tubulin/α-tubulin-β46  Cabazitaxel 836 5.4 
 
 
All the interactions outlined in Table 1 are implemented in cancer, however their 
applicability as therapeutic targets differ. The relevance and implication of inhibition 
of the BCL-2 family proteins and the mDM2 interaction have been outlined 
previously outlined. The β‐catenin–/CREB‐ binding protein interaction is relevant 
predominantly in colon cancers, as β-catenin is mutationally activated is 85 % of 
colon cancers. The β-catenin pathway is implicated in cancers as it regulates 
expression of a range of genes involved in promoting cell proliferation and 
differentiation via the recruitment of transcription factors 34.  IAP, inhibitor of 
apoptosis, are a family of proteins involved in the regulation of the cell's decision to 
live or die in response to stresses. IAPs exert their effects via interactions with 
SMAC, second mitochondria-derived activator of caspases, a mitochondrial protein 
which promotes cytochrome-c dependent activation. Therefore disruption of this 
interaction may lead to apoptosis and programmed cell death47. Tubulins are 
components of microtubules, which make up the cytoskeleton; they are important in 
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a number of cellular processes and are critical for cell division, therefore disruption 
of the system is an attractive cancer target48. Mammalian target of rapamycin 
(mTOR) has emerged as a critical effector in cell-signaling pathways commonly 
deregulated in human cancers49. mTOR has many binding partners, one of which is 
FKBP12.  FKBP12 belongs to a family of proteins that have propyl isomerase 
activity, therefore is involved in protein folding and is a regulator of the cell cycle50. 
Consequently dysregulation of mTOR may lead to dysregulation of protein folding 
and the cell cycle.  
Thus far in this thesis the concept of protein-protein interactions has been thought of 
as two proteins with a defined 3-dimentional globular structure binding together. 
However, many proteins are inherently unfolding, meaning they do not adopt a 
defined three-dimensional structure; either entirely or in parts, when alone in 
solution51, 52. Indeed more than a third of the eukaryotic proteins have been shown to 
contain intrinsically disordered regions of over 30 residues in length53. There are 
multiple advantages for a protein to be inherently unfolded; firstly the unfolded 
nature of the protein will allow for a larger surface area for interactions than that of 
globular proteins. Secondly, the flexible nature of inherently unfolded proteins 
allows a conformational flexibility and exposure of short linear peptide regions and 
interaction-prone structural motifs, this allows the protein to interact with many other 
proteins, rendering many inherently unfolded proteins promiscuous.  The structural 
and biochemical properties of disordered regions make such proteins ideal for 
specific recognition of interaction partners, therefore proteins that participate in the 
binding and regulatory/signalling functions are enriched for intrinsically discorded 
regions51-55.  
Many therapeutically relevant PPIs consist of one of the binding partners being an 
inherently disordered protein; with many undergoing a disorder to order transition 
upon binding56. This process means the there are often weak interactions per unit of 
surface area because the binding energy is spent to organize the disordered partner; 
the weakness of the interaction may facilitate tighter binding of a small drug 
molecule to the structured partner as compared with the natural but disordered 
protein ligand56. Knowledge of the disorder to order process and the final ordered 
structure may aid drug discovery.    
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1.2 Drug Design approaches 
 
1.2.1 Alternative to HTS 
 
As previously discussed current HTS libraries may not be amenable to PPI targets. 
This could be rectified by re-designing and building new compound HTS libraries; 
however this would be costly and time consuming. An alternative to the HTS 
approach is to use rational/structure based drug design. This process is still quite 
young and requires adaptation and revisions for each project, however it is becoming 
an integral part of the drug discovery process57.  
For rational based drug design high resolution structural information about the target 
(ideally both apo and in complex) should be available. For drug discovery, structural 
determination is primarily conducted through X-ray crystallography, however other 
structural techniques (such as NMR) could be useful during the process. 
Computational methods are also becoming widely used in drug discovery58, 59. There 
have been vast improvements in computational approaches, however there are still 
limitations; current state-of-the-art docking programs correctly dock ~70–80% of 
ligands when tested on large sets of protein–ligand complexes60, 61. Therefore despite 
the considerable progress achieved in structure-based virtual ligand screening and 
computer-aided drug design, the accurate prediction of binding affinities remains an 
elusive holy grail57, 62, 63. Consequently computational methods are often powerfully 
used in conjunction with both structural and biophysical methods. 
 
1.2.2 Improvements in structure determination methodology  
 
The increase in rational/structural based drug design, can at least in part be attributed 
to the improvement in structure-determination methodology59. The production and 
isolation of pure protein samples has become more routine leading to the increased 
production of higher quality protein for crystallisation (as well as for NMR and other 
structural methods)64, 65.  
X-ray crystallography accounts for ~90 % of all structures deposited in the Protein 
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Data Bank (PDB). It uses the diffraction of X-rays by molecules within a crystal to 
calculate an electron density map, into which an atomic model of the molecule can 
be built. There are a number of difficulties with X-ray crystallography, some of 
which are practical (e.g. crystal growth and manipulation) and others are 
fundamental (e.g. the phase problem), however the ability to achieve resolutions that 
are theoretically only limited by X-ray wavelength (and crystal quality) is the reason 
it is currently the preferred choice for high resolution structure determination. 
Typically, crystal structures determined with data below 2-2.5 Å are acceptable for 
drug design purposes since they have a high data to parameter ratio, and the 
placement of atoms in the electron density map is unambiguous (hence why NMR is 
not ideal for structure determination for drug discovery)58. The R factor and Rfree 
reported for a model are measures of the correlation between the model and 
experimental data. The Rfree should be below 28% (ideally below 25%), and the R 
factor below 25% in order for the structure to be used for drug design58. A further 
advantage of crystallography over other structural determination techniques is that 
ordered water molecules can be visible in the experimental data57. Knowledge of the 
water content in binding sites maybe critical during lead optimization as water 
displacement may contribute significantly to the binding affinity.  
There have been significant improvements in the crystallisation process, both in the 
attainment of crystals and in solving structures. The availability of commercial 
crystallisation screens and the use of liquid-handling robots that can dispense such 
screens have decreased the time spent in obtaining the first crystal hit66-68. Liquid-
handling robots can dispense protein drops volumes of 25–100 nL of protein69; this 
has allowed poorly expressing proteins which were once unworkable for 
crystallisation, to be used in screens. X-ray data collection has been simplified by the 
introduction of crystal mounting and alignment robots and rapid detectors70, allowing 
for unattended data collection and has generally allowed for more data to be 
collected within a given time. The development of hot beam lines has also decreased 
the time required per data set. All of the above has streamlined the crystallisation and 
data collection process. In addition to the improvements in crystallisation tools, there 
have been vast improvements in solving the experimental data71. Application of 
synchrotron radiation to single wavelength anomalous diffraction (SAD) and multi-
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wavelength anomalous diffraction (MAD) techniques has revolutionized phase 
determination72, commonly using substituted selenomethionines, but also other 
heavy atoms such as argon and even simple halides have been used73. The 
determination of phases has been accelerated by powerful Patterson methods and 
direct methods for locating the anomalous scatterers71, 74. New approaches have 
provided fully automated phasing71, 75. Molecular replacement has become the 
technique of choice for solving crystal data if suitable structural homologues are 
available in the PDB. Approximately 70% of structures in the PDB were solved by 
molecular replacement (although this number is constantly increasing). A general 
rule states that for molecular replacement to be successful there must be 50% 
sequence similarity between the two proteins.  
NMR is another structure determination method which may be useful in 
rational/structure based drug design. Although not ideal for structure determination 
(due to a lower resolution than crystallography) it does have uses in terms of binding 
site determination and stoichiometry when a crystal structure is not available and 







C) absorb electromagnetic radiation at the 
resonant frequency determined by the isotope, exciting these nuclei to a high-energy 
state. When these nuclei relax back to their equilibrium state they release radiation, 
the frequency of which is characteristic of their chemical environment and allows the 
mapping of interatomic distances (through bonds and through space). This results in 
an ensemble of possible structures and typically the quality of the 20 most probable 
structures is assessed by their root mean square deviation (rmsd). NMR has the 
advantage that proteins are observed in solution and flexible regions that may not be 
resolved by X-ray crystallography can be seen in multiple conformations, providing 
information about the dynamics of protein folding, protein binding interactions and 
stoichiometry. NMR also requires less protein at lower purity, and samples can be 
reused for several experiments76. However there are several disadvantages to using 
NMR, the most important of which are the size limitation (current technology means 
NMR for 3D structure solution is restricted to proteins <30 kDa in the majority of 
cases), and the low resolution. The major obstacle in the determination of large 
proteins (>30 kDa) and complexes by NMR spectroscopy is the increased difficulty 
of extracting useful structural information as the size of the system to be studied 
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increases. As resonance overlap becomes a significant problem with the increased 
size of macromolecules, unambiguous sequence specific assignment of both the 
backbone and side-chains becomes difficult. This, combined with the disappearance 
of peaks due to relaxation processes leads to a reduction in the number of distance 
constraints typically used for structure calculation. Orientation constraints derived 
from residual dipolar couplings help to overcome the size limitations by providing 
long-range information on the relative orientation of distant parts of the structure77-80. 
However, they do not provide translational information and by themselves cannot be 
used to generate an unambiguous solution80. NMR structures are not assigned a 
resolution in the same way X-ray crystal structures are, but a good NMR structure is 
considered to equate to a 3- 3.5 Å X-ray crystal structure i.e. inadequate resolution 




C, which can result in altered expression and purification requirements, and they 
must be stable at room temperature in buffers that are typically low salt and below 
physiological pH (5-6), to slow exchange of amides with the solvent. 
Small-angle X-ray scattering (SAXS). SAXS is a low resolution structure 
characterization method in solution, used to assess the overall shape (envelope) and 
oligomeric state of proteins and protein complexes80. As the technique only generates 
low-resolution data, high-level structural conclusions cannot be drawn. However 
SAXS may be useful for the analysis of flexible systems including multi-domain 
interactions (which could apply to PPIs)81. SAXS will also give data regarding the 
purity and homogeneity of the sample and the overall shape and size of the 
molecules present in the sample. Such details, purity, homogeneity and flexibility, 
can be used when assessing how likely a protein is to crystalize, therefore SAXS can 
be a useful tool when deciding on a construct for crystal trials (for example does 
removing a flexible loop region improve crystallisation properties?).   
SAXS data can in no way replace X-ray crystallography data but instead can be a 
powerful tool when used in combination, as it can be used as a tool for crystal model 
validation. The use of SAXS to investigate the solution properties of crystal 
structures was pioneered in the 1970s and early 1980s, with the development of 
methods to predict theoretical scattering from crystal structures80. SAXS can be used 
as a tool for molecular replacement using the program FSEARCH82, which uses the 
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shape envelopes generated by SAXS for the determination of low resolution phases. 
Following the correct positioning of the molecular envelope in the unit cell the low 
resolution phases can be extended to crystallographic resolution. This is a promising 
method which has already been used successfully for several proteins80, and 
continues to be developed83. In the same way that SAXS will not replace 
crystallography data, it will not replace NMR, although it can be complementary.  As 
previously mentioned there is a size limitation to NMR; SAXS data can provide 
information on the global shape of the macromolecule that can be introduced into the 
NMR structure calculation and reduce this ambiguity. The inclusion of potentials for 
the refinement of NMR structures against SAXS data have been introduced into 
several popular structure calculation packages, and have been shown to significantly 
improve the accuracy of calculated structures84, 85. 
There are other structure determination methods that are rapidly improving and 
increasing in popularity; namely cryo-electron microscopy (EM), neutron diffraction 
and X-ray free-electron lasers (X-FEL). EM was classed as a low resolution 
technique however the development of new detector hardware has led to much 
higher resolutions86. This is evident from a series of new structures at near-atomic 
resolution87-92. As a general rule EM has been limited to molecules >300 kDa93, 
however this limit is decreasing, as last year human γ-secretase complex (170 kDa) 
was solved  at a resolution of 4.5 Å94. One major advantage of EM over X-ray 
crystallography is that the molecule of interest does not have to be crystallized, 
therefore flexible proteins and larger complexes can be visualized by this method. 
Despite the vast advances in EM over recent years, the power of EM still lies in its 
complementarity with X-ray crystallography. Neutron diffraction is a technique 
analogous to X-ray crystallography, using neutrons diffracted from protons within a 
crystal instead of electrons. This allows hydrogens to be visualised which offers 
information about protonation states and hydrogen bonding. This technique is still 
limited by the lack of neutron sources and challenging experimental requirements 
(large crystals are required and data collection can take 1-3 days compared to 
minutes with synchrotron X-rays).  X-FEL is a technique still very much in its 
infancy, however it is deemed the future of X-ray crystallography. As the X-ray 
pulses in this technique are coherent, the phase problem would be overcome and the 
increased brightness compared to synchrotron radiation is thought to limit radiation 
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damage, therefore overcoming two considerable problems with current X-ray 
methodologies95. 
 
1.2.3 Rational drug design strategies 
 
One rational approach to PPI inhibitor design uses the secondary structure at the 
interface as a starting point for inhibitor design. In terms of PPIs there has been much 
focus and consequently success in targeting α-helix mediated PPIs as they have been 
recognized as more tractable from a chemical perspective96. The α-helix is the most 
abundant secondary structure motif and it stands to reason therefore that a significant 
population of PPIs should involve α-helices20, 97. The α-helix has 3.4 residues per 
turn, a rise of 0.54 nm per turn and is defined by backbone dihedral angles θ and ψ of 
−60° and −45°. The spacing of side chains is such that they are situated above one 
another every 3–4 residues; thus the α-helix can be considered to have three distinct 
faces96-98. In many cases of α-helix mediated PPIs, there are predominantly 
hydrophobic residues at the i, i + 3(4), i + 7 positions, which make key contacts with 
a reasonably deep α-helix binding cleft96. Should an α-helix be found at a PPI 
interface, a mimetic that reproduces the key recognition features of the helix (such as 
the key side chains) might act as a competitive inhibitor96.  
There are two leading mimetic inhibitor design strategies: peptide mimetics that 
replicate the local topography of the structural motif99, and non-peptidic scaffolds 
that mimic the surface formed by non-sequential hot-spot residues (i, i + 3(4), i + 7) 
of the α-helix100, 101. 
 
1.2.3.1 Peptide mimetics 
 
Peptides are highly conserved and have a complex set of functions which a small 
molecule may not be able to mimic fully102. However, as peptides have poor 
transport properties and are sensitive to proteolytic degradation they are considered 
therapeutically undesirable103. In addition, synthetic peptides are less organized and 
may lack secondary structure in solution compared to when part of their parent 
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protein, potentially increasing the entropic cost of binding104. Several stabilisation 
approaches are being explored to replicate the local topography of an α-helical motif 
found at a protein interface while also addressing the problems of proteolytic 
stability and other pharmacokinetic factors. Strategies for helix stabilisation include 
salt bridges, metal chelates and covalent cyclisation methods such as disulphide and 
lactam bridges105, 106. There are several considerations required before constraining 
peptides, firstly although it seems intuitive that helical content should be maximized 
to decrease the entropic penalty of binding, this risks constraining a peptide in an 
inactive confirmation. Consequently a less well-defined conformation may be 
considered adequate with a linker introduced merely to reduce the number of degrees 
of freedom of the peptide in the unbound state. Consideration should also be given to 
which amino acids to crosslink and their relative positions, where in the sequence 
they should be and the length and flexibility of the linkers96. 
	  
1.2.3.2 Non-peptidic scaffold mimics  
 
Proteomimetics match the topography of the original α-helix by mimicking the 
spatial orientation of its key recognition residues, rather than recapitulating the 
helical conformation96, 107. Within an α-helix there is a hydrogen bond network 
which stabilizes the helical conformation and orients the key binding residues along 
the solvent-exposed surface. It is possible to simplify this pharmacophore to a rod-
shaped object presenting side chains in a spatial orientation comparable to that of a 
native α-helix. Such molecules are likely to be more synthetically tractable and 
confer more drug like properties. This pharmacophore may allow the development of 
a template scaffold amenable to many different PPIs simply by matching side chains 
to the helical target of interest96. 
 
The Hamilton group identified the first true α-helix mimetic108; a series of 
trisubstituted 3,2′,2″-terphenyl derivatives in which the aryl core assumes a staggered 
conformation projecting the ortho substituents to mimic the position of the i, i + 3(4) 
and i + 7 residues of the helix. This series of compounds, and derivatives have 
demonstrated inhibitory capabilities (IC50 in the nanomolar range) for numerous PPIs 
including calmodulin/phosphodiesterase, Bcl-xL/Bak and gp41 assembly 
interactions108-110. Further studies have shown the ability of these ligands to disrupt 
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interactions in cells using the BH3-mediated interaction with Bcl-xL in HEK293 
(human embryonic kidney) cells as a model111, 112. As these ligands have a template 
scaffold it is important to establish selectivity, in this case selective inhibition of the 
Bcl-xL/Bak interaction over the p53/hDM2 PPI was indeed achieved by a subtle 
exchange of a methyl-1-naphthyl for methyl-2-naphthyl side chain in the terphenyl 
sequence111. 
 
Since this initial success considerable efforts have been invested in development of 
scaffolds which have a more versatile synthesis amenable to library generation and 
greater drug like properties96, 113-115. Although structural rigidity is important in 
reducing the entropic cost, it may also be beneficial to have some flexibility to 
maximise the interactions with the target through induced fit96. Oligobenzamide 
mimics, developed by the Wilson group, appear to allow some flexibility98. Further 
structural studies by the Hamilton group on the oligobenzamide mimics suggested 
that backbone curvature can be controlled to match that of target α-helices by using 
combinations of pyridine and benzene rings in the scaffold116. The Wilson group 
have demonstrated the inhibition properties of 3-O-alkylated aromatic oligoamides 
demonstrating that this scaffold could generate compounds with comparable affinity 
to the native peptide against the p53/hDM2 interaction98. The synthesis of this 






Figure 2 - Proteomimetic scaffolds96 a) Core structue of a 3,2’,2’’ – terphenyl scaffold 
developed by the Hamilton group; the first true α helix mimetic. b) Wilson group 3-O 


























1.3 Characterisation of binding interface 
 
Both computational analysis and rational design require an intimate knowledge of 
the protein structure to identify binding hot-spots, ideally this structure will be a 
crystal structure. However, in some cases the crystal structure is not available, in 
such cases other methods must be utilised to understand the binding interface. These 




1.3.1 Ligand discovery by phage display 
 
Phage display is a powerful combinatorial method, using technology based upon the 
ability of phage particles to display various structures (including peptides and larger 
protein scaffolds) on the bacteriophage coat proteins, by insertion of the encoding 
nucleotides into the phage DNA. This allows the development of large and diverse 
libraries (>1011) using simple molecular biology methods118, which can be amplified 
via passage through a bacterial host (such as E. coli), making phage library 
generation relatively cheap and quick. The phage display experiment consists of: 
isolation of the protein target, incubation with the phage library, washing away of 
non-binding phage, elution and amplification of the phage that bind. This process 
(panning) is repeated to obtain high affinity binders to the target protein (Figure 






Figure 3 - A schematic showing the general protocol of a phage display experiment. 
 
 
The high affinity binders can be assessed for binding affinity to the target protein and 
the location of high affinity binding peptides may highlight a PPI binding hot-spot. 
This peptide can then be taken forward to be used in computational screening or 
rational design. As phage do not operate under the same evolutionary pressures as 
natural binding partners, it is reasonable to believe that epitopes distinct from those 
found on the natural ligand will be discovered; it is also possible that transient 
binding sites or sites which are induced by the binding of the phage-derived ligand 
will be discovered. As PPI interfaces are large this further exploration of the 
interface may yield binding sites which otherwise would have remained unexplored. 
Phage display may also identify localised binding epitopes that are readily 
transferred to potent small molecules scaffolds. The pharmacophore of the binders 
may also shed light upon the properties of both the binding interface and any 
potential small molecules119.  
Phage display has advanced to not only display short peptides but also more complex 
binders such as non-antibody binding proteins. In terms of binding proteins 
antibodies are the most commonly used121. However, as there are limitations to using 
antibodies in vitro, efforts have been made to engineer non-antibody/artificial 
binding proteins which mimic the molecular recognition properties of antibodies but 
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with improved properties122. Non-antibody proteins are in general small (200 amino 
acids), monomeric, stable and easily expressed in E. coli. Most do not contain 
cysteines, enabling the introduction of a cysteine for site-specific coupling of biotin, 
fluorescent labels, or polyethylene glycol to enhance their utility or stability. These 
characteristics make non-antibody proteins powerful tools capable of replacing 
antibodies in a range of applications including research123, diagnostics124, in vivo 
drug discovery studies125 and even as a novel class of therapeutics126 including 
multivalent and/or multi-specific protein therapeutics127. Phage display methods will 
be a powerful tool for selection of high affinity binding scaffolds.  
The Adhiron122 (commercially known as Affimer) is a non-antibody scaffold based 
upon a consensus sequence of plant-derived photocystatins which are small (ca.100 
a.a.) protein inhibitors of cysteine proteases128. This consensus protein displays good 
protease inhibitor activity as well as the properties of non-antibody binding proteins 
(small, monomeric, high solubility, high stability, lack of disulphide bonds and 
glycosylation sites), therefore it is a good scaffold for peptide presentation. The 
inhibitory sequences with Gln, Val, Val, Ala, Gly and Pro, Trp, Glu loops of the 
consensus photocystatin were replaced with nine randomized amino acid positions in 
each loop (Figure 4). The peptide loop regions are suitable for molecular recognition 
and are expected to adapt to form molecular contacts with a wide range of targets 
allowing interactions with protein pockets, protein surfaces, peptides and small 
molecules. The Adhiron scaffold yields high-level purification of soluble protein 
(typically 10–100 mg/L) from E. coli and displays high thermostability with a 
melting temperature of 101 °C122. There has been some success in the generation of 
high affinity binding Adhirons122 and the generation of Adhirons which inhibit PPIs 


























Figure 4 – Adhiron non-antibody binding scaffold, variable loops are highlighted in blue. 
PBD 4N6T122. 
 
1.3.2 Biophysical analysis 
Biophysical analysis of the native PPIs as well as ligand binding (either in the form 
of phage display generated peptide/non-antibody binding proteins or small 
molecules) is an important part of the drug discovery process. Many biophysical 
methods will give an overall affinity of the two interacting molecules but different 
methods will give additional information (e.g. thermodynamic and kinetic 
information) and it is therefore important to consider the data parameters required 
when deciding which biophysical method to use. Below the biophysical techniques 
used during this project are described, and briefly those used within the drug 
discovery process.   
Fluorescence anisotropy assays are used to measure rotational diffusion of a 
molecule (tumbling rate). This rotational diffusion is primarily affected by the 
molecule size, the larger the molecule the lower the rotational diffusion. This 
rotational diffusion can be measured by the ratio of polarized light within the total 
light intensity. When polarized light is applied to a group of randomly oriented 
fluorophores, most of the excited molecules will be those oriented within a particular 
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range of angles to the applied polarisation. If they have low rotational diffusion 
(larger molecules) the fluoresced light will remain polarized (high anisotropy). When 
the fluorophores can freely change their orientation (high rotational diffusion of 
small molecules) before re-emitting the photons, the degree of polarisation of the 
emitted light will be reduced (low anisotropy). Therefore this phenomenon can be 
used to measure the potency of binding events. One of the protein partners (generally 
a smaller peptide) is fluorescently labeled, upon binding to a larger protein the 
rotational diffusion is reduced, increasing the fluorescence anisotropy. Plotting the 
fluorescence anisotropy against protein concentration of the unlabeled protein 
partner allows the calculation of Kd.  This assay can also be adapted to measure the 
affinity of inhibitors. Starting with a pre-bound complex the rotational diffusion of 
the fluorophore will be low; therefore the fluorescence anisotropy will be high. 
When an inhibitor disrupts this complex, the rotational diffusion of the fluorophore 
will increase, resulting in a decrease in fluorescence anisotropy (Figure 5).  
 
Figure 5 – Schematic demonstrating the fluorescence anisotropy assay, both in direct 
binding and competition mode 
 
This technique is relatively high throughput and amenable to robotics, making it an 
appropriate tool for primary screening, both in direct binding and competition mode. 
It is limited as one of the proteins (ideally the smaller binding partner) is attached to 
a fluorophore. There is a chance that the fluorophore itself may bind the protein, 
however this is easily controlled for. A more likely situation is that the fluorophore 
inhibits binding. However there are many different fluorophores which can be used, 
and they can be attached at different positions on the molecule. Therefore it is likely 
that the limitation of fluorophore inhibiting binding can be overcome.    
 22 
Isothermal titration calorimetry (ITC) gives thermodynamic data about an interaction 
by directly measuring the heat that is released or absorbed when a complex is formed 
(protein–protein or protein–ligand complex formation)1. An isothermal titration 
calorimeter consists of two cells, a sample cell and a reference cell. A syringe is used 
to titrate one binding partner into the sample cell containing the other binding 
partner. This will cause a heat change in the sample cell. The power required to 
maintain isothermal conditions between the sample and the reference cell is 
measured by a calorimeter. A plot of power (µcals-1) against time (min) shows a 
series of peaks of heat flow (power). The area under the peaks gives the enthalpy 
(ΔH) of binding129, 130. A binding isotherm obtained from the plot of heat of 
formation against the molar ratio of ligand to biomolecule (gives information about 
the enthalpy (ΔH), the association constant (Ka) and the stoichiometry (n) of binding, 
which can be used to calculate changes in entropy (ΔS) and Gibbs Free Energy 
(ΔG)130, 131.  
ITC is a label free method, therefore there is no concern that a label, such as a 
fluorophore, will inhibit or indeed promote binding. ITC is also a method where 
neither binding partner is immobilized; therefore there is no concern about the 
orientation of one of the binding partners being restrictive for binding. In addition, it 
does not have limitations associated with clarity of the solution, molecular weight, 
temperature or pH. A limitation of this technique is that it is relatively low 
throughput and is therefore used as a secondary screening method to eliminate false 
positive hits after primary screening in the drug design process. 
Surface plasmon resonance (SPR) is a technique that measures the interaction of 
molecules through changes in the refractive index that occur when ligands that are 
bound to a surface interact with another molecule in solution1. SPR occurs when 
light is reflected off thin metal films. A fraction of the light energy at a specific angle 
(SPR angle) can interact with delocalised electrons within the metal film (plasmon) 
resulting in a reduction in the reflected light intensity. If binding occurs to the 
immobilized target the local refractive index changes, leading to a change in SPR 
angle, which can be monitored in real-time by detecting changes in the intensity of 
the reflected light. The rates of the change in reflected light intensity can be analysed 
to give association and dissociation rate constants. The ratio of these values gives the 
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apparent equilibrium constant (affinity). The size of the change in SPR signal is 
directly proportional to the mass being immobilized and can thus be interpreted 
crudely in terms of the stoichiometry of the interaction.  
SPR directly measures the on and off rates of the interaction and this may be 
important for lead optimization. A limitation of SPR is that one of the binding 
partners (ideally the smaller partner) must be immobilized on to the chip. This adds 
concern that the orientation of this molecule may hinder binding, for example if the 
binding site is occluded. However there are many different ways a molecule can be 
captured on a chip (amide coupling, streptavidin-biotin or His-nickel) so different 
approaches can be tested to optimize binding. 
Microscale thermophoresis (MST) is a relatively new biophysical technique that 
enables the analysis of molecular interactions in solution at the microlitre scale. MST 
measures the movement of molecules along temperature gradients, an effect termed 
thermophoresis. Molecules will move away from localized heat; this movement is 
affected by size, charge and entropy of the molecules; therefore the thermophoresis 
of a molecule will be different when within a complex. The thermophoresis of 
fluorescently labeled molecules is measured by monitoring the fluorescence 
distribution inside a capillary. In solution the fluorescence distribution is 
homogeneous. When a microscopic temperature gradient is established by an IR-
Laser, a new fluorescence distribution arises (Figure 6)132. MST is time and cost 
effective, with low sample consumption and fast measurement of samples. MST can 
measure a broad range of affinities and sizes, therefore is useful for the testing of 
small molecules. However like fluorescence anisotropy, one component must be 





Figure 6 - An illustration of the theory behind microscale thermophoresis, figure adapted 
from the NanoTemper user manual 
 
Förster Resonance Energy Transfer (FRET) is also used to measure molecular 
interactions. FRET is the radiationless transmission of energy from a donor molecule 
to an acceptor molecule. The donor initially absorbs the energy and the energy is 
subsequently transferred to the acceptor when in close proximity (typically 10-100 
Å). This resonance interaction occurs over greater than interatomic distances, 
without conversion to thermal energy, and without any molecular collision. For 
FRET to occur the excitation spectrum of the acceptor must overlap the fluorescence 
emission spectrum of the donor133. One of the major advantages of FRET is that it 
can be conducted in cellulo (as well as in vitro), unlike the other biophysical 
techniques described. FRET can also be used as a molecular ruler as the FRET 
efficiency (Q) is proportional to 1/distance to the power 6 (r6) between the two 
fluorophores.  
 
As can be seen, each of the biophysical techniques, ITC, SPR, fluorescence 
anisotropy, MST and FRET, have different strengths and weaknesses and therefore 
are appropriate to use at different parts of the drug discovery process, both for PPI 
characterisation and testing of small molecules. Each of the biophysical techniques 
give an indication of binding affinity, however there are other techniques which give 
other information, for example circular dichroism (CD), differential scanning 
calorimetry (DSC) and mass spectrometry. 
 
The main application of CD is measuring the secondary structure content of proteins, 
CD can also be used to give an indication of protein stability, both in different 
buffers and thermal stability by thermal melt. CD functions through the interaction of 
circularly polarized light with chiral molecules. Circular polarised light has a 
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“handedness”; it is either rotating left or right. Bonds around a chiral centre absorb 
left and right polarised light differently; it is this difference that is measured by the 
spectrapolarimeter (CD spectrometer). The spectrapolarimeter light source switches 
between left and right polarized light and the samples absorbance of each type of 
light is compared; the difference between the two signals is known as the ellipticity  
(θ). In practise the protein concentration and the path length of the cuvette are used 
to give mean residue ellipticity (MRE).  
 
Each secondary structure has a characteristic CD signature, these spectra are shown 
in Figure 7134. The α-helix spectra has two minima 208 nm and 222nm; these can be 
followed to assess protein stability. As the protein unfolds, for example due to heat, 


























Figure 7 - UV CD spectra associated with various types of secondary structure. The two 
most common secondary structures are labelled. Solid line = α-helix; dotted line = β sheet. 
Figure adapted from134 
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Other techniques such as DSC and fluorescent reporter dye assays can give 
information about the thermal stability of a protein, although neither give 
information about secondary structure. DSC can be particularly useful if refolding 
information is required. Fluorescent reporter dye assays are high throughput and 
therefore can be useful for the characterisation of larger libraries. Mass spectrometry 
has been recognised as having a potential for fast, sensitive and high throughout 
analysis of weak covalent complexes135. As well as providing exact mass and 
sequence specific information, mass spectrometry has been reported to provide 
dissociation constants of protein–ligand complexes from titration experiments136; 
information on conformational changes upon binding (from ion mobility 
measurements and collision cross section calculations)137; location of the binding site 
(from epitope mapping approaches)138; binding stoichiometry and binding specificity 
(from competition experiments)139; isotopic information such as oxidation states of 
binding metal ligands140; relative quantification or subunit exchange that can occur 
within multicomponent- protein complexes141. 
Each of the techniques described have been used within drug discovery projects, 
either to characterise the binding event of the native interactions or the ligand/target 
interaction.  As each of the techniques is able to measure different parameters 
consideration should be given to the techniques capabilities before deciding which 









1.4 The targets of interest  
 
1.4.1 Targeted therapy 
 
 
The two PPIs investigated in this thesis are the HIF-1α/p300 and the eIF4E/eIF4G 
interactions; both targets are implicated in cancer development. Cancer is a major 
concern to public health and although the mortality rate is decreasing, cancer remains 
one of the biggest problems of the modern medical era142. As well as only seeing 
modest reductions in mortality rate, many current cancer treatments such as 
chemotherapy and radiotherapy are associated with an abundance of adverse effects. 
The adverse effects occur because such treatments target the obligate rapid 
proliferation of cancer cells143. Therefore such treatments are targeting all targeting 
all rapidly dividing cells, not just cancer cells. Patients can expect to suffer fatigue, 
hair loss and nausea as well as many other debilitating symptoms143. It is for these 
reasons that the development of novel anti-cancer agents is of paramount importance. 
To achieve this, new targets must be identified and novel methods of intervention 
developed. These new targets should not target all rapidly dividing cells but target 
cancer cells more specifically. Targeted therapies are substances that block the 
growth and spread of cancer by interfering with one of the specific hallmarks of 
cancer highlighted in Figure 8, it is suggested that most, if not all cancers have 
acquired the same set of functional capabilities during their development, albeit 







Figure 8 – Schematic showing the specific hallmarks of cancer, adapted from144. 
 
 
One approach for target selection is to compare the amounts of individual proteins in 
cancer cells with the amounts found in normal healthy cells. Proteins more abundant 
in cancer cells than in normal healthy cells would be potential targets, especially if 
they are known to be involved in cell growth or survival. Another approach to 
identify potential targets is to determine whether cancer cells produce mutant 
proteins that are involved in cancer progression. Once a potential target has been 
identified, the next step is to develop a therapy that affects the target in a way that 
interferes with its ability to promote cancer cell growth or survival. For example, a 
targeted therapy could reduce the activity of the target or prevent it from binding to a 
receptor. Targeted therapies do have some limitations, one is they are more prone to 
resistance, which mainly occurs in two ways; the target itself changes through 
mutation so that the targeted therapy no longer interacts well with it, and/or the 
tumor finds a new pathway to achieve tumor growth that does not depend on the 
target. Resistance can be overcome, or at least slowed; by using the therapies in 
combination with either another targeted therapy or chemotherapy.  
 
Targeted therapy is based on the basic principle of preferentially killing cancer cells, 
without having any significant toxic effect on normal cells. This can be achieved by 
targeting specific proteins mutations and interactions, as previously described, and 
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additionally as a targeted delivery approach. Many of the adverse effects of current 
cancer therapy can be attributed to ineffective delivery of specific molecules, this 
leads to ineffective therapeutic drug concentration reaching the tumor site, adverse 
effects caused by nonspecific tissue distribution of anticancer agents, and acquired 
resistance of the cancer cell upon chemotherapy that triggers cross-resistance to a 
wide range of different drugs. A targeted delivery approach would mean that the 
active agent was spatio-temporally delivered to the correct location at the appropriate 
time145. Targeting strategies have attempted to take advantage of low extracellular 
pH often found in tumours, elevated enzymes in tumour tissues, the hypoxic 
environment inside the tumour core and tumour-specific antigens expressed on tumor 
cell surfaces145. Recent advances in targeted delivery have focused on prodrugs and 
carriers146. The prodrug concept is an alternative approach to design less reactive and 
less cytotoxic form of anticancer drugs147, 148. Pharmacologically inert drug molecule 
derivatives that can be converted to their active form in vivo, either enzymatically or 
non-enzymatically, to exert a therapeutic effect are used146. Traditional produgs 
temporarily alter the physicochemical properties of drugs to improve drug 
pharmacokinetics, prolong action, reduce adverse effects and increased selectivity. 
To become a targeted prodrug the prodrug is conjugated to a carrier such as sugars, 
growth factors, vitamins, antibodies, peptides and synthetic polymers that can 
transport the drugs to tumours and subsequently release it outside or inside the 
tumour cells, therefore the drug is inactive until at the tumour site.  This targeting 
can be achieved in different ways. One such way is to develop a carrier such as 
monoclonal antibodies149, 150 that binds to antigens or receptors expressed on tumor 
cell surface. If used in combination with a targeted therapy, targeted delivery will be 
a very powerful tool for limiting adverse effects and intensifying the effect of the 
anti-cancer agent.  
 
Inhibitors against HIF-1α/p300 and the eIF4E/eIF4G would be a targeted therapy. 
HIF-1α/p300 inhibitors could be a targeted therapy for solid tumours such as breast 
cancers as such tumours have a limited blood supply151. eIF4E has been shown to be 
up-regulated in multiple cancer types, including malignancies of the prostate, breast, 
stomach, colon, lung, skin, and the hematopoietic system152, eIF4E/eIF4G inhibitors 
could therefore be a targeted therapy against these cancers. 
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The role of each of these interactions in cancer development will be briefly described 





Hypoxia inducible transcription factor (HIF) is a transcription factor and is regarded 
as a potential protein for targeted cancer therapy due its role within cells in hypoxic 
environments153. As the multiplication of cancer cells is rapid, tumours quickly 
outgrow their blood supply. This results in a hypoxic environment, which is 
characteristic of cancerous cells. The hypoxic environment may therefore be 
exploitable in cancer therapy153. There are three isoforms of HIF; HIF-1, HIF-2 and 
HIF-3143. Although the exact role of each isoform is not fully established, it is HIF-1 
that is described as the messenger to activate transcriptional responses to hypoxia 
and therefore regarded as a potential cancer target143. HIF-1 is a promiscuous 
heterodimeric transcription factor; composed of an α subunit and a β subunit154. The 
link between HIF-1 and cancer was established by immunohistochemical analysis of 
human cancer biopsies155. The level of HIF-1α has been shown to be increased in 
cancer cells relative to normal tissue, in the majority of cancers155. Furthermore, 
experimental data has complemented clinical data, showing that in the absence of 
HIF-1α there is decreased tumour growth, vascularization and metastasis156; whereas, 
the opposite is true when HIF-1α is over expressed. This demonstrates a causal 
relationship between HIF-1α and cancer progression157. Numerous studies have been 
conducted giving evidence that HIF-1α activation promotes oncogenesis or cancer 
progression. Clinical data has also linked high levels of HIF-1α to a poorer prognosis 
and increased mortality rate158. Therefore there is an extensive bank of data 
demonstrating the relationship between HIF-1α and cancer. 
 
 
The β subunit is constitutively expressed in the nucleus whereas the stability, 
subcellular localization and transcriptional potency of the α subunit is affected by 
oxygen concentration153. HIF-1α is continuously expressed at a low level in the cell, 
however in normoxic conditions HIF-1α is rapidly degraded, most prominently via a 
Von Hippel–Lindau tumor suppressor (pVHL)-mediated ubiquitin-proteasome 
pathway (Figure 9)143. This process is initiated by the hydroxylation of two proline 
 31 
residues by HIF-prolyl hydroxylase (HPH). HPH requires oxygen to complete this 
hydroxylation and oxygen availability is the rate-limiting step in this reaction159. 
Upon hydroxylation, pVHL is able to bind to HIF-1α, which subsequently allows the 
recruitment of the E3 ligase complex. This allows the attachment of ubiquitin via the 
lysine residues of HIF-1α, thereby marking HIF-1α for degradation. Due to the rapid 
nature of this pathway HIF-1α has a half life of less than 5 minutes in normoxic 
conditions; resulting in no detectable protein in normoxic cells160. However, in 
hypoxic environments oxygen availability is limited, therefore hydroxylation of the 
prolines is inhibited. Consequently HIF-1α is not rapidly degraded and the stability 
and transcriptional activity of HIF-1α increases within the cell. This allows HIF-1 to 





Figure 9 - HIF-1α/p300, cartoon representation illustrating the importance of HIF-1α for 
transcription in hypoxic environments.  
 
The hypoxia response elements have many roles in normal and cancer biology. 
These include angiogenesis161, stem cell maintenance162, metabolic 
reprogramming163, autocrine growth factor signaling164, metastasis165 and providing a 
mechanism of resistance to radiation and chemotherapy166. It is therefore 
unsurprising that there are also many molecular mechanisms to inhibit the activity of 
HIF-1α. These mechanisms include decreasing mRNA levels, decreasing protein 
synthesis, increasing degradation, inhibiting heterodimerization, inhibiting the HIF-
1α/DNA interaction and decreasing the transcriptional activity of HIF-1166. A 
reduction of transcriptional activity could be achieved by targeting the interaction 
between HIF-1α and its co-activator p300166. It is this interaction which is of interest 
 32 
for this project. p300 and the paralogous  CREB binding protein (CBP) bind to many 
transcription factors to control expression of their targets genes. The structure and 






Another way in which cancer cells may be targeted preferentially over healthy cells 
is to target translation initiation factors (which translate oncogenes), one such 
initiation factor is Eukaryotic translation Initiation Factor 4E (eIF4E). The control of 
translation of mRNA is crucial for gene expression and is one of the key ways in 
which protein levels may be selectively regulated167. Translation requires an 
initiation step where the cap at the 5’ end of an mRNA binds to eIF4E, which 
recruits the ribosome168. This initiation is mediated by many eukaryotic initiation 
factors (eIFs) and is regulated via changes in their phosphorylation states and by 
endogenous protein167. An important step in this initiation is the formation of 
eukaryotic initiation factor 4F, which is made up of three subunits; eIF4E, the Cap 
binding protein, eIF4A the RNA helicase, and eIF4G the multidomain adaptor. 
eIF4E is described as the master switch that controls eukaryotic translation167. eIF4E 
is responsible for the delivery of the 5’ end of the mRNA to the RNA helicase 
eIF4A167. eIF4E is the rate limiting protein within the complex, as eIF4E activity is 
tightly regulated via an interaction between either eIF4G or endogenous 4E-binding 
protein (4E-BP) (Figure 10). The interaction with 4E-BP negatively regulates the 
formation of the eIF4F complex, as the availability of eIF4E to complete the 
complex relies on release from 4E-BP169. Therefore the binding of eIF4E is 
competitive between eIF4G and 4E-BP168. When hypophosphorylated 4E-BP binds 
eIF4E with high affinity, preventing the eIF4E/eIF4G interaction. 
Hyperphosphorylation of 4E-BP causes dissociation of the 4E-BP/eIF4E complex, 
allowing eIF4E to bind to eIF4G, resulting in the formation of eIF4F complex. 
mRNA’s with unstructured UTR are translated preferentially to mRNAs with 
structured UTR’s; many mRNA’s of proteins associated with cancer have structured 
UTR’s. Therefore an increase in eIF4F formation enhances the translation of a subset 
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of mRNAs involved in critical cellular processes implicated in oncogenesis such as 
cell proliferation, evasion of apoptosis, angiogenesis, and metastasis. Targeting the 
transcription of such mRNA’s by either dose or targeted delivery of an eIF4F 
complex inhibitor may decrease the transcription of oncogenes without the adverse 
effects of inhibiting all cap depended transcription. The role of eIF4E in translation is 
discussed further in 4.1 Introduction to eIF4e/eIF4g. 
 
 
Figure 10 – Schematic illustrating the importance of the eIF4e/eIF4g binding event in 
translation. A) complex formed for cap dependent translation to occur. B) complex formed 



















Chapter 2 : Materials and Methods 
 
2.1 Materials  
 
2.1.1 Bacterial Strains and Vectors 
Competent DH5α Escherichia coli (E. coli) cells (Invitrogen, genotype: F- endAI 
hsdRJ7 (r-k, Mk+) supE44 thi-I λ- recAl gyrA96 relAI deoR Δ(lacZYA-argF)-U169 
Φ80dlacZΔM15)170 were used for propagation of ligand insert-vector construct DNA 
and plasmid amplification. 
The E. coli expression strains BL21 (DE3) pLysS (F- ompT gal dcm lon hsdSB(rB- 
mB-) λ(DE3) pLysS(cmR)) Star, Gold and Rosetta 2 (Statagene) encoding T7 RNA 
polymerase and chloramphenicol resistance and were used for over-expression of 
protein from plasmid DNA. E. coli ER2738 cells (NEB, F´proA+B+ lacIq 
Δ(lacZ)M15 zzf::Tn10(TetR)/ fhuA2 glnV Δ(lac-proAB) thi-1 Δ(hsdS-mcrB)5) were 
used for the amplification of phage. 
  
Vectors used throughout this study were: pGEX-6p-2 (GE Healthcare), with 
ampicillin resistance; pET-28b-Prescission and pET-28a (Novagen), with kanamycin 
resistance. The fusion tag SUMO was added to pET-28a and GFP to pET-28b-
Prescission, by H. Jenkins (University of Leeds). All plasmid amplification and 
protein expression strains were stored as glycerol stocks at -80 °C. 
2.1.2 cDNA and primers 
The cDNA templates for proteins p300 and eIF4E were purchased from Source 













Table 2 – The names and sequences of all the primers used in this study (all 5’-3’) 
Primer Name Sequence 
p300 (330-430) forward TATTGGATCCGCTGATCCAGAGAAGCG 
P300 (340-430) reverse ATTCTCGAGTTAAGCATTTTTGAGGGGGAG 
p300 (323-423) forward TATTGGATCCATGGGTTCTGGAGCAC 





Full HIF-1α forward TATTGGTACCTCTGATTTAGCATGTAGACTGCT
G 
Full HIF-1α reverse GCTCACCATACCGTAACCACCGTTAACTTGAT
CCAAAGCTCTGAG 
HIF-1α helix 2 forward GAAGTGAACGCGGCGGCGGGTGGTTACGGTA
TGGTGAGC 
HIF-1α helix 2 reverse TATTGGTACCCAGCTGACCAGCTATGATTGCG
AAGTGAACGCGGCG 
HIF-1α helix 3 forward CGCGCGCTGGATCAGGTGAACGCGGCGGGTG
GTTACGGTATGGTGAGC 
HIF-1α helix 3 reverse TATTGGTACCGAAGAACTGCTGCGCGCGCTGG
ATCAG 
HIF-1α helix 2+3 forward TATTGGTACCCAGCTGACCAGTTATGATTGTG 






YFP reverse TATTGGATCCTTACTTGTACAGCTCTC 
TEV-nHIF (HIF-1α/p300 








fusion construct  ) 
TATTCTCGAGTTAGTTAATTGATCCAAAGCTC
AG 
p300 mutant H20A forward TTTGCATGCTGCTAAGTGCCAGCGCCG 
p300 mutant H20A reverse AGGAGAACAAGCTGCTGC 
p300 mutant L20M forward GAAGAATGTCATGAACCACATGACACAC 
p300 mutant L20M reverse ATTGTGCGACAGTGGGGA 
p300 mutant I71M forward TCGACAAATCATGTCACACTGGAAG 





All cultures were grown in 2x YT media supplemented with the appropriate 
antibiotic. The antibiotics were added from stock solutions, (see Table 3 for stock 
solutions and working concentrations). Stock solutions of antibiotics were stored at   
-20 °C. 2xYT Media was prepared with 16 g tryptone soya broth, 10 g yeast extract 
and 5 g sodium chloride per litre of dd H2O which was then autoclaved. 
 
 
Table 3 – Concentrations of antibiotics used in this study, all diluted in ddH2O 




Kanamycin 50 50 
Ampicillin 100 100 
Chloramphenicol 34 34 




2.1.4 General reagents 
 
The reagents zinc sulphate, magnesium chloride, nickel sulphate, ethanol, sodium 
phosphate, iron chloride, cobalt chloride, nickel chloride, potassium phosphate, 
xylene cyanol, ammonium chloride, lactose, Tetramethylethylenediamine (TEMED), 
coomassie brilliant blue R-250, PIPES, chloramphenicol and aspartate were all 
purchased from Sigma-Aldrich. Sodium chloride, bromophenol blue, glycerol, 
calcium chloride, glucose, boric acid, methanol and acetic acid were all purchased 
from Fisher Scientific. Tryptone soya broth and yeast extract were purchased from 
Oxoid. Reagents Ficoll 400 and glutathione were purchased from Alfa Aesar. Agar, 
imidazole, manganite chloride and agarose were all purchased from Acros Organics. 
Copper chloride was purchased from Riedel-de-Haen (Seelze). 
Tris(hydroxymethyl)aminomethane (Tris), Ethylenediaminetetraacetic acid (EDTA), 
sodium dodecyl sulfate (SDS), Isopropyl β-D-1-thiogalactopyranoside (IPTG), 
kanamycin and ampicillin were all purchased from Melford. Sodium sulphate and 
magnesium sulphate were purchased from Glycon. Triton x100 and potassium 







Table 4 – Buffers commonly used in this study 
Experiment Buffer 
p300 CD 40 mM sodium phosphate pH 7.5 
100 mM sodium chloride 
1 mM DTT 
5 % glycerol 
eIF4E CD 40 mM sodium phosphate pH 7.5 
200 mM sodium chloride 
1 mM DTT 
5 % glycerol 
Adhiron CD 40 mM sodium phosphate pH 7.5 
100 mM sodium chloride 
1 mM DTT 
5 % glycerol 
p300 fluorescence anisotropy 40 mM sodium phosphate pH 7.5 
100 mM sodium chloride 
1 mM DTT 
5 % glycerol 
0.1 % triton x100 
eIF4E fluorescence anisotropy 40 mM sodium phosphate pH 7.5 
200 mM sodium chloride 
1 mM DTT 
5 % glycerol 
0.1 % triton x100 
p300 phage display peptide 
fluorescence anisotropy 
40 mM sodium phosphate pH 7.5 
100 mM sodium chloride 
1 mM DTT 
5 % glycerol 
p300 ITC 40 mM sodium phosphate pH 7.5 
100 mM sodium chloride 
5 % glycerol 
Adhrion SPR 8 mM disodium hydrogen phosphate 
1.5 mM potassium dihydrogen phosphate 
3 mM potassium chloride  
137 mM sodium chloride, pH 7.4, 
NMR 10 mM Tris-HCl pH 6.9  
50 mM sodium chloride  
2 mM DTT  
2% glycerol 
eIF4e crystallography 20 mM Hepes pH 7.5 
100 mM sodium chloride 
1 mM DTT  
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5 % glycerol 
Initial crystal screens (p300 
and HIF-1α/p300 fusion 
construct  ) 
20 mM Tris pH 7.5 
100 mM sodium chloride 
1 mM DTT 
5 % glycerol 
Adhiron crystallography 20 mM Hepes pH 7.5 
100 mM sodium chloride 
1 mM DTT  
5 % glycerol 
Lysis buffer 20 mM TRIS pH 7.9 
500 mM sodium chloride  
TBS-T 50 mM Tris pH 7.6 
150 mM NaCl 
0.05% Tween 20 
TBE running buffer 45 mM TRIS-borate pH 8.3 
1 mM EDTA pH 6.8 
SDS loading buffer 100 mM TRIS 
4% (w/v) SDS 
20 % (v/v) glycerol  
200 mM DTT 
0.2% (w/v) bromophenol blue 
SDS running buffer 25 mM Tris pH 6.8 
0.1% (w/v) SDS 
190 mM glycine  
DNA loading buffer 0.43% bromophenol blue 
0.42% xylene cyanol FF 
25% Ficoll 400 
Transformation buffer 10 mM PIPES  
15 mM CaCl2,  
250 mM KCl.  
55 mM MnCl2 
p300 biotinylation 50 mM HEPES pH 7.5 
150 mM sodium phosphate  
5 mM calcium chloride 
 
 
2.2 Methods  
 
 
2.2.1 Recombinant DNA techniques 
 
2.2.1.1 Touchdown PCR 
All Touchdown PCR experiments were conducted in 0.2 mL thin-walled dome 
capped tubes (Alpha Laboratories). The total reaction mixture was 100 µL containing 
10µL 10x Pfu Ultra II polymerase buffer (Stratagene), 10 µL 10x dNTP stock 
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solution (2.5 mM of each dNTP, invitrogen), 10 µL 10 µM forward primer, 10 µL 10 
µM reverse primer, 2 µL PCR DNA template, 1 µL Pfu Ultra II DNA polymerase 
(Stratagene) and 57 µL water. PCR was conducted in a G-storm thermocycler (GRI 




Table 5 – Protocol used for touchdown PCR 
 
Step number Number of cycles Temperature (°C) Time 
1 1 96 2 












4 1 72 4 
* decrease by 0.5 °C each cycle 
 
 
PCR samples were purified by agarose gel electrophoresis and extracted using the 
QIAquick gel extraction kit (QIAGEN), following the manufacturers recommended 
protocol. 
 
2.2.2 Agarose Gel Electrophoresis 
1.4% (w/v) agarose gels were prepared with 0.5x TBE buffer containing 1x RedSafe 
Nucleic Acid Staining Solution (Invitrogen). Prior to loading 10x DNA loading 
buffer was added to the samples. Gels were run at 95 V in 0.5x TBE buffer until 
bands were sufficiently separated. 2-log DNA ladder (New England Biolabs) was 
included alongside the samples. 
 
2.2.3 Restriction endonuclease digests 
For diagnostic digests, a total reaction mixture of 10 µL was used and for large scale 
digests a total reaction mixture of 100 µL was used. All digests were conducted in 
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1.5 mL Eppendorf tubes. The large scale digests consisted of 50 µL DNA product, 4 
µL of each appropriate restriction enzyme (20,000 units New England Biolabs), 10 
µL Buffer 4 (New England Biolabs), 10 µL 10x BSA (New England Biolabs) and 
water (22 µL). The mixture was incubated at 37 °C overnight and then the DNA was 
purified by agarose gel electrophoresis and gel extracted according to the QIAquick 
Gel Extraction Kit Protocol (QIAGEN). Diagnostic digests were carried out using 8 
µL DNA product, 0.5 µL of each appropriate restriction enzyme (New England 
Biolabs), 10 µL Buffer 4 (New England Biolabs), 10 µL 10x BSA (New England 
Biolabs). The mixture was incubated at 37 °C for one hour and then the DNA was 
purified by agarose gel electrophoresis and gel extracted using the QIAquick Gel 
Extraction Kit Protocol (QIAGEN). 
 
2.2.4 Ligations  
Ligations were conducted in 1.5 mL Eppendorf tubes and incubated at room 
temperate for 30 minutes. Each reaction contained 1 µL digested insert, 6 µL purified 
digested plasmid, 1 µL T4 DNA ligase (New England Biolabs) and 2 µL 5x ligase 
buffer (New England Biolabs). 
 
2.2.5 Competent DH5α E. coli cell preparation 
200 mL 2xYT was inoculated with DH5α E. coli cells from glycerol stock and 
incubated at 37 °C, with aeration at 100-110 rpm, for approximately 6 hrs. The 
temperature was decreased to 18 °C, with shaking at 100-110 rpm until OD600 = 0.6-
0.7. The culture was then incubated on ice for 10 min, followed by centrifugation at 
13,000 × g for 10 min at 4 °C. The pellet was resuspended in a total of 80 mL ice 
cold transformation buffer and incubated for 10 min on ice. The centrifugation was 
repeated. The pellet was resuspended in 18.6 mL ice cold transformation buffer and 
1.4 mL Dimethyl sulfoxide (DMSO) were slowly added with continual stirring. The 
culture was incubated on ice for a further 10 min, aliquoted and frozen in liquid 




100 µL of competent E. coli DH5α or BL21 expression strains were transformed 
with 10 µL of ligated product and incubated on ice for 30 min. For kanamycin and 
chloramphenicol-resistant transformations 400 µL 2xYT was then added to the 
transformation mixture and incubated at 37 °C for one hour with aeration. The cells 
were then centrifuged at 3500 × g for one minute, 400 µL of supernatant was then 
removed and the pellet resuspended. Transformed cells were incubated at 37 °C 
overnight on agar plates (31 g/L 2xYT media, 15 g agar) which contained 
appropriate antibiotic. 
 
2.2.7 Colony PCR 
Single Colonies from the ligation plate were picked and transferred to a 2xYT agar 
plate supplemented with appropriate antibiotic and incubated at 37 °C overnight to 
create a master plate. PCR templates of each picked colony were made by 
resuspending the remainder of each colony in separate 1.5 mL Eppendorf tubes 
containing 30 µL of water and then boiling them for five minutes. The PCR was 
carried out in 0.2 mL thin-walled dome-capped PCR tubes (Alpha Laboratories) in 
the G storm-thermocycler (GRI Labcare). Each tube contained a total reaction 
mixture of 30 µL consisting of 3 µL 10x thermopol buffer (New England Biolabs), 3 
µL 10x dNTP stock solution (2.5 mM each dNTP), 3 µL 10 µM vector primer, 3 µL 
10 µM insert primer, 3 µL PCR template, 0.5 µL Taq polymerase (New England 
Biolabs) and 14.5 µL water was used. The PCR protocol used is outlined in Table 4. 
The resulting PCR products were run on an agarose gel and those which showed a 
single band of the correct size were presumed to be positive. The presumed positive 
colonies were picked from the master plate and overnight cultures were grown from 
which plasmids can be extracted. Presumed positive colonies were confirmed by 
sequencing (cogenics, UK). 
 
 Table 6 – Protocol used for single colony PCR 
 
Step Number Number of cycle Temperature (°C) Time (min) 
1 1 96 2 
2 25 95 0.5 
  54 0.5 
  72 1/kb 
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2.2.8 p300 mutant cloning 
 p300 mutants, H20A, L47M and I17M were cloned by Quickchange from the GST-
p300 construct. Quickchange was performed as per the Q5 site directed mutagenesis 






2.2.9 Overnight cultures 
Cultures were initiated by inoculation of 2xYT with appropriate antibiotic from 
either a single colony from a transformation plate or by a scrape from a glycerol  
stock. Starter cultures of 10 mL were grown in 50 mL falcon tubes and incubated at 
37 °C with aeration overnight. 
 
2.2.9 Plasmid DNA extraction and glycerol stock preparation 
Plasmid DNA was extracted from 10 mL of overnight culture using QIAprep spin 
miniprep kit (QIAGEN) as per the manufacturers handbook. For large scale plasmid 
DNA extraction 3 mL overnight culture was used to inoculate 300 mL 2xYT, which 
were incubated at 37 °C overnight. The plasmid DNA was extracted using QIAprep 
spin maxiprep kit (QIAGEN) as per the manufacturers handbook. The extracted 
DNA samples were stored at -20 °C. Each new plasmid obtained from positive 
colonies was transformed into both DH5α and BL21 E. coli strains and glycerol 
stocks of the resulting cells were produced by the addition of 0.5 mL sterile 60 % 
glycerol to 1.2 mL of overnight culture before storing them at -80 °C. 
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2.2.10 Sanger DNA sequencing 
Each new plasmid made was sequenced prior to expression and solubility trials to 
test for possible mutations introduced during the ampification PCR step. 1 mL of 
2xYT agar with appropriate antibiotic was set in 2 mL sterile screw cap tubes. Stabs 
were made by pipetting of 5 µL overnight culture on to the agar surface and then  
stabbing a hole into the agar with the pipette tip. The bacterial stabs were sent to 









2.3 Protein expression and purification 
 
 
2.3.1 General techniques  
 
2.3.1.1 Protein Expression Trials  
 For small-scale over-expression trials, 1 mL of overnight culture was used to 
inoculate 10 mL 2xYT (supplemented with appropriate antibiotic) in a 50 mL falcon 
tube. Cultures were incubated at 37 °C with aeration until an OD600 0.6-0.8 was 
reached. Protein expression was induced by addition of sterile IPTG to the culture at 
a final concentration of 0.1-0.4 mM (outlined in appropriate results section for 
protein expression trials and 2.3.2 Specific Protein Expression) and the culture was 
then incubated at 18 °C with aeration overnight. Cells were harvested by 
centrifugation at 3500 × g at 4 °C for 20 minutes. Cell pellets were resuspended in 
Lysis buffer. 5 U DNase I and 2 mM MgCl2 were added to the suspensions prior to 
lysing the cells. Cells were lysed by 5 cycles of freeze/thaw. The lysate was 
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centrifuged at 13000 × g for 25 minutes at 4 °C. Both the pellet and supernatant were 
analysed by SDS-PAGE. 
 
2.3.1.2 OD600 measurement 
The Optical Density (OD) of cell cultures was read with a spectrophotometer 
(Helious β) set to 600 nm by using 1 mL of culture in a plastic cuvette (brand) after 
the spectrophotometer was zeroed against a blank sample (1 mL of un-inoculated 
media). 
 
2.3.1.3 Nickel affinity chromatography 
For purification of protein with a His tag from cultures ≤ 1 L a 1 mL Ni2+ sepharose 
HisTrap HP column (GE Healthcare) was used and for purification of protein from 
cultures > 1 L a 5 mL Ni2+ sepharose HisTrap HP column (GE Healthcare) was used. 
Columns were attached to a peristaltic pump at room temperature. The maximum 
flow rate used was 1 mL/min for the 1 mL column and 5 mL min for the 5 mL 
column. Columns were washed with 5 column volumes of water, charged with 0.1 M 
NiSO4 and equilibrated with 5 column volumes of Lysis buffer before loading the 
filtered supernatant. The filtered supernatant was passed through the column and the 
flow through was collected. The column was then washed with 5 column volumes of 
Lysis buffer. Elution was carried out by increasing concentration of imidazole in 
Lysis buffer (50 mM-200 mM). All wash fractions were collected and analysed by 
SDS-PAGE. Columns were stored in 20% ethanol. 
 
2.3.1.4 Glutathione affinity chromatography 
Proteins fused to a glutathione S-transferase (GST) tag were purified with 
approximately 10 mL Glutathione Superflow Resin (Generon) packed in a free-flow 
gravity column, attached to a peristaltic pump at room temperature. The column was 
washed with 5 column volumes of water and equilibrated with 5 column volumes of 
Lysis buffer. The lysate was then added to the column and mixed with the beads. The 
mixture was left for 10 min to allow binding. The mixture was then allowed to flow 
through the column and the flow through was collected. The column was washed 
with 5 column volumes of Lysis Buffer, then with 5 column volumes of Lysis buffer 
supplemented with 1 M sodium chloride, followed with a further wash with 5 
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column volumes of Lysis buffer. The protein was eluted with 20 mM glutathione pH 
7.0 (made up with Lysis buffer). All wash fractions were collected and analysed by 
SDS-PAGE. Columns were stored in 20% ethanol. 
 
2.3.1.5 Size exclusion chromatography 
Size exclusion chromatography was performed on a Superdex 75 (26/60) column 
(GE healthcare) attached to an Akta prime system at 4 °C. The absorbance of the 
sample was monitored at 280 nm throughout. The column, which is stored in 20% 
ethanol, was washed with water and equilibrated with appropriate buffer. 5 mL of 
protein sample (after affinity chromatography) was loaded onto the column using a 5 
mL injection loop. The method for size exclusion chromatography is summarized in 
Table 7. Upon completion of the method, the column was washed with water and 
stored in 20% ethanol. Each fraction from within the peak of the UV trace was 





Table 7 – Method used for size exclusion chromatography  












0 0 2 0 1 Load No No  
10 0 2 0 1 Inject Yes Yes 
20 0 2 0 1 Load No Yes 
110 0 2 3 1 Load No Yes 
320 0 2 0 1 Load No No 
 
2.3.1.6 Protein concentration  
Protein was concentrated using an Amicon Ultra centrifugal filter (Millipore), by 
centrifugation at 2770x g until the desired concentration was reached. The 
concentration of protein was routinely measured using a protein assay reagent dye 
(Bio-Rad). 200 µL of dye was added to 800 µL of water and then either 20 µL of 
buffer (blank) or protein sample was added to this mix. The solutions were placed in 
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a plastic cuvette (Brand) and the absorbance measured at 595 nm in a 
spectrophotometer (Helious β). Firstly the spectrophotometer was zeroed against the 
blank then the absorbance of the sample was measured. In the assay an absorbance of 
1 signifies a concentration of 1 mg/mL. The assay is accurate for readings between 
0.2-0.8, if outside this range the volume of protein sample added should be adjusted 
accordingly.  
 
2.3.1.7 Protease expression 
 
Both SUMO and PreScission protease were routinely produced in house (glycerol 
stock donated by Thomas Edwards, University of Leeds). 1 L of 2xYT was 
inoculated with 10 mL of each overnight culture. Cells were grown 37 °C until an 
OD600 0.6-0.8 was reached, induced with 0.5 mM IPTG and incubated for 18 hours.  
Cells were harvested by centrifugation, lysed by sonication; soluble protein was 
separated from the insoluble fraction by centrifugation. SUMO-protease was purified 
by nickel affinity chromatography and PreScission-protease was purified by 
glutathione affinity chromatography.  
  
2.3.2 Specific Protein expression 
 
2.3.2.1 p300 and HIF-1α/p300 fusion construct protein expression 
 
10 mL BL21 Gold cells containing GST-p300/GST-HIF-1α/p300 fusion construct   
overnight culture were used to inoculate 1 L of 2xYT (supplemented with ampicillin) 
in a 2 L baffled flask. Cells were grown to OD600 = 0.6-0.8, induced with 0.1 mM 
IPTG supplemented with 50 µM zinc sulphate and incubated for 18 hours at 18 °C. 
Cells were harvested by 20 minute centrifugation (3500 × g at 4 °C). Cell pellets 
were resuspended in Lysis buffer, 5 U DNase I and 2 mM MgCl2 were added to the 
suspensions prior to lysing the cells. Cells were disrupted by sonication (soniprep 
150, 200 mm probe) on ice in a glass beaker, 3 cycles of sonication, 20 seconds on 
40 seconds off. Then the soluble protein was separated from insoluble protein by 
centrifugation (13000 × g for 25 minutes at 4 °C). The supernatant was decanted and 
filtered through a 0.45 µm Amicon syringe filter. GST-p300/GST-HIF-1α/p300 
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fusion construct   was purified by glutathione affinity chromatography. The GST was 
cleaved by PreScission protease (1 mg of protease per 20 mg of GST-p300, 
incubated for 16 hours at 4°C) and separated from p300 and HIF-1α/p300 fusion 
construct   by size exclusion chromatography.  
 
p300 mutants (H20A, L47M and I71M) were all purified in the same way as wild-
type p300.  
 
2.3.2.2 15N-p300 protein expression 
 
15N-GST-p300 was purified after autoinduction with a glucose to lactose ratio 1:4; 
the full media recipe is outlined in Table 8. The cells were grown at 37 °C for four 
hours and then 20 °C for 40 hours. Cells were harvested and the protein purified in 






Table 8 – Composition of the media used to express 15N-p300 
100 mL 10x M9 medium 
60 g Na2HPO4  /L 
30 g KH2PO4 /L 
5 g NaCl /L 
5 g N15H4Cl 
10 mL 100x Trace elements 
5 g EDTA /L 
0.83 g FeCl3.6H2O /L 
84 mg ZnCl2 /L 
13 mg CuCl2.2H2O /L 
10 mg CoCl2.6H2O /L 
10 mg H3BO3 /L 
1.6 mg MnCl2.6H2O /L 
20 mL 50x 5052 
25 % glycerol (w/v) 
2.5 % glucose (w/v) 
10 % lactose (w/v) 
1 mL 1 M MgSO4 
0.3 mL 1 M CaCl2 




















2.3.2.3 Biotinylation of p300 
Biotin-depsipeptide coupling to the N-terminal glycine of p300 was catalysed by 
sortase A171. The reaction consisted of 100 µM p300, 300 µM biotin-depsipeptide 
and 20 µM sortase (both produced in house by Dan Williamson, University of 
Leeds), the reaction was incubated at 37 °C with agitation for 3.5 hours. The biotin-
p300 was separated from the unreacted biotin-depsipeptide by dialysis and from the 
sortase A by nickel affinity chromatography (the sortase A has a His tag). The 
biotinylation was confirmed by western blot and mass spectrometry. 
 
 
2.3.2.4 eIF4E protein expression  
Overnight cultures were grown in minimal media (Table 9) and 400 µL of this 
overnight culture was used to inoculate 400 mL auto-induction media ( 
Table 10). The culture was grown for 4 hours at 37 °C with aeration, then reduced to 
20 °C with aeration until no more cell growth was apparent (no more increase in 
OD600). 
1 mL Thiamin (1 mg/mL) 
1 mL 1 M ampicillin 
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Table 9 – Autoinduction overnight media 
Solution Composition  Volume (µL) 
H2O H2O 4775 
MgSO4 1 M MgSO4 10 
1000x trace elements 50 mM FeCl3 
20 mM CaCl2 
10 mM MnCl2 
2 mM CoCl2 
2 mM CuCl2 
2 mM NiCl2 
2 mM Na2MoO4 
2 mM H3BO3 
1 
40 % glucose 40% glucose (w/v) 62.5 
25% aspartate 25% aspartate (w/v) 50 
50x M 1.25 M Na2HPO4 
1.25 M KH2PO4 
2.5 M NH4Cl 




Table 10 – Autoinduction expression media 
Solution Composition  Volume (mL) 
ZY media 5 g/L yeast extract 
10 g/L tryptone  
383 
MgSO4 1 M MgSO4 0.8 
1000x trace elements See Table 5 1 
50x 5052 25% glycerol (w/v) 
2.5% glucose (w/v) 
10% lactose (w/v) 
8 
50x M See Table 9 8 
 
Cells were harvested by centrifugation (20 minutes 3500 × g at 4°C) and 
resuspended in 15 mL Lysis buffer per 400 mL culture. 5 U DNase I and 2 mM 
MgCl2 were added to the suspensions prior to lysing the cells. Cells were disrupted 
by sonication, 3 cycles of sonication, 20 seconds on 40 seconds off. Then the soluble 
protein was separated from insoluble protein by centrifugation (13000 × g for 25 
minutes at 4°C). The supernatant was decanted and filtered through a 0.45 µm 
Amicon syringe filter. SUMO-eIF4E was purified by nickel affinity chromatography 
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and then by size exclusion chromatography. The SUMO was then cleaved by SUMO 
protease and separated by a second a Ni2+ column after dialysis. eIF4E was then 
further purified by a second size exclusion chromatography.  
 
 
2.3.2.5 Adhirons  
Adhirons were in pET-11 and expressedin Rosetta 2 cells. 10 mL overnight culture 
was used to inoculate 1 L of 2xYT in a 2 L baffled flask, cells were were grown to 
OD600 = 0.6-0.8 and induced with 0.1 mM IPTG and incubated for 18 hours at 18 °C. 
Cells were harvested by 20 minute centrifugation (3500 × g at 4°C). Cell pellets were 
resuspended in Lysis bufer. 5 U DNase I and 2 mM MgCl2 were added to the 
suspensions prior to lysing the cells. Cells were disrupted by sonication, 3 cycles of 
sonication, 20 seconds on 40 seconds off. Then the soluble protein was separated 
from insoluble protein by centrifugation (13000 × g for 25 minutes at 4°C). The 
supernatant was decanted and filtered through a 0.45 µm Amicon syringe filter. The 
adhirons were purified by nickel affinity chromatography and then by size exclusion 
chromatography. 
 
2.3.3 Protein characterization 
 
2.3.3.1 SDS PAGE gel electrophoresis 
Sodium dodecyl sulphate polyacrylamide (SDS-PAGE) gel electrophoresis was 
performed based on the method described by Lamemmli172. 15 % gels were prepared 




Table 11. Samples were mixed with loading buffer in a 1:1 ratio and boiled for 10 
minutes and were electrophoreses through SDS PAGE gels in SDS running buffer at 
35mA. The broad range molecular marker (NEB 2-212 kDa) was included in each 
gel. Proteins were visualized using coomassie blue stain (45% (v/v) methanol, 10% 
(v/v) acetic acid, 0.25% (w/v) coomassie brilliant blue R-250) and destained in 30% 






Table 11 – Composition of a 15 % SDS PAGE gel 
Solution 15% Resolving gel Stacking gel  
H2O 3.3 mL 2.1 mL 
30% bis-acrylamide 
(37.5:1) 
4 mL 0.5 mL 
1.5 m Tris (pH 8.8) 2.5 mL - 
1 M Tris (pH 6.8) -  0.38 mL 
10% SDS 100 µL 30 µL 
10% APS 100 µL 30 µL 
TEMED 10 µL 10 µL 
 
 
2.3.3.2 Mass spectrometry 
To confirm the mass of each protein 1 mg/mL of protein was analysed by high mass 
liquid chromatography mass spectrometry (LC-MS). The column was reverse phase; 
the method involved gradient elution of water in acetonitrile with 0.1% formic acid. 
Analysis was conducted on a Waters-Micromass ZMD spectrometer using 
electrospray ionization. 
 
2.3.3.3 Circular Dichroism (CD) Spectroscopy 
Spectra were recorded on a chirascan circular dichroism spectropolarimeter (Applied 
Photophysics), at 20 °C, using 1 mm cells and a scan speed of 5 nm/min. The spectra 
were averaged over 3 repeats with a buffer baseline subtracted. Protein 
concentrations of approximately 0.2 mg/mL were used (although the exact 
concentration was used to allow determination of MME). The helical content of each 









2.3.4 Biophysical Assays 
 
2.3.4.1 Fluorescence Anisotropy  
 
2.3.4.1.1 Direct binding 
p300 or eIF4E protein was serially diluted in buffer (different buffers are used for 
different protein targets, outlined in Table 4) labeled peptide (40 nM) (FITC-HIF-1α 
or FITC-eIF4G) was added, and the plates were then incubated for 30 minutes at 
room temperature. Each experiment was run in triplicate and the fluorescence 
anisotropy measured using a EnVision 2103 MultiLabel plate reader (Perkin Elmer) 
with excitation at 480 nm and emission at 535 nm (5 nm bandwidths). In parallel, a 
control experiment was performed in which no labeled peptide was added and the 
volume made up with additional buffer, this blank was subracted from the raw data 
each of the three repeats. The intensity was calculated for each point using Equation 
1 and used to calculated anisotropy using Equation 2. From a plot of anisotropy 
against protein concentration the minimum and maximum anisotropies were obtained 
using a logistic sigmoidal fit in OriginPro 8.6. This allowed the conversion to 
fraction bound (Equation 3). The data were then fitted using Equation 4 in OriginPro 
8.6 to determine the dissociation constant, Kd. 
 
I = (2PG) + S (Equation 1)  
R = (S - PG) / I (Equation 2)  
Lb = (R - Rmin) / ((λ(Rmax – R)) + R – Rmin) (Equation 3)  
y=((Kd +x+[FL])-√((Kd +x+[FL])2 -4x[FL]))/2 (Equation 4)  
 
R= anisotropy, I= total intensity, P=perpendicular intensity, S= parallel intensity, G 
= an instrument factor set to 1, Lb = fraction ligand bound, λ = Ibound/Iunbound = 1, 
[FL] = concentration of fluorescent peptide, Kd = dissociation constant, y = Lb 
multiplied by [FL], x = protein concentration 
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2.3.4.2 Competition  
Unlabeled peptide (HIF-1α/eIF4G) or compound was serially diluted across a 384 
well plate in buffer (Table 4) and 40 nM labeled peptide and protein were added 
sequentially (0.1 µM p300 or 1 µM eIF4E). The plates were then incubated for 30 
minutes at room temperature. Each experiment was run in triplicate and the 
fluorescence anisotropy measured using an EnVision 2103 MultiLabel plate reader 
(Perkin Elmer) with excitation at 480 nm and emission at 535 nm (5 nm 
bandwidths). A control experiment was performed in which no labelled peptide was 
added and the volume made up with additional buffer, this blank was subtracted from 
the raw data each of the three repeats. Intensity and anisotropy were calculated as 
above using Eq. 1 and Eq. 2 respectively. Plots of anisotropy against unlabeled 
peptide were fitted to a logistic sigmoidal dose response model to determine an IC50. 
 
2.3.4.2  Isothermal Titration Calorimetry 
ITC experiments were conducted at 25 °C in 40 mM sodium phosphate, 100 
mM sodium chloride and 5% glycerol. 10 µM p300 was present in the cell and 
100 µM HIF-1α in the syringe. One injection of 10 µL for 20 seconds of HIF-
1α was made every 300 seconds for 30 injections. Buffer was also titrated in to 
protein to give a baseline integral. This baseline was then subtracted to give a 
baseline-subtracted thermogram. This thermogram was then modeled by one-




1 pM biotin-p300 was isolated on to one flow cell of a streptavidin chip (120 
response units), at a flow rate of 5 uL/min, while the other flow cell was left 
unfunctionalised. 5 concentrations of Ad34 (100 nM-1 µM) were tested. Each 
concentration was flowed over both the functionalised and the unfunctionalised flow 
cells at 40 µL/min and the on- and off-rates were calculated using the Biacore 
software. The on- and off-rates were used to calculate the Kd. 
 
d[AB]/-dt = ka[A][B] • d[AB]/dt = kd[AB] (Equation 5) 




The BLitzTM (ForteBio) dip and read Ni biosensors were used to estimate the affinity 
of p300 (10 µM) binding to immobilized Adhirons (1 µM) and a global fit was used 
to calculate the binding affinities using the advanced kinetic software. 
 
2.4 Phage Display Experiments 
 
2.4.1 Peptide phage display 
 
The biotin-p300/biotin-eIF4E (10 pM) was mixed with each phage library (10 µL of 
1x1013 plaque forming units (pfu) /mL), incubated at room temperature for one hour, 
then isolated on to a streptavidin plate via the biotin tag (ten minute incubation), 
additional biotin (0.1 mM final concentration) was added to each well to block the 
unbound streptavidin (5 minute incubation at room temperature). The wells were 
then emptied and washed 3 times with high and low salt TBS-T (0.5 M NaCl and 1.5 
M NaCl respectively). The phage were then eluted (500 µM HIF-1α/500 µM eIF4G). 
To re- amplify the phage, ER2783 cells were grown to mid- log phase (OD600 = 0.6-
0.8) and the elutes were added (one elute condition per culture). The cultures were 
then grown at 37 °C with vigorous shaking (300 rpm) for 4.5 hours, although the first 
10 minutes of this growth period the shaking was set to 80 rpm. To isolate phage the 
cultures were then pelleted and the supernatant was mixed with a chilled 20% PEG 
8000/2.5 M NaCl solution and the mixture was centrifuged at 13,000 rpm for 20 
minutes (at 20 °C). The pellet was resusspended in 1 ml TBS, spun down at 13,000 
rpm, then the chilled 20 % PEG 8000/2.5 M NaCl solution was again added to the 
supernatant and incubated on ice for 30 minutes. The mixture was again centrifuged 
at 13,000 rpm for 5 minutes and the pellet resuspended in TBS. 1011 pfu (as 
calculated by a phage titer as per the NEB phage titer protocol) were added to start 
the next round of panning, in total three panning rounds were completed. 
 
2.4.1.1 Enrichment ELISA 
Streptavidin plates coated in biotin-p300/biotin-eIF4E (5 µg/mL) were incubated at 
room temperature for 30 minutes. The plates were washed with TBS-T to remove 
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excess target. 1 x 1010 pfu of re-amplified phage from each panning elute were added 
and incubated for one hour at room temperature, ( and also added to an uncoated well 
as a control). The plates were washed with TBS-T and anti M13-HRP antibody was 
added and incubated for one hour, washed with TBS-T, developed with 100 µl/well 
TMB. Plate was read at 370 nm. 
 
2.4.1.2 Peptide Phage Display Sequencing 
DNA was isolated from pan elute 1 and 3 and from the unpanned library and PCR 
was used to amplify the DNA. Blunt end repair of the resultant ds-DNA was 
conducted using Illumina Paired-end DNA sample preparation kit. The primers with 
the unique bar codes (Illumina adaptors) were ligated to each fragment and the 
fragments with the adaptors were amplified by a second round of PCR. This resulted 
in 12 different pools which each had a unique bar code; the unpanned 7mer and 
12mer libraries were also sequenced to assess the presence of any propagation 
related clones at the start of the experiment.  Sequencing was performed by the 
Centre for Genomic Research, University of Liverpool. The Matlab analysis was 
performed (Jonathan Stott, AstraZeneca) using scripts based on published code173 
and modified for correctness and the specific sequences used. Modifications used 
were: 
• Cope with smaller files by not discarding partial blocks 
• Allow for variable length adaptor sequences, and unequal adaptor sequences 
• Allow for variable file tags (i.e. not just Illumina) 
• Allow for variable length peptide libraries (tested with 7-mer and 12-mer) 
 
Scripts were run over all 'pure' 7-mer and 12-mer libraries. Locus specific sequences 
rather than full primers were used and the quality control cut off was A (quality score 
of 32, the original scripts used a quality control of 15173. 
 
2.4.2 Adhiron phage display 
 
p300 was expressed and biotinylated as described above. Biotin-p300 was added and 
incubated on pre-blocked streptavidin plate, the plate was then washed using a 
KingFisher robotic platform (ThermoFisher) and 1012 cfu of the pre-panned phage 
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library was added and incubated for 2.5 h with shaking. Wells were washed ten times 
and eluted with 100 µL 0.2 M glycine (pH 2.2) for ten minutes neutralized with 15 
µL 1 M Tris-HCl (pH 9.1), further eluted with triethylamine 100 mM for 6 min, and 
neutralised with 1 M Tris–HCl (pH 7). Eluted phage were used to infect ER2738 
cells for 1 h at 37 °C and 90 rpm then plated onto LB agar plates supplemented 
carbenicillin and grown overnight. All colonies were scraped into 5 mL of 2xYT 
with carbenicillin and 1 x 109 M13K07 helper phage were added. After an overnight 
incubation phage were precipitated with 4 % PEG 8000, 0.3 M NaCl and 
resuspended in 1 ml of 10 mM Tris, pH 8.0, 1 mM EDTA (TE buffer). 2 µL phage 
suspension was used for the second round panning using streptavidin magnetic beads 
as opposed to streptavidin plates (Invitrogen); otherwise the second pan was 
conducted in the same way as the first pan. The third pan was conducted using 
neutravidin high binding capacity plates (Pierce). During the fourth and final pan 50 
µM of HIF-1α peptide was added as competitor before elution. After final pan 
colonies were picked, an ELISA was conducted to select positive clones (in the same 
way as the enrichment ELISA) which were sent for Sanger sequencing 
 
 




2.5.1.1 General techniques  
2.5.1.1.1 Factorials 
Initial factorial screens were set up routinely using the commercially available 
screens: 
Hampton Research: Crystal Screen I and II, Index, Salt RX 
Emerald Biosystems: Wizard I, II, III and IV  
Molecular Dimensions: Morpheus, Midas, Pact   
 
Screens were either set up manually or using a Douglas Instruments Oryx 6 plate 
loader/NT8 robotics system. Typically drops of 0.2 µL of protein in a 1:1 drop ratio 
with mother liquor were used in 96 well MRC 2-drop sitting drop plates (Molecular 
 57 
Dimensions). Wells were filled with 80 µL mother liquor and sealed with Viewseal 
pressure adhesive clear seals and incubated at 4 °C, 18 °C and 25 °C.   
2.5.1.1.2 Optimisation  
Initial hits from the factorial screens were optimised in 24 well hanging drop plates, 
typically with 1 µL protein and 1 µL mother liquor (although this ratio was varied). 
Initial optimisations centred on the variation of precipitant and pH.  
2.5.1.1.3 Cryo cooling 
Crystals were picked using a nylon loop mounded on a cryo pin (Hampton Research) 
and submerged in to 1 µL of mother liquor + appropriate cryo protectant. Crystals 
were then immediately immersed in liquid nitrogen for storage.   
Data collection 
All data was collected at Diamond light source at various beamlines. 
 
2.5.1.2 Apo_eIF4E crystallography  
eIF4E was purified into buffer 20 mM Hepes pH 7.5, 100 mM sodium chloride, 1 
mM DTT  and 5 % glycerol. Crystals grew overnight in the condition 17.5% PEG 
4000, 0.2 M ammonium citrate, 3 % trehalose at 25 °C. Crystals were cryo-protected 
with 20 % glycerol. Crystals diffracted to 2.4 Å at diamond light source. The 
structure was solved by molecular replacement using PDB:2W97174, using Phaser175 
and the structure was then refined using Phenix176 and Refmac177. Structure 
determination was primarily performed by Thomas Edward (University of Leeds). 
 
2.5.1.3 Adhiron crystallography  
Ad34 was concentrated to 10 mg/mL and crystalized in the condition 0.8 M di-
sodium succinate pH 7. The crystals grew overnight at 18 °C. They were picked and 
cryo protected with 20 % glycerol. The structure was solved using molecular 
replacement using PDB:4N6U122. Initially Ad34 was subjected to molecular 
replacement with no loops present using the program Balbes178, and Buccaneer179 
was used to rebuild the loops. The structure was then refined using Phenix176 and 
Refmac177. Structure determination was primarily performed by Thomas Edward 
(University of Leeds). 
 58 
2.5.2 NMR 
The NMR experiments were all conducted in 10 mM Tris-HCl pH 6.9, 50 mM NaCl, 
2 mM DTT and 2% glycerol. PDDP1 peptide (300-750 µM) was titrated into 230 µM 
15N-p300. Data were collected on a 600 MHz Agilent NMR system at 25 °C and. 
The size of the shift for each peak was measured and those with the largest shift were 
mapped on to p300 (assignments from BMRB: 6268180). Analysis was conducted 
using CCPN Analysis software. 
 
2.5.3 SAXS 
p300, co-purified HIF-1α/p300 (co-purificatoin was completed by incubation of HIF-
1α and p300 in a 1.5:1 molar ratio for 30 minutes on ice and purification by size 
exclusion chromatography) and HIF-1α/p300 fusion construct were purified in to the 
buffer 20 mM Tris pH 7.5, 100 mM sodium chloride, 1 mM DTT and 5 % glycerol, 
various concentrations were tested (outlined in the HIF-1α/p300 results section). 
SAXS experiments were conduced at Stanford Synchrotron Radiation Lightsource. 
Data was analysed using ATSAS program suite. 
 
2.5.4 Docking 
Docking was performing by George Burlsem (University of Leeds) using 
HADDOCK (High Ambiguity Driven protein−protein Docking)181. Using the NMR 
structure of p300 (PDN:1L8C182) and the crystal structure of Ad34. The restraint 











Chapter 3 : HIF-1α/p300  
 
3.1 Introduction to HIF-1α/p300 
3.1.1 Hypoxic response  
 
Hypoxia is an almost universal hallmark of solid tumours; the ability to adapt to 
hypoxic environments is crucial to their growth and survival155, 183.  In the main, this 
adaption is mediated by transcriptional activation of genes that facilitate short-term 
adaptive mechanisms (e.g. increased vascular permeability, vasodilatation, glucose 
transport, switch to anaerobic metabolism), as well as long-term adaptive 
mechanisms (e.g. angiogenesis)184-187. This coordinated homeostatic response is 
mediated in large part through the activation of the transcription factor hypoxia-
inducible factor 1 (HIF-1). HIF-1 is responsible for the activation/transcription of 
>100 genes which are crucial for the cells adaptation to hypoxia, including 
oncogenes and the inactivation of tumor suppressor genes. Tumour hypoxia and 
overexpression of HIF-1 have been associated with resistance to some therapies, 
increased risk of invasion and metastasis, and poorer outcome in malignancies188. 
HIF-1 activity in tumors is dependent upon availability of the HIF-1α subunit, the 
levels of which increase under hypoxic conditions (as discussed in Chapter 1 : 
Introduction). The near universality of hypoxia in human tumors and the centrality of 
the HIF-1 pathway in adapting to the hypoxic environment suggest that inhibition of 
the HIF-1 pathway may have therapeutic utility as an antitumor strategy. Inhibition 
of the function of HIF-1 in tumors may reduce angiogenesis and thereby contribute 
directly to tumour cell death189.  
  
HIF-1 is a heterodimer consisting of two subunits; an oxygen-sensitive HIF-1α and a 
constitutively expressed HIF-1β, both subunits are members of the basic helix–loop–
helix (bHLH) proteins of the PER-ARNT-single-minded protein (SIM) (PAS) family 
of transcription factors190. The regulation region of HIF-1α is dependent on the 
Oxygen Dependent Degradation Domain (ODDD) and two transactivation domains: 
the N-terminal transactivation domain or N-TAD and the C-terminal transactivation 
domain or C-TAD191; located towards the C-terminus. The C-TAD is involved in 
modulating the transcriptional activation of HIF-1α under hypoxic conditions, in 
contrast to the N-TAD, which is involved in the stabilisation of HIF-1α. The N 
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terminal region of HIF-1α has a basic helix-loop-helix (HLH) domain and enables 
binding of HIF-1α to the hypoxia response elements (HRE), located in the enhancer 
and promoter regions of various genes143. The domain structure of HIF-1α is 





The stability and transcriptional activity of HIF-1α increases under hypoxic 
conditions. Regarding stability: HIF-1α is continuously expressed at a low level in 
the cell, however in normoxic conditions HIF-1α is rapidly degraded, most 
prominently via a Von Hippel–Lindau tumor suppressor (pVHL)-mediated ubiquitin-
proteasome pathway143. This process is initiated by the hydroxylation of two proline 
residues within the ODDD by the enzyme prolyl hydroxylase-domain protein 
(PHD)159. Upon hydroxylation, pVHL is able to bind to HIF-1α, which subsequently 
allows the recruitment of the E3 ligase complex. This allows the attachment of 
ubiquitin via the lysine residues of HIF-1α, thereby marking HIF-1α for degradation. 
Due to the rapid nature of this pathway HIF-1α has a half life of less than 5 minutes 
in normoxic conditions; resulting in no detectable protein in normoxic cells160. 
However, in hypoxic environments oxygen availability is limited, therefore 
hydroxylation of the prolines is inhibited, resulting in an increased level of HIF-1α. 
Although the most prominent, the pVHL pathway is not the only pathway controlling 
levels of HIF-1α. Another mechanism is the recruitment of the murine double minute 
2 (Mdm2) ubiquitin-protein ligase to HIF-1α by binding of the tumor suppressor p53, 
which results in a decrease in HIF-1α levels by promoting Mdm2-mediated 
ubiquitination and proteasomal degradation of HIF-1α192. In addition, Hsp90 
interacts directly with HIF-1α and has been suggested to promote a conformational 
change in HIF-1α, which leads to inhibition of the dimerization with HIF-1β193. 
Figure 11 - Cartoon representation of the domain structure of HIF-1α 
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Regarding transcriptional activity: cells transduce decreased O2 concentration into 
increased HIF-1 activity via an O2-dependent post-translational modification. In 
hypoxic conditions the C-TAD is able to interact with transcriptional co-activators, 
such as p300 (CH1 domain). This interaction is unable to occur in normoxia due to 
the oxygen-dependent hydroxylation of Asn803, located within the C-TAD. 
Hydroxylation of Asn803 is mediated by an asparaginyl hydroxylase, known as factor 
inhibiting HIF-1 (FIH-1), which prevents HIF-1α from interacting with the 
transcriptional co-activators such as the CH1 domain p300194.  As a result, in 
hypoxic conditions, there is a decreased rate of HIF-1α degradation, so more HIF-1α 
is available, as well as an increase in transcriptional activity195.  
The co-activator protein p300 is paralogous to CBP, they are thought to control gene 
expression by relaxation of the chromatin structure at the gene promoter via  intrinsic 
histone acetyltransferase activity, they also recruit basal transcriptional machinery 
including RNA polymerase to the promoter196. The multidomain proteins p300 and 
CBP are very similar in structure197, they consist of key domains including; the 
nuclear interaction domain (Nu), the CREB and MYB interaction domain (KIX), 
cysteine/histadine regions (CH/TAZ), a histone acetyltransferase domain (HAT) and 
a bromodomain (Br)198. The structure if p300/CBP is summerised in Figure 12. The 
CH1 domain of both proteins interacts with the CTAD of HIF-1α, this domain only 










Figure 12 - p300 and CBP domain representation and comparison. A) Cartoon representation if the domain structure of both p300 and CBP. B) Comparison of the amino acid 
sequence of the CH3 domain of p300 and CBP.   
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As is highlighted above there are many different pathways for HIF-1 stabilisation 
and increased activity in hypoxic environments. HIF-1 is also involved in many 
hypoxia signaling pathways.  This is turn means there are many different potential 
targets for small molecule intervention. 
 
3.1.2 Inhibitors of the hypoxic response via HIF-1  
 
There has been much focus on inhibiting elements of the hypoxic response199; HIF-1 
inhibitors can be broadly classified by their mechanism of action. Although, one 
common denominator of most, if not all, HIF-1 inhibitors identified thus far is a lack 
of specificity, indicative of hitting multiple targets and pathways; HIF-1 inhibition 
cannot be easily separated from other activities exerted by these agents199. This 
means that mechanism of action can be difficult to decipher, this is compounded by 
the fact that many of the known inhibitors were discovered through cell-based 
screening, which offers little information regarding the mechanism of action. The 5 
classifications of HIF-1 inhibitors are (1) HIF-1α mRNA expression,  (2) HIF-1α 
protein translation, (3) HIF-1α protein degradation, (4) HIF-1α DNA binding and (5) 
HIF-1α transcriptional activity199. 
 
2.1.2.1 HIF-1α mRNA expression 
It has been suggested that, under hypoxic conditions, levels of HIF-1α mRNA may 
be a limiting factor affecting the rate of HIF-1α protein translation200. Molecule 
EZN-2698 is an RNA antagonist, which is composed of a third-generation 
oligonucleotide; a technology that specifically binds and inhibits the expression of 
HIF-1α mRNA. It has shown potent (IC50 = 1-5 nM) and selective inhibition of HIF-
1α mRNA and protein expression in both normoxia and hypoxia. Mice models 
demonstrated a dose-dependent and highly potent down regulation of endogenous 
HIF-1α and VEGF in the liver. Tumor reduction was found in nude mice implanted 
with DU-145 human prostate cancer cells treated with EZN-2968201. This indicated 
that inhibition of HIF-1α mRNA has potential as a target for cancer therapeutics.  
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2.1.2.2 HIF-1α protein translation 
Several agents have been described that may affect the rate of HIF-1α protein 
synthesis199. One such agent is Topotecan (Figure 13), an FDA approved drug 
currently used as a second line therapy for patients with small cell lung or ovarian 
cancer199. Topotecan works by inhibiting topoisomerase I by inducing the formation 
of stable Top1-DNA cleavage complexes, which in the presence of DNA replication 
generates double strand DNA breaks and cytotoxicity, limiting HIF-1α translation. 
Recently, it has been shown that administration of daily Topotecan in combination 
with the anti-VEGF antibody Bevacizumab exerts synergistic antitumour activity in 
xenograft models, providing a rationale for clinical development of this combination 
strategy202; which, as discussed previously, should limit resistance. Other 
topoisomerase 1 inhibitors have been developed, one such inhibitor is EZN-2208 
(Figure 13). EZN-2208 has better pharmacokinetic properties and a longer half-life 
than Topotecan, making it more suitable for chronic suppression of the HIF-1 
pathway203. Other agents and targets that affect HIF-1α protein translation include; 
Digoxin, a cardiac glycoside, which inhibits the translation of HIF-1α by an mTOR-
independent mechanism, and PX-478, an agent that potentially inhibits HIF-1α 
translation through multiple mechanisms, although non have been confirmed.   
 
Figure 13 – Structure of Topotecan (chem draw image drawn from pubchem, pubchem ID – 
60700) and EZN-2208 (chem draw image drawn from pubchem, pubchem ID – 59443782) 
 
2.1.2.3 HIF-1α degradation pathway 
Heat shock protein 90 (Hsp90) is a molecular chaperone that controls the folding and 
regulates the function of many proteins, including receptor tyrosine kinases, 
serine/threonine kinases, transcription factors and activated oncoproteins204. 
Disruption of Hsp90 function has been shown to promote HIF-1α degradation via a 
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novel, oxygen-independent E3 ubiquitin ligase and diminishes HIF-1α transcriptional 
activity205. In the presence of Hsp90 inhibitors HIF-1α undergoes VHL-independent 
proteasomal degradation205; HIF-1α heterodimers may also not acquire the proper 
conformation and therefore fail to recruit cofactors important for HIF-1-mediated 
transcriptional activity206. The first Hsp90 inhibitor was a natural product, 
Galdanamycin (Figure 14), which exerted its inhibitor activities by competing with 







Figure 14 – Structure of Geldanalycin (chem draw image drawn from pubchem, pubchem 
ID – 5288382) 
 
2.1.2.4 HIF-1 binding to DNA  
Inhibition of HIF-1 DNA binding to the hypoxia responsive element (HRE); a step 
required for transcription induction, is also a potential mechanism by which small 
molecules may inhibit HIF-1 activity199, 207. Proof of principle was established using 
a cyclic peptide, Echinomycin (Figure 15), which was known to bind DNA in a 
sequence-specific fashion. It was shown that Echinomycin inhibits the DNA/HIF-1 
interaction more potently than DNA/AP-1 or DNA/NF-KB, binding, providing 
evidence of selective inhibition based on recognition of DNA sequences207. 













Figure 15 – Structure of Enhinomycin (chem draw image drawn from pubchem, pubchem 
ID –23724556) 
 
2.1.2.5 HIF-1α transcriptional activity 
Dimerization of HIF-1α and HIF-1β is critical for both transcriptional activity and 
DNA binding and therefore has been described as an optimal point of interception209. 
The Tavasolli group used a genetically encoded HTS platform210, 211 for the 
identification of cyclic peptides that are able to disrupt the dimerization. The cyclic 
peptide cyclo-CLLFVY was identified from a plasmid encoded library of 3.2 million 
cyclic peptides. The compound was tested in vitro and in cells and was shown to 
disrupt HIF-1 dimerization by binding the PAS-B domain of HIF-1α209.  
Inhibition of the proteasome leads to an accumulation of HIF-1α212, although, this 
HIF-1α that accumulates is transcriptionally inactive213. A proteasome inhibitor, 
Bortezomib (Figure 16), has been FDA approved. As well as inhibiting the 
proteasome at low nanomolar concentrations Bortezomib was also able to limit the 
HIF-1α/p300 interaction, by improving the binding of FIH to HIF-1α214. FIH is a 
dioxygenase that hydroxylates Asn803 in the C-terminal transactivation domain of 
HIF-1α; this prevents the recruitment of the co-activator p300. There have been 
efforts to directly disrupt the HIF-1α/p300 interaction, thus far with limited success. 
It was reported that an agent Chetomin (Figure 16) inhibited HIF-1α by disrupting 
the HIF-1α/p300 interaction189, however work by the Schofield group has 
demonstrated that Chetomin works by ejecting structurally important zinc from 
p300, therefore destroying one of the binding partners not directly disrupting the 
interaction215.  As p300 has other roles within the cell this is not a viable therapeutic. 
Therefore more work is needed to develop inhibitors of the HIF-1α/p300 interaction. 
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As discussed in the introduction current high throughput screens are not often 
amenable to PPIs, therefore focus may shift towards rational/structure based design 
methods. To do this, a detailed understanding of the interaction, both structurally and 




Figure 16 – Structure of Bortezomib (chem draw image drawn from pubchem, pubchem ID 




3.1.3 Structural information of HIF-1α/p300 
The starting point for structure based and rational drug design of an inhibitor is to 
analyse the structural and biophysical data of the interaction. The interaction between 
the CH1 domain of p300 and the C-TAD of HIF-1α Figure 17182 was solved by using 
multidimensional NMR methods (PDB:1L8C182, 1L3E197).  
 68 
 
Figure 17 - Pymol illustration of the interaction between p300 (green) and HIF-1α (blue). 
PBD ID:1L8C182 
 
Previous studies have highlighted key regions of HIF-1α (helix 2 and helix 3) to 
interacting with the CH1 domain of p300 by hydrophobic or polar interactions197. 
Further mutational studies such as alanine scanning have indicated key binding 
residues of HIF-1α216. Residues Cys800 and Asn803217-219 located in helix 2 have been 
highlighted as key binding residues in cellular screens. However the two residues are 
not hydrophobic but polar; which is unusual for PPIs and the binding events from 










Figure 18 -Pymol image illustrating the key binding residues (cyan) of HIF-1α helix 2 
(blue) binding to p300 (green). PDB:1L8C182. 
 
Helix 3 contains 3 key binding residues, Leu818, Leu822216 and Val825197; three 
hydrophobic residues, so this is a hydrophobically driven interaction. The binding of 
helix 3 is illustrated in Figure 19. 
 
 
Figure 19 - Pymol illustration of the key binding residues (cyan) of HIF-1α (blue) helix 3 
binding to p300 (green). PDB:1L8C182. 
 











further analysis is would be useful locate a binding hot-spot to target with a small 
molecule. A fluorescence polarisation (FP) experiment was conducted220 to compare 
interactions of various peptide lengths derived from HIF-1α C-TAD with p300; the 
HIF-1α peptide lengths tested are illustrated in Figure 20220.  The peptides were N-
terminally labelled with fluorescein (FITC). 
 
 
Figure 20 - Peptide lengths tested for binding affinity. Image adapted from220 
 
The binding affinities for the peptides are outlined in Table 12220. From this 
experiment the authors concluded that the C-terminus of HIF-1α C-TAD is important 
for binding, this correlates with previous studies197, 216, 218, 219. However the data does 
not narrow down the interaction area to one of the individual helices and the 
interaction area is still relatively large. 









In 2010 work by the Arora group attempted to decrease the size of the interaction 
interface by focusing on one of the two key helices. An ITC binding experiment 







FITC-HIF-1α 776–826 189 ± 45 nM 
FITC-HIF-1α 786–826 166 ± 66 nM 
FITC- HIF-1α 788–822 > 3000 nM 
FITC-HIF- 1α 776–813 > 3000 nM 
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AcTAADCEYNAR), which corresponds to the helix 2 region; encompassing the key 
binding residues Cys800 and Asn803 was conducted.  
They found that this short peptide region had a binding affinity to p300 of 825 nM. 
They recognised that synthetic mimics of these domains could potentially inhibit 
HIF-1α/p300 interaction and as a result down-regulate the expression of genes 
encoding vascular endothelial growth factor (VEGF) and its receptor VEGFR-2, 
which are involved in the induction of new blood vessels (angiogenesis) in solid 
tumors. As discussed in the introduction short peptides typically require stabilizing 
moieties to retain their folded conformation once excised away from the protein 
environment. To stabilize this helical region they utilized the hydrogen bond 
surrogate (HBS) approach. They made three hydrogen bond surrogates (HBS-3 was a 
negative control) and used CD to show all 3 hydrogen bond surrogates had a helical 
component, and a higher % of helicity than the unconstrained peptide. The potential 
for the HBSs to down-regulate the HIF-1α induced transcription of VEGF gene in 
HeLa cells under hypoxic conditions was assessed by real time quantitative RT-PCR, 
HBS-2 showed a good level of % transcriptional inhibition (45% comparable to 
Chetomin) (positive control) 50%). HBS-2 had a binding affinity for p300 by ITC of 










Table 13 - Summary of biophysical and in vitro data for peptides designed to target HIF-
1α/p300 interactions217. 




40 950 ± 90 0 ± 3 
HBS-2 
 
53 420 ± 35 45 ± 8 
HBS-3 
 
51 >>2200 2 ± 7 
Peptide AcTAADCEYNAR 15 825 ± 50 8 ± 3 
Chetomin - - 120 ± 25 50 ± 5 
 
Further analysis has indicated that HBS-2 does not disrupt the interaction by 
denaturation of p300 in the same way as has been shown with Chetomin; HBS-2 
does not alter the CD spectrum of p300, indicating that the structure of p300 is not 
altered dramatically (i.e. unfolded) in the presence of HBS-2. Furthermore a cell 
viability assay demonstrated that HBS-2 does not display significant cytotoxicity217.  
This work would indicate helix 2 is a promising target; however further work by this 
group has focused on the helix 3 region, resulting in doubt as to which helix is best to 
target. A computational alanine scan was conducted which suggested that Leu819 was 
not a significant contributor to binding affinity as was initially suggested216; instead 
Leu822, Asp823 and Gln824 were identified as key binding residues221. In a similar way 
to the piece of work described previously, HBS peptides were prepared, although this 
time mimicking the helix 3 region (Leu822, Asp823 and Gln824), HBS-1 was the 
molecule under investigation (expected to have the highest potency), HBS-2 had a 
point mutation of a key binding residue (Leu822-Ala822), so would be expected to bind 
with a lower affinity, acting as a negative control; a peptide (an unconstrained 
analogue of HBS-1), was also made allowing for the evaluation of the effect of helix 






Again the constrained peptides showed a characteristic α-helical circular dichroism 
spectroscopic signature in aqueous buffer compared to the unconstrained peptide.  
The affinity of each of these agents for p300 was measured by tryptophan 
fluorescence spectroscopy. As there is one tryptophan in p300, located in the helix 3 
binding pocket (Trp403), it is a sensitive probe for interrogating binding of helix 3 
mimetics. Using this fluorescence method, it was calculated that HBS 1 bound to 
p300 with a Kd = 690 ± 25 nM, this, as expected, was a higher affinity than HBS-2 
(negative control with point mutation) and the unconstrained analogue of HBS-1, 
peptide 3; as a comparison HIF-1α C-TAD786–826 binds p300-CH1 with a K d= 38 ± 
0.14 nM. In addition to the Trp403 fluorescence change experiment, evidence for 
binding in the helix 3 binding pocket has come from HSQC NMR experiments, with 
prominent shifts occurring from residues around the helix 3 binding site, including 
Trp403. In addition it was shown that HBS-1 is able to disrupt the HIF-1α/p300 (Ki = 
1.2 µM) using a fluorescence polarisation competition assay, whilst neither HBS-2 or 
peptide 3 caused reproducible inhibition of the complex221.  
Based on the confirmed ability of HBS-1 to bind p300 and disrupt the p300/HIF-1α 
interaction, the potential of HBS-1 to down-regulate hypoxia-inducible promoter 
activity in cellulo using a luciferase-based reporter gene system was investigated. A 
construct containing five tandem repeats of the HRE consensus sequence found in 
the VEGF promoter (TACGTGGG), cloned upstream of the human CMV minimal 
promoter was used to drive expression of firefly luciferase222. HBS-1 at a 
concentration of 50 µM reduced luciferase expression by 25%. At the same 
concentrations, specificity control HBS-2 and unconstrained peptide 3 were found to 
be less effective. The luciferase reporter assays suggest that treatment with HBS 1 
results in a statistically significant down-regulation of HIF-1α inducible transcription 
in this cell line.  It was confirmed by western blot that the down-regulation was not 
as a result of decreased expression of HIF-1α. The ability of HBS-1 to inhibit 
hypoxia-induced transcription of target genes (VEGFA, SLC2A1/GLUT-1, and 
LOX) was evaluated using real-time quantitative RT-PCR (qRT-PCR) assays. HBS-
1 reduced expression levels of VEGF by 50% at 10 µM and greater than 60% at 50 
µM; showing marked dose dependence. Expression of SLC2A1 (GLUT1) gene, one 
of the markers of glycolysis, showed dose dependent inhibition (50-60%) and LOX, 
the hypoxia-inducible gene that has been shown to promote metastasis, was also 
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decreased in a dose dependent manner (55-70%). An ELISA showed that HBS-1 also 
down-regulated VEGF protein levels in HeLa cells in a dose-dependent manner. As 
with HBS peptide targeted against the helix 2 binding site, this HBS peptide is not 
cytotoxic. The investigators went further using a mouse xenograft tumour model to 
assess the in vivo efficacy of HBS-1. HBS-1 was retained in plasma at much higher 
concentrations compared with the unconstrained peptide, suggesting that the 
internally constrained structure of HBS-1 impacts favourably on serum stability. This 
observation is supported by the fact that proteases largely bind and cleave peptides in 
extended conformations223; the plasma stability of HBS-1 is also consistent with the 
published stability of hydrocarbon-bridged helices224. Throughout the course of the 
treatment and at the experiment endpoint, mice treated with HBS 1 had smaller 
tumours with median tumour volume reduction of 53% compared with the mice from 
the control group; they also showed no distress or significant weight loss.   
Another piece of work by this group again targeted the helix 3 domain, this time 
using an oxopiperazine helix mimetic (OHMs) scaffold225. OHMs are assembled 
from naturally occurring amino acids with the nitrogen atoms of neighbouring 
backbone amides constrained with ethylene bridges providing a non-peptidic chiral 
scaffold that displays protein-like functionality as the bridges confine the side chain 
groups in orientations that mimic α-helices. Molecular modelling suggests that the 
low-energy conformation of the oxopiperazine scaffold presents side chain 
functionality to mimic the arrangement of the i, i+4, and the i+6/i+7 residues on α-
helices (Figure 21A)226. A further advantage of OHMs is their chiral backbone; 
chiral scaffolds are expected to interact with molecular binding pockets with higher 
specificity. Three of the key binding residues, Leu818, Leu822, and Gln824, can be 
mimicked by oxopiperazine. Four analogues were designed and synthesised (Figure 
21B), OHM-1 contains projections representing all three key residues from HIF-1α: 
R1 as Leu818, R2 as Leu822, and R4 as Gln824. The R3 position of the oxopiperazine 
scaffold is not predicted to make contacts with the target protein; an alanine residue 
was inserted at this position. OHMs 2 and 3 are single mutants of OHM-1 with R4 
and R2 positions, respectively, substituted with alanine residues. Based on 
computational analysis and the relative contributions of Leu822 and Gln824, OHM-2 
would be expected to bind p300 with a much higher affinity than OHM-3, as Gln824 
in the R4 is a weak contributor to binding where as Leu822 in the R2 position is 
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predicted to make a larger contribution to binding affinity, therefore the substitution 
to alanine in OHM-2 would be expected to have a larger effect than in OHM-3.  
 
Figure 21 - OHM helix mimetics. A) molecular modelling suggests the scaffold projects the 
side chains in the same special orientation as a helix. B) Four OHM compounds were 
designed and synthesised. Image adapted from225. 
 
Intrinsic tryptophan fluorescence spectroscopy was again used to measure binding 
affinity to p300 CH1 domain; the results are summarised in Table 14. OHM-1, which 
represented all three key side chains, had the highest affinity of the OHMs. OHM-2, 
which contains the two critical leucine residues but lacks Gln824, binds with a slightly 
reduced affinity for OHM-1, confirming the computational prediction that Gln824 is a 
weak contributor to binding. The negative controls OHMs 3 and 4 displayed very 
weak affinities for p300. 
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Table 14 – Binding affinities of OHM ligands225 
Ligand Kd 
HIF1α C-TAD786–826 38 nM 
OHM-1 530 nM 
OHM-2 620 nM 
OHM-3 >>10 µM 
OHM-4 >>10 µM 
 
The results signify that the designed scaffolds are able to target the protein of interest 
in a predetermined manner. NMR was used to further characterise the binding; 
concentration-dependent shifts of several residues were observed upon addition of 
OHM-1. The NMR results, along with the fluorescence binding experiments, provide 
strong evidence that the rationally designed topographical mimics of helix 3 are 
binding in the predicted binding sites of their intended targets. The luciferase-based 
reporter assay again showed a dose-dependent reduction in the promoter activity. 
The ability of OHMs to inhibit transcription of three selected HIF target genes, 
VEGFA, LOX, and GLUT1, was assessed using real-time quantitative RT-PCR 
(qRT-PCR) assays in A549 cells. OHMs 1 and 2 at 10 µM down-regulate the mRNA 
expression levels of the critical angiogenesis regulator vascular endothelial growth 
factor (VEGFA) by 80% and 90%, respectively. In comparison, control compounds 
had no effect on VEGFA mRNA levels at these concentrations. Similar levels of 
decrease were observed for lysyl oxidase (LOX) and glucose transporter 1 (GLUT1) 
expression. OHM-1 caused changes in 32 transcripts by at least fourfold (P ≤ 0.005) 
and 597 transcripts by at least twofold (P ≤ 0.005), of these transcripts 11 are 
validated as HIF-1α target genes227. 
The ability of OHM-1 to reduce the tumour growth rate in a mouse xenograft models 
was assessed; the treated group had a smaller median tumour volume (103 mm3) 
compared with the control group (186 mm3). This indicated that OMH-1, a mimetic 
of the helix 3 region of HIF-1α, is a potential cancer therapeutic.  
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It can be seen that both helix 2 and helix 3 have been mimicked and have 
successfully inhibited the HIF-1α/p300 interaction. Therefore further work is 
required to resolve which of the helical sites is the more prominent binding hot-spot, 
indeed if either of these regions is a hot-spot of the interface, as there is a potential 
that a hot-spot is located at an unexplored region of the interaction interface. There is 
also a potential that there are no binding hot-spots of this interaction and the full 
length HIF-1α C-TAD is required for high affinity binding. If this is the case it does 
not mean that the interaction is “undruggable”, just structure-based rational design 
will be more difficult as there is no clear starting point. 
 
3.2 HIF-1α/p300 Aims 
 
The aim of this part of the project was to further characterise the HIF-1α/p300 
interaction using a combination of biophysical and structural techniques. It was 
hoped that an increased understanding of the binding interface and the location of 
binding hot-spot will aid rational drug design. Two approaches were envisioned to 
probe the HIF-1α binding surface on p300: first, by analysis of the binding of shorter 
HIF-1α peptide fragments; and second, by phage display experiments. Binding 
analysis of fragments of the native peptide allow identification of the highest affinity 
region of the HIF-1α peptide, whereas phage display permits the unbiased 
exploration of the p300 CH1 protein surface to discover high affinity binders. The 
location and binding mode of phage display derived ligands provides new 















3.3 HIF-1α/p300 cloning and expression 
 
 
As discussed in the introduction structural and rational drug design methods may be 
a way to yield inhibitors of protein-protein interactions (such as HIF-1α/p300). For 
such design strategies to be successful an intimate knowledge of the binding 
interaction and protein binding partners, both structurally and biophysically must be 
gained. Before binding and structural studies can be conducted, the protein partners 
must first be cloned and expressed/synthesised. In this section the cloning and 
expression of p300 and HIF-1α proteins is described. 
 
3.3.1 p300 CH1 cloning 
 
Two different p300 CH1 lengths were cloned, p300330-420 and p300323-423. The two 
lengths were chosen because firstly, 330-420 fits with the structured region of p300 
as shown in the NMR structure182; as a crystal structure of p300 was an aim of the 
project having a highly ordered protein structure will be an advantage. However it 
has been reported that for maintenance of full HIF-1α activity p300 resides 323-423 
are required197. Also previous work characterising the HIF-1α/p300 interaction by 
the Arora group used this longer construct217, 221, 225. The additional C-terminal 
residues are illustrated in Figure 22; there is no structure available which shows the 
additional N-terminal residues. The entire unstructured region was not removed (cut 
to residue 417) as it is likely that some C-terminal residues will be required for the 






Figure 22 – Illustration of the the additional C terminal residues (cyan) for the two p300 
constructs (Pymol, cartoon). PDB ID: 1L8C182. 
 
The CH1 domain of p300 (p300330-420 p300323-423) was produced by PCR during PCR 
the restriction sites BamHI (N-term) and Xho1 (C-term) were added. The primers 





Table 2). The PCR products were ligated in to three plasmids:  
• pET-SUMO-28a, the SUMO tag aids solubility and purification228;  
• pGEX-6P-2, the GST tag again aids solubility and purification229  
• pET-GFP-28b-PreScission, the GFP tag can be used for FRET, this plasmid 
also contained a HIS tag for purification230.   
 
Positive constructs were identified by colony PCR and diagnostic digest and 
subsequently confirmed by sequencing. The plasmid (pGex-6p-2 as an example) 








3.3.2 Expression Trials 
 
E. coli BL21 (DE3) pLysS expression strains Gold, Star and Rosetta 2, were 
transformed with each construct, from which expression trials were conducted. The 
different strains contained mutations from BL21 (DE3) pLysS231, 232, outlined in 
Table 15. 
 
Table 15 – Summary of difference in expression strains used in expression trials231, 232 
Strain Mutation 
BL21 (DE3) pLysS star mutated  Rnase E 
BL21 (DE3) pLysS gold lack the Lon protease and deficient in 
OmpT protein  
BL21 (DE3) pLysS rosetta 2 rare tRNA included 
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Initially expression trials were conducted using the p300330-420 construct. The 
expression strains were tested first, small scale (10 mL) cultures were produced, 
initial induction was with 0.4 mM IPTG incubated at 18°C for 18 hours. For GST-
p300330-420 (37 kDa) each of the expression strains yielded soluble protein, with the 
greatest expression ratio of insoluble to soluble protein from Gold cells. SUMO-
p300330-420 (24 kDa) expressed well, however the protein was predominantly 
insoluble under these expression conditions. Again GFP-p300330-420 (42 kDa) 
expressed well under these expression conditions, particularly in Star cells however 
the protein was largely insoluble. The SDS PAGE gels from these expression trials 




Figure 24 - SDS PAGE analysis of expression trials of p300330-420 in expression strains E. 
coli BL21 (DE3) pLysS GOLD/ROSETTA 2 (R2)/STAR. I =insoluble fraction S=soluble 
fraction A) GST-p300 (37 kDa).  B) SUMO-p300 (24 kDa). C) GFP-p300 (41 kDa). D) 
Broad range molecular weight marker (2-212 kDa). 
 
The expression trials indicated that the most promising construct was GST-p300330-
420 expressed in E. coli BL21 (DE3) pLysS Gold cells; therefore this construct was 
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taken forward for further optimization. Although it should be noted that the other 
constructs may still be useful for specific experiments (for example GFP-p300 for 
fluorescence studies such as FRET).   
 
p300 is a zinc binding protein (Figure 25A)197, many zinc binding proteins require 
additional zinc either during induction or purification, and it has been shown, 
particularly for p300, that the concentration of zinc present has a profound influence 
on the fold of the protein180. De Guzman et al., demonstrated by CD that with no 
additional zinc, p300 is only partially folded (Figure 25B top), however they also 
demonstrated by NMR when too much zinc was present p300 was unfolded (Figure 
25B bottom)180. As the zinc concentration affects the fold of the p300 it would be 
expected that for suboptimal zinc concentrations there would be a higher percentage 
of protein in the insoluble fraction. IPTG concentration can also affect the expression 
levels of soluble protein. Therefore expression trials investigating the concentration 
of zinc (no zinc, 50 µM zinc sulphate at induction or 100 µM at lysis) and IPTG 
concentration (0.1 mM, 0.2 mM and 0.4 mM) were conducted. These trials showed 
the highest protein concentration in the soluble fraction to be under the conditions 50 
µM zinc sulphate at induction and 0.1 mM IPTG. This condition was taken forward 
and the presence of EDTA (1 mM) and DTT (1 mM) was investigated. More protein 





Figure 25 - Effect of zinc and reducing agents on p300 expression, solubility and fold. A) 
pymol image of p300 coordinating 3 zinc molecules (pale blue) , each zinc is coordinated by 
3 cysteines and a histamine. PDB:1L8C182 B) The effect of zinc concentration on protein 
structure by CD (top) and NMR (bottom)figure adapted from180. C) Expression trails of 
GST-p300 (37 kDa) in the presence and absence of DTT and EDTA. 
 
From this series of expression trials the expression condition; induction by 0.1 mM 
IPTG, 50 µM zinc sulphate at induction at 18°C for 18 hours was taken forward to a 
larger scale induction, the full purification protocol is outlined in Chapter 2 : 
Materials and Methods. A 2 L culture under the outlined conditions yielded 40 mg of 
protein post affinity chromatography purification (GST column). The vast majority 
of this protein was GST-p300 however there was some smaller contaminating 
proteins present (as seen on the SDS page gel). Most likely, these proteins were GST 
and small degradation products (Figure 26A). This protein was then further purified 
by size exclusion chromatography. GST-p300 eluted from the S75 column at 140 
mL, which from the calibration of column indicated a protein of the correct size. The 
size was confirmed by SDS PAGE and mass spectrometry. Unfused GST was still 
present (as seen on the SDS PAGE gel), however this was not a problem when p300 
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was cleaved from GST using PreScission protease (1 mg of protease per 20 mg of 
GST-p300, incubated for 16 hours at 4°C) as the size difference was large enough 
(27 kDa GST to 10.8 kDa p300) for good separation off the S75 gel filtration column 
(Figure 26B and C). 10 mg of pure p300330-420 was obtained and confirmed by SDS 
PAGE (insert Figure 26C) and mass spectrometry. 
 
 
Figure 26 - p300330-430 purification A) SDS PSGE gel of the purification of GST-p300 by 
affinity chromatography (GST column). B) SDS PAGE gel illustrating the cleavage of GST-
p300 by PreScission protease. C) Size exclusion chromatography spectra showing the 
separation of GST (26.8 kDa – 154 mL) from p300 (10.8 kDa – 210 mL). Insert SDS PAGE 
gel showing pure p300 after size exclusion chromatography. 
 
The fold and stability of p300330-420 was assessed by CD. A classical spectra 
indicative of an α-helical secondary structure was obtained134 (Figure 27A). The 
secondary structure could be disrupted by the addition of 1M EDTA, again 
confirming the structural importance of zinc (Figure 27A). A thermal melt 
demonstrated the stability if this construct. The protein was not fully denatured up to 







Figure 27 - CD analysis of p300330-420. A) p300 (18.5 µM) spectra in the presence and 
absence of EDTA. B) Thermal melt of p300, minima 208 plotted. 
 
 
The second p300 construct p300323-423 was also cloned in to pET-SUMO-28a, pGEX-
6P-2 and pET-GFP-28b-PreScission; E. coli BL21 (DE3) pLysS expression strains 
Gold, Star and Rosetta 2 (Table 15) were transformed with the constructs. p300323-423 
expressed well with a GST tag in Gold cells, GST-p300 also expressed well in 
Rosetta 2 and Star cells, however it was decided that GST-p300 in Gold cells would 
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be the construct taken forward to remain constant with the p300330-420 construct. An 
identical expression and purification protocol to p300330-420 was used. A 4 L growth 
of GST-p300323-423 yielded 350 mg of protein after affinity chromatography and 200 
mg post size exclusion chromatography. GST-p300323-423 was cut by PreScission 
protease and p300323-423 was separated from GST by size exclusion chromatography 
p300323-423 was also pure and stable. However, the p300323-423 expression and 
purification was not consistently reproducible, further use of this protein revealed a 
tendency for aggregation, as shown by gel filtration with the band at 23 kDa. It is 
believed p300323-423 may dimerise as there was a band on the SDS PAGE gel slightly 
below the 27 kDa band for GST and the 185 mL elution volume corresponds to a 
22.8 kDa protein (a dimer of the 11.4 kDa monomer p300 protein, which should be 
eluted at 210 mL) (Figure 28). However it is unusual for a dimer to be seen on the 
denaturing SDS PAGE gel, therefore this may be a contamination product as 
opposed to a dimer.  




Figure 28 - Illustration of the potential dimerization of p300 (323-423). The p300 peak 
elutes at 185 mL (opposed to 210 mL, the expected elution volume for a monomer) .SDS 
PAGE gels prior to and post size exclusion chromatography show a band at approximately 
23 kDa.  
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The fold and stability of the p300323-423 monomer and the product eluted at 185 mL 
(potential dimer) were compared by CD. There was a difference in the spectra of the 
potential dimer and the monomer (Figure 29). The monomer has a classical α-helical 
secondary structure signature, however the dimer does not; this could be because 
there is more than one species present in the sample. The minima of the potential 
dimer spectra is closer to 200 nm, which is more indicative of an irregular 
structure134. Further analysis e.g. using NMR, may reveal if the structure is dimeric 
(for example is there a miss coordination of zinc). In addition alternative expression 
systems (such as arctic express cells or autoinduction) or simply re-optimisation of 
the expression and purification of the p300323-423 construct could be conducted to 
reproducibly obtain pure monomeric protein.  
 
As the p300330-420 construct was pure and monomeric and obtained in good yield, this 
protein was taken forward for binding and structural studies. From this point forward 







































3.3.3 p300 labeling  
 
For some biophysical and structural assays the p300 protein needed to be labelled, 
for example to immobolise p300 for SPR and to 15N labelled for NMR. 
 
For protein isolation there are many methods for protein labelling including; 
derivatisation of cysteine residues233, labelling lysine or N-terminal amino groups 
with activated esters, periodate or PLP-mediated oxidation of the N-terminus for 
oxime ligation234 and native-chemical ligation235. Each of these methods has its 
limitations. The ability to control the location of the label has distinct advantages 
over uncontrolled labelling, therefore the method used was chemo-selective N-
terminal labelling using depsipeptide substrates for the transpeptidase sortase A171. 
This method required an N-terminal glycine, although it must be in a sterically 
unhindered position. Fortuitously an N-terminal glycine was left after GST-p300 was 
cleaved with preScission protease.  
 
Firstly it was assessed if the N-terminal glycine of p300 was sterically accessible and 
therefore amenable to this labelling method. A depsispeptide with a UV active group 
was synthesised and purified and the sortase A expressed by George Burslem and 
Dan Williamson (University of Leeds). Four reactions were set up in buffer 50 mM 
Hepes pH 7.5, 150 mM sodium phosphate and 5 mM calcium chloride at 37 °C and 
the reactions were sampled every hour for a 5 hour period to investigate optimal 
labelling. The reaction conditions are summarised in Table 16. 
 
 
Table 16 - Reaction conditions to investigate the ligation of a depsipeptide to the N terminal 
glycine of p300 
 Reaction 1 Reaction 2 Reaction 3 Reaction 4 
Sortase (µM) 10 10 20 20 
Depsipeptide (µM) 150 300 150 300 




The reactions were sampled hourly and analysed by SDS PAGE. The fluorescent 
depsipeptide and sortase A can be seen in Figure 30A and B. After incubation, the 
SDS PAGE gels showed a band at around 11 kDa which is around the size for p300 
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and just above 27 kDa which is sortase. Both of these bands fluoresce when 
illuminated with UV (Figure 30), indicating that they are protein (p300 and sortase 
respectively) depsipeptide complex. An example gel is shown in Figure 30C and D 









This trial indicated that the N terminal glycine was sterically accessible, as can be  
seen by the UV fluorescence of the p300, indicating that the depsipeptide was 
attached (Figure 30). Therefore a large scale reaction was conducted using a biotin-
depispeptide (synthesised by George Burslem and Dan Williamson)  (Figure 31A). 
From the trial reactions, the reaction 4 condition 100 µM p300, 300 µM biotin-
Figure 30 – Depsispeptide ligation trials. A) and B) Analysis of  depsipeptide and sortase 
pre-reaction.  A) SDS PAGE coomassie stained. B) SDS PAGE under UV showing the 
fluorescence of the depsipepide.  C) and D) Analyssi of reaction at the 5 hour time point.  
C) SDS PAGE coomassie stained   showing a band at 10.8 kDa (p300) and 27 kDa 
(sortase). D) SCS PAGE under UV, the both the p300 and sortase bands fluoresce, 
indicating a protein-peptide complex.    
 90 
depsipeptide and 20 µM sortase was used and the reaction was incubated at 37 °C 
with agitation for 3.5 hours. The biotin-p300 was separated from the unreacted 
biotin-depsipeptide by dialysis and from the sortase A by affinity chromatography. 
As the sortase had a His tag a nickel column was used. The biotin-p300 was eluted in 
the 50 mM imidazole elute. SDS PAGE analysis indicated that the biotinylation was 
successful, with a slight increase in the band height of biotin-p300 compared with 
wild type p300 (Figure 31B), biotinylation was subsequently confirmed by 





























Figure 31 - Biotinylation of p300.  A) Biotin-depsipeptide. B) SDS PAGE gel shows a slight 
increase in size in biotin-p300 from wildtype p300.  
 
For NMR studies p300 was labelled with 15N, as p300/CBP had already been 
assigned. 13C labelling was not required182. Expression of 15N-p300 by IPTG yielded 
potentially misfolded protein in low yield so autoinduction was attempted. An 
adaptation of the 15N media (outlined in Chapter 2; Materials and Methods, 2.3.2.2 
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15N-p300 protein expression) was used; the 20% (w/v) glucose generally used was 
replaced with the 50x 5052 from the Studier autoinduction protocol236 (25% glycerol, 
2.5% glucose and 10% lactose). Cells were grown at 37 °C for 4 hours (an OD600 of 
0.22), temperature was then decreased to 20 °C and cells were incubated for 40 
hours.  The cells were harvested and purified as described in Chapter 2 ; Materials 
and Methods. From 2 L 50 mg of protein was eluted from the GST column, 
approximately 2/3 of this was GST-15Np300 with the contaminating protein being 
GST (Figure 32A). The GST- 15Np300 fusion was cut with preScission protease 
(Figure 32B) and separated by size exclusion chromatography (Figure 32C), the 
labelling was confirmed by mass spectrometry. 
 
 
Figure 32 - 15Np300 purification. A) SDS PAGE gel post affinity chromatography showing 
a band at 37 kDa which is most likely to be GST-15Np300. B) SDS PAGE analysis of the cut 
GST-15Np300, both GST (27 kDa) and 15Np300 (11 kDa) band can be seen. C) SDS PAGE 




3.3.4 HIF-1α peptide 
 
For much of the biophysical and structural characterisation of the interaction 
peptides were synthesised by George Burslem (University of Leeds) using Fmoc 
protected solid phase peptide synthesis (FITC-HIF-1α794-804 and FITC-HIF-α816-826) 
or purchased from Proteogenix (HIF-1α786-826, HIF-α782-826, HIF-α782-793, HIF-α782-789, 
HIF-α790-804, HIF-α782-804, HIF-α794-826, HIF-α805-826, HIF-α794-815, HIF-α805-815, FITC-
HIF-1α786-826 and FITC-HIF-α794-826). Both unlabelled and N terminally fluorescein  
(FITC) labelled peptides were used. However, for in cellulo studies, such as cellular 
FRET a synthesised peptide cannot be used, for this reason HIF-1α peptides of 
various lengths were cloned with a YFP tag. Yellow fluorescent protein (YFP) was 
selected as a partner for the GFP-p300 construct. However such clones were never 
used in the project therefore protein expression was not optimised. 
 
Pure folded p300 protein (as seen by SDS PAGE, mass spectrometry and CD) was 
produced and was therefore taken forward to characterise the binding to HIF-1α.  
 
 
3.4 HIF-1α/p300 charcterisation 
 
Knowledge of the native HIF-1α/p300 interaction, including a detailed understanding 
of how the two proteins interact structurally and biophysically will aid rational drug 
design. In this section, the work completed to probe the interaction for the discovery 
of hot-spots will be discussed. Two different approaches were used; analysis of the 
binding of shorter HIF-1α peptide fragments and phage display experiments. Binding 
analysis of fragments of the native peptide allow identification of the highest affinity 
region of the HIF-1α peptide, whereas phage display permits the unbiased 
exploration of the p300 CH1 protein surface to discover high affinity binders. Two 
phage display technologies were used237: a peptide phage library (NEB238-240) and an 
Adhiron122 (commercially known as Affimer241, 242) phage library. The location and 
binding mode of phage display derived ligands provides new information on suitable 




3.4.1 Biophysical assessment of HIF-1α786-826/p300 interaction 
 
 
p300 was cloned and expressed, and CD indicated that p300 is folded. To assess the 
activity of the p300 protein, binding experiments were conducted; these binding 
studies included fluorescence anisotropy and ITC. For the initial binding experiments 
a 41 residue HIF-1α construct was used (C-TAD HIF-1α786-826). This construct 
consisted of the N terminal region which has previously been highlighted as key for 
binding220 and both helix 2 and helix 3 which have been highlighted as containing 
key binding residues216. This peptide was purchased from Porteogenix, France. The 





The direct binding of HIF-1α786-826 to p300 was initially tested using fluorescence 
anisotropy. p300 was serially diluted  into labelled FITC-HIF-1α786-826 (40 nM) and 
incubated for 30 minutes at room temperature . The Kd for this interaction was 
measured as 16.11 ± 0.06 nM. The Kd reported in the literature for HIF-1α776–826 
binding to p300 is 189 ± 45 nM220. The difference in the Kd can be attributed to 
construct and assay variation. A control fluorescence anisotropy experiment was 
conducted  where GST was serially diluted  into labelled FITC-HIF-1α786-826 (40 nM) 
and incubated for 30 minutes at room temperature, no change in anisotropy was 
measured up to 10 µM GST, indicating no binding of FITC-HIF-1α786-826 to GST. 
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Figure 34 - Fluorescence anisotropy binding analysis of the HIF-1α/p300 interaction 
expressed as % bound. The plate was incubated for 30 minutes at room temperature. 
 
A time course experiment was conducted to investigate the importance of incubation 
time (Figure 35). The experiment was conducted in the same way as above, however 
the plate was read after 30 minutes, after 5 hours and after 18 hours. As can be seen 
from Figure 35 there is little difference in binding over the time period tested (Kd 30 





Figure 35 – Time course of plate incubation for fluorescence anisotropy analysis. Plate 




The effect of incubation temperature, between 25°C and 40 °C, on binding was also 
investigated (Figure 36). The experiment was conducted in the same way as 
previously described, however rather than at room temperature the incubation was 
conducted at a controlled temperature. It can be seen from Figure 36A that the 
temperature had an effect on the overall anisotropy, which can be attributed to the 
amount of kinetic energy in the system, however temperature appears to have 
minimal effect on affinity (Kd’ s: 25 °C = 384.1 ± 131 nM, 30 °C = 290.9 ± 97.5 nM, 










Figure 36 – Effect of temperature on fluorescence anisotropy analysis, plates incubated 
between 25 °C and 40 °C for the HIF-1α/p300 interaction. A) Data represented as 




A lack of sensitivity to incubation time and incubation temperature within the 
specified range is important for a high throughput assay. The more sensitive an assay 
is the less amenable to robotics it will be.  
 
An orthogonal assay, ITC, was used to confirm the direct binding of HIF-1α786-826. 
This assay confirms to what extent, if any, the fluorescein impacts upon binding. ITC 
also gives thermodynamic information regarding the entropic and enthalpic 
contributions. At 25 °C a Kd of 45 nM was measured; this fits well with the Kd 
measured by fluorescence anisotropy (at room temperature) and the published 
affinity. The stoichiometry (N) is 0.61, although slightly low this is likely indicative 
of 1:1 binding, N is likely to be slightly low if the concentration of active protein 
does not match the calculated total protein present or there are errors within 
calculated concentrations. The entropy (ΔS) was measured to be -52.46 Jmol-1Deg-1 
and the enthalpy (ΔH) was measure to --57.32 kJmol-1. These data, are summarised 



























Figure 37 - ITC data for the HIF-1α/p300 interaction at 25 °C. 
A B 






















Table 17 - Summary of the ITC data for the interaction of HIF-α/p300 interaction measured 
at 25°C 
N 0.61 
ΔH (kJmol-1) -57.32 
ΔS ( Jmol-1Deg-1) -52.46 




The Kd of an interaction is dictated by the Gibbs free energy of binding (ΔG) 
(Equation 7), which results from the ultimate balance of desolvation and attractive 
forces, the more negative ΔG the more favorable the interaction. ΔG is made up of 
two components, enthalpy (ΔH) and entropy (ΔS) (Equation 8). The energies of all 
bonds that are made and broken during the process contribute to the enthalpy change, 
whereas all ordering and/or disordering processes in the protein, peptide/compound 
and solvent contribute to the entropy change243. The negative enthalpy for the HIF-
1α786-826/p300 interaction indicates that the interaction is enthalpically driven, on a 
simplistic level this means that the binding occurs via specific molecular interactions, 
such as hydrogen bonds, as opposed to a entropically driven interactions which are 
more likely to be driven by hydrophobic interactions and solvent ordering effects243.  
 
Ka = e-ΔG/RT (Equation 7) 
 
ΔG = ΔH - TΔS (Equation 8) 
 
 
Both of the biophysical assays used, fluorescence anisotropy and ITC, measured the 
affinity of the HIF-1α/p300 interaction to be low nanomolar affinity. The ITC has 
confirmed the interaction to be enthalpically driven. To use rational based drug 
design the interaction interface had to be explored further, as the experiments 
conducted to measure overall binding affinity offer no information regarding the 
location of binding hot-spots. This information was ascertained in two ways; firstly 
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by the binding analyses of shorter fragments of the HIF-1α peptide constructs and 
secondly by phage display experiments.  
 
3.4.2 Exploration of the binding interface using HIF-1α peptide fragments 
 
HIF-1α786-826 which was measured to have a binding affinity of 16.11 ± 0.06 nM by 
fluorescence anisotropy, was broken up into potential key binding areas and peptides 
of such regions were either synthesised by George Burslem (University of Leeds) 
(FITC-HIF-1α794-804 and FITC-HIF-α816-826) or purchased from Proteogenix (HIF-
1α786-826, HIF-α782-826, HIF-α782-793, HIF-α782-789, HIF-α790-804, HIF-α782-804, HIF-α794-
826, HIF-α805-826, HIF-α794-815, HIF-α805-815, FITC-HIF-1α786-826 and FITC-HIF-α794-826). 
The length of the peptides are summarised in Figure 38. Each of these peptides was 
assessed for affinity to p300 to ascertain which regions are more important for 





Figure 38 - Schematic showing the peptide HIF-1α fragments  purchased to investigate 
binding hot spot regions on HIF-1α 
 
α-helices have been highlighted as major binding hot-spots of PPIs20, 96, 97, so initial 
assessment centered on identification of the highest affinity helix. The affinity of 
helices 2 and 3 was investigated by fluorescence anisotropy using FITC-HIF-1α794-
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(compared to 16 ± 0.06 nM for HIF-1α786-826): FITC-HIF-1α816-826 Kd approximately 
200 µM and FITC-HIF-1α794-804 Kd > 1 mM. Notably, FITC-HIF-1α816-826 had a 
higher affinity than FITC-HIF-1α794-804, indicating that helix 3 has a higher affinity 
than helix 2; therefore helix 3 may be important for high affinity binding of the 
native complex. To examine further the binding energy contributions of the 
individual helices to the interaction and the effect of linking, peptide FITC-HIF-
1α794-826, comprising helices 2 and 3 with the intervening linker region, was also 
tested in the fluorescence anisotropy assay. A Kd of 6.74 ± 0.54 µM was measured, 
showing that linking helices 2 and 3 together results in an increase in affinity for 
p300 compared with either individual helix. Linking can increase binding affinity 
either through enhanced local concentration of each binding entity (avidity or chelate 
effect), or through co-operative interaction between them mediated through allosteric 
conformational change in the binding site. To distinguish between chelate and 
allosteric co-operativity, the fluorescence anisotropy assay was used to test the 
binding of FITC-HIF-1α816-826 in the presence of HIF-1α794-804 (unlabeled). This 
demonstrated that the presence of HIF-1α794-804 had no effect on the affinity of FITC-
HIF-1α816-826, suggesting either an avidity (chelate) effect or a direct contribution 
from the linker, rather than allosteric co-operativity between helix 3 and helix 2 
(Figure 39b). The avidity effect is modest, however, as the affinity measured 
for FITC-HIF-1α794-826 implies less than additive contributions from the individual 
binding energies of helices 2 and 3. This is consistent with the linker sequence 







































Figure 39 - Fluorescence anisotropy investigation of native HIF-1α fragments 
binding. a) Binding of the fluorescein labeled helical regions of HIF-1α C-TAD, 
FITC-HIF-1α794-804 (violet) FITC-HIF-1α816-826 (red) to p300 CH1 compared to FITC-
HIF-1α786-826 (black). b) Assessment of the co-operativity the helical regions of HIF-
1α. FITC-HIF-1α781-816 (green), FITC-HIF- 1α816-826 (red) and FITC-HIF-1α816-826 in 
the presence of unlabeled HIF-1α794-804 (brown). Note the overlap of the red and grey 
data sets. c) Schematic of the peptide fragments using in this experiment. 
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All of the peptides illustrated in Figure 38 were tested in a fluorescence anisotropy 
competition assay; however only peptides that contained more than one helix were 
able to disrupt the HIF-1α/p300 interaction (Figure 40). HIF-1α782-826 inhibited the 
interaction with the greatest potency (IC50 = 0.59 ± 0.05 µM).  HIF-1α794-826 showed 
a greater capability to disrupt the complex than HIF-1α782-805 demonstrating the 







Figure 40 - Fluorescence anisotropy competition assay to test the disruption of the HIF-1α 
C-TAD/p300 CH1 complex by HIF-1α CTAD fragments. HIF-1α782-826 (black) HIF-1α794-826 
(red) and HIF- 1α782-805 (violet). 
 
To further investigate the importance of helix 3, mutants of p300 (H20A, L47M, 
I71M, Figure 42) in the HIF-1α helix 3 binding pocket (as shown in the NMR 
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Figure 41 – CD spectrum showing the α-helical secondary structure of the p300 mutants. 
a)H20A. b) L47M. c) I71M  
 
H20A was selected, as the NMR structure shows this residue makes a contact to 
HIF-1α, and mutation to alanine would remove this contact. Both L47M and I71M 
were selected as we hypothesised they would introduce steric clashes. Each of the 
three mutants caused a reduction in the binding affinity of to FITC-HIF-1α786-826, 
with the greatest effect observed for I71M, which caused a 18-fold reduction in 




























































































Table 18 - Affinity of p300 helix 3 binding pocket mutant proteins binding to FITC-















Taken together, these data validated helix 3 as the most important of the helical 
regions of HIF1-α in terms of affinity.  This information was taken forward to design 















p300 Kd (nM) 
Wild type 16.11 ± 0.06 
H20A 25 ± 0.35 
L47M 29.55 ± 5.58 





Figure 42 - Investigation of the HIF-1α helix 3 binding pocket on p300. a) Schematic 
highlighting the three residues of the helix p300 binding pocket of p300 which were 
mutated. b) Fluorescence anisotropy comparison of the binding of FITC-HIF-1α786-826 to 
wild-type p300 (black) and mutant p300 I71M (red). 
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3.4.2.1 Small molecule HIF-1α/p300 inhibitors 
 
 
As previously discussed the exploration and characterisation of binding a given 
interface is required to aid rational drug design. Helix 3 has been identified as a key a 
contributor of HIF-1α binding to p300 via native fragment binding studies. This 
information can be used in different ways, e.g. by docking of large computational 
libraries to the helix 3 binding pocket and/or by the design of secondary structure 
mimics of helix 3. Docking studies identified numerous compounds, which were 
then purchased and screened. None of the compounds tested disrupted the HIF-
1α/p300 interaction with meaningful potency (IC50 < 50 µM). Greater success was 
achieved using α-helix mimetics; this piece of work was published in ChemBioChem 
in 2014244.  
 
Oligoamide helix mimetics 98, 245 were designed that mimic the key functionalities 
and spatial orientation of Helix 3. Helix 3 presents hydrophobic residues (Leu818, 
Leu822, Val825) along one face of the helix at the i, i + (3)4 and I + 7 positions182. A 
mimetic (p300-oligoamide 1) was prepared (by George Burslem, University of 
Leeds) that recapitulates the Leu818, Leu822, Val825 residues of Helix 3 (Figure 43A). 
This compound was tested in the fluorescence anisotropy competition assay and 
disrupted the HIF-1α/p300 interaction with an IC50 = 9.19 ± 0.9 µM ( 
Figure 43B). This is significantly better than the sequence (EELLRALDVN) 







Figure 43 – Design and testing of p300-oligoamide 1 compound. A) The oligoamide 
presents three key side chains, Leu818, Leu822, Val825. Helix 3 of HIF-1α in blue, key side 
chains highlighted in magenta. Pymol cartoon. B) Fluorescence anisotropy competition assay 
measuring the disruption of FITC-HIF-1α/p300 interaction.  
 
A small library of helix mimetics with alternative side chains to probe the relative 
importance of the side chain size and polarity was then prepared (George Burslem). 
The compounds and their IC50 values are summarised in Table 19. The most potent 
compound was the compound with the matched side chains to native helix 3 (p300-
oligoamide 1 IC50 = 9.19 µM). Incorporation of larger aromatic side chains (as in 
p300-oligoamide 6) in any position had a detrimental effect on inhibition. In addition 
the structure activity relationship studies suggest that the R1 side chain makes 
important contacts within the binding cleft through solvophobic effects. This is 
evidenced by the reduced affinity of p300-oligoamide 3 (because a methyl group was 
shown to diminish inhibition of the interaction) and p300-oligoamide 10 (because the 



















The most potent compound (oligoamide 1, with the matched side chains to helix 3) 
was also tested against another PPI, eIF4E/eIF4G, to give an indication of selectivity. 
The compound had a 100-fold selectivity for disruption of HIF-1α/p300 over 
eIF4E/eIF4G (IC50  > 1mM). An N-alkylated oligoamide (Figure 44) as opposed to 
the O-alkylated scaffold was also synthesized117, 246 (Valeria Azzarito, University of 
Leeds) and tested in the assay, however this mimetic did not disrupt the HIF-
1α/p300. The magnitude of the decrease in affinity is somewhat surprising and 
implies that some affinity of oligoamide 1 may be coming form the scaffold itself 















Native helix 3 Ac-GTEELLRALDQVNAAG-NH Inactive 
p300-oligoamide 1 iBu iBu iPr 9.2 ± 0.9 
p300-oligoamide 2 iPr iBu iBu 24 ± 1.6 
p300-oligoamide 3 Me iPr iBu 216 ± 16 
p300-oligoamide 4 iBu iBu iBu 9.8 ± 1.3 
p300-oligoamide 5 iBu iPr iBu 13 ± 1.5 
p300-oligoamide 6 benzyl benzyl benzyl 56 ± 6.0 
p300-oligoamide 7 iPr iPr iPr 39 ± 4.0 
p300-oligoamide 8 iBu iPr iPr 17 ± 0.7 
p300-oligoamide 9 benzyl iPr iPr 20 ± 0.8 


















Therefore increased understanding of the binding interaction between HIF-1α/p300 
directly allowed for the development of molecules that disrupt the interaction. The 
study of the binding interface highlighted the helix 3 binding region to be a key area 
for binding, and as a result the mimic of this region yielded low µM inhibitors of the 

























Figure 44 - N-linked oligoamide alpha helix mimetic 
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3.4.3 Exploration of the binding interface by phage display 
 
The absence of a dominant fragment of the HIF-1α C-TAD, as seen by the native 
fragment studies, encouraged us to perform phage display studies to identify short 
but high potency peptide sequences that may serve as better starting points for small-
molecule elaboration.   
 
One of the limitations of using native HIF-1α is that the explored interface is 
confined to the native HIF-1α sequence. The individual helices and short peptide 
regions have a low affinity for p300; however it is possible that non-native short 
peptides are able to bind to p300 with higher affinity than the native peptides. Such 
peptides can be generated by unbiased phage display. High affinity binders will have 
multiple uses. Firstly a phage display derived high affinity peptide binder may bind 
to p300 at a different site to the HIF-1α peptide (which be used to generate potential 
allosteric inhibitors), this site would have remained unexplored if only the native 
sequence binding was investigated. Secondly the phage display derived higher 
affinity peptides may bind in the same hot-spot region identified by the native 
binding study (in the case of the HIF-1α/p300 interaction, the helix 3 binding 
pocket); however, as the phage display derived peptides maybe higher affinity 
modelling their pharmacophore in a small molecule or helix mimetic may yield a 
higher affinity ligand than modelling the pharamacophore of the native peptide. 
Phage display may also provide tools that can be used both in vitro and in vivo. 
 
3.4.3.1 Peptide phage display 
 
Phage display technologies can be used to present many different forms of binder; in 
this study 7mer and 12mer peptides libraries (NEB238-240) were tested. Both libraries 
were used; the 7mer library should have full coverage (all amino acids represented in 
all positions238-240), however due to the length of the 7mers the generation of high 
affinity binding peptides was anticipated to be less likely. The 12mer library does not 
have full coverage, but the longer peptide may yield higher affinity peptide binders. 
As well as the two phage libraries, two different buffer conditions were used in the 
wash step: a high sodium chloride (1.5 M) and low sodium chloride (0.5 M) buffer 
(TBS+0.1% tween) were used to eliminate any nonspecific electrostatic 
contributions. Elution using native HIF-1α786-826 (500 µM) was performed to ensure 
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elution of specific binders. The experiment was also performed with a different 
protein (eIF4E); this parallel experiment acted as a selectivity control. 
 
p300 was selectively N-terminally labelled with biotin using a biotin-depsipeptide 
and sortase A (synthesised and expressed by George Burslem and Dan Williamson, 
University of Leeds)171 to enable immobilisation on to streptavidin plates 
(optimisation for this method is outlined in the p300 labelling section (3.3.3)). Three 
panning rounds were completed. The phage pool was enriched from the unpanned 
library to round three, although in some cases this enrichment was not sequential 
(Figure 45). The eluents for the unpanned libraries, round 1 and round 3 were sent for 
next generation sequencing using the Illumina platform173. 
 
 






























































12 libary,1.5 M NaCl wash 
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3.4.3.1.1 Peptide phage display clone selection and sequencing  
 
Next generation sequencing was used to limit false positives. False positives have 
been reported for many phage display experiments. There are two main reasons for 
the occurrence of false positives; firstly the binding of the phage to other components 
that are present such as contaminants in the target sample, the solid phase (plastic 
plates, beads), the capturing reagents (streptavidin, protein A/G, biotin, secondary 
antibody) or substances used for blocking the solid surface (bovine serum albumin, 
milk); such binders are classified as selection-related target-unrelated peptides. The 
amount of selection-related target-unrelated peptides can be minimized by using 
different or alternate platforms (beads or plates) and substances (blocking or 
capturing reagents) through the panning rounds. The two wash conditions used 
during the experiment may also reduce the amount of selection-related target-
unrelated peptides. Eluting the phage with an excess of the native binding partner 
(HIF-1α) will ensure that only the phage specifically bound to the protein will be 
eluted; however the limitation to this approach is that any phage which are not 
competitive with the native binding partner or any phage of significantly higher 
affinity than the native peptide will not be eluted247. To circumvent this limitation 
after the phage were eluted the wells were washed with 0.2 M glycine pH2.2 (which 
would elute any phage of higher affinity) and these washes were stored a -80 °C, 
ensuring a potential to sequence those phage of higher affinity then was able to be 
eluted with the native peptide if deemed necessary after the peptides were sequenced 
and tested for affinity to p300. 
 
Another class of target-unrelated peptides is propagation-related clones248, 249. In this 
case selection is driven by a faster propagation rate of some phage clones (known as 
“growth advantage”). Recovery of such clones is independent of their affinity to the 
target protein (p300) because the advantage in replication enables them to prevail in 
the phage pool. During the amplification step after each round of panning such phage 
clones achieve a higher titer. Within a few rounds of panning, these clones may 
dominate although they are unrelated to the target or any other component of the 
screening system. This faster propagation of certain phage clones may result from a 
mutation in the phage genome, which influences the ability of the virus to infect host 
bacteria or accelerates the process of phage particle assembly. It may also be an 
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intrinsic property of the displayed peptide itself, without any causative mutation247, 
248. Certain phage clones replicate slower because displayed sequences impede the 
phage assembly process to a greater extent. It is impossible to display some peptide 
sequences on the surface of phage, because they are not compatible with the phage 
replication process. On the other hand, some sequences allow a relatively faster 
propagation rate, and such clones are therefore more likely to be isolated. In M13-
based libraries (such as the NEB libraries), proline is an example of an amino acid 
residue that is over represented, whereas cysteine is under represented250. This 
phenomenon is known as sequence bias. Certain peptides which exhibit this growth 
advantage are frequently reported, for example the 7mer peptide, HAIYPRH, has 
been selected numerous times against a plethora of different targets. It has been 
shown that phage clones displaying HAIYPRH amplify at a dramatically faster rate 
than other clones due to a G→A mutation in the Shine-Dalgarno sequence of p2, a 
protein involved in the replication process249. This mutation increases expression of 
p2, which results in faster replication of the phage genome and speeds up the entire 
phage generation process247, 249, 251. 
 
The propagation related clones are more difficult to control and minimize. Sanger 
sequencing of clones requires the isolation of DNA from individual phage clones, 
this is labour intensive and is therefore rarely used to analyse more than 100 clones, 
which may mean only propagation related clones are sequenced. However with the 
advance of next generation sequencing (NGS) it is now possible to sequence 
thousands of inserts in parallel251. Illumina platform is currently the leader in the 
NGS industry and most library preparation protocols are compatible with the 
Illumina system. Illumina deep-sequencing technology analyses a library of blunt-
ended double stranded DNA (dsDNA) fragments and generates up to 109 base pair 
(bp) reads in a single run. Illumina offers the highest throughput of all platforms and 
the lowest per-base cost252.  
 
To prepare clones for sequencing, DNA was isolated from pan 1 and 3 elutes and 
from the unpanned library; PCR was used to amplify the DNA. Blunt end repair of 
the resultant ds-DNA was conducted using Illumina Paired-end DNA sample 
preparation kit. The primers with the unique bar codes (Illumina adaptors) were 
ligated to each fragment and the fragments with the adaptors were amplified by a 
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second round PCR. This resulted in 12 different pools which each had a unique bar 
code; the unpanned 7mer and 12mer libraries were also sequenced to assess the 
presence of any propagation related clones at the start of the experiment. The matlab 
analysis was performed by Jonathon Stott, AstraZeneca; the scripts were adapted 
from published scripts173 and used to separate the sequences into the individual 
experimental conditions and rank the sequence in order of frequency173. The top 5 
clones from each of the conditions and their frequency in the pool is summarised in 








Table 20 – Top 5 peptide phage display sequences for each of the peptide phage display condition 
 
Condition Unpanned sequences and frequency Round 1 sequences and frequency Round 2 sequences and frequency 
7mer library 





































































































































Analysis of the sequences was conduced (using pLogo, a motif visualisation tool 
where residue heights are scaled relative to their statistical significance253.) to assess 
if there was any strong consensus in the amino acid present. No strong consensus 
was seen. Three peptides were selected for synthesis (Proteogenix, France):  
VHWDFRQWWQPS, (phage display derived peptide 1; PDDP1) 
SGVYKVAYDWQH (PDDP2) and ATNLFKS (PDDP3). The next generation 
sequencing showed an increase in enrichment of these peptides through the panning 
rounds (Figure 46). 
 
 
Figure 46 – Increased representation of the 12mer peptides from the unpanned library to 
round1 and to round 3 as shown by next generation sequencing.  
 
3.4.3.1.2 Phage display derived peptide analysis 
 
Initially the FITC-labelled peptides were tested for binding to p300 using a 
fluorescence anisotropy assay. The highest affinity peptide was PDDP1 with an 
affinity of 20.67 ± 3.17 µM (Figure 47). Although this is a relatively low affinity for 
phage display-derived peptides, where low nM and pM binders are often 
generated251, 254, the phage display-derived peptide had a higher affinity for p300 
than any of the HIF-1α C-TAD peptide fragments of similar length discussed 
previously and was within the same range as HIF-1α794-826, the peptide containing 























selectivity for p300 over eIF4e. PDDP1 is predicted be 35% helical in isolation (as 
assessed by Agadir255), indicating that a helical bound conformation is plausible.  
 
To locate the binding site of the PDDP1 on p300 15N-1H HSQC experiments were 
performed; PDDP1 was titrated (300 µM-750 µM) into a solution of 15N-labelled 
p300 (230 µM). Peak shifts were observed confirming binding (Figure 47a). The size 
of the shift for each peak  (Figure 47b) was measured and those with the largest shift 
were mapped on to p300 (assignments from Biological Magnetic Resonance Bank 
(BMRB): 6268180). The location of the shifts indicates that PDDP1 may bind towards 
the top of the helix 3 binding pocket; the red area highlighted in Figure 47c 
highlights a potential groove for interaction. In addition a shift was observed in the 
Trp indole peak; a change in the Trp environment has previously been used as an 
indicator of ligand binding to the helix 3 binding pocket225. 
 
To further corroborate the binding of the phage display derived peptide in the helix 3 
binding site, the binding of the FITC-PDDP1 to both the wild type p300 and p300 
with mutations in the helix 3 binding pocket (H20A, L47M, I71M) was investigated 
using fluorescence anisotropy. The mutant L47M and I71M bound to PDDP1 with a 
statistically significant reduced affinity (P<0.05) (Table 21). The reduction in binding 
affinity complements the NMR data, as the decrease in binding affinity of the mutant 
indicates that PDDP1 may bind towards the top of the helix 3 binding pocket. The 
location of L47M and I71M is highlighted in Figure 47c (magenta). This additionally 
highlights the HIF-1α helix 3 binding pocket as a key binding area. 
 
Table 21 - Binding study of p300 helix 3 binding pocket mutant proteins binding to 
FITC-HIF-1α786-826 as measured by fluorescence anisotropy 
p300 Kd (µM) 
Wild type 20.67 ± 3.17 
H20A 57.71 ± 7.87* 
L47M 57.76 ± 7.82* 
I71M 36.73 ± 11.0 
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Figure 47 - Analysis of the binding site of PDDP1. a) p300 15N-1H HSQC experiment, p300 
(black) upon titration of PDDP1 at increasing concentrations, 300 µM (blue), 545 µM 
(green) and 750 µM (red). Insert shows a concentration-dependent shift in one peak and no 
effect on another peak upon titration of peptide. b) Bar chart showing the size of the shift of 
all the assigned peaks (BMRB-6268) of p300 after titration of 750 µM PDDP1. c) Mapping 
of the largest shifts (red) in or around the helix 3 binding site of p300 (green), the helix 3 of 
HIF-1α is shown in blue with the rest of the peptide shown in teal.  The two mutations which 
cause a statistically significant decrease in affinity (L47M and I71M) are highlighted in 
magenta.  d) Fluorescence anisotropy direct binding measurement of FITC-PDDP1 binding 
to mutant p300 L71M, the Kd of the mutant is significantly higher then that of wild-type 
(p<0.05). 
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3.4.3.2 Adhiron phage display experiment  
 
The second phage display experiment used non-antibody binding proteins presented 
on the surface of the phage as opposed to short peptides; such scaffolds are designed 
to constrain and present variable peptide sequences for protein recognition256.  
Molecules that bind to proteins with high specificity and affinity are important as 
therapeutic and diagnostic agents in medicine, and as tools in basic and applied 
research. The majority of such binders are in the class of monoclonal antibodies, 
however there are limitations to use of antibodies including high molecular weight, 
limited tissue penetration, instability, high production cost and potential 
immunogenicity257. Therefore alternatives to antibodies which have favourable 
biochemical properties and lower production costs are being generated, proteins with 
a variety of functions have been tested as backbones for affinity molecules by 
converting them to a library of protein binders following randomisation of amino 
acids at the binding surface. Thus far 20 different scaffolds have been developed242, 
258-284; the scaffold used in this study was the Adhiron scaffold (commercially named 
Affimer241,242). Adhirons are engineered non-antibody binding proteins which mimic 
the molecular recognition properties of antibodies but with improved properties 
(small, monomeric, thermostable, soluble and easy to express in E. coli and 
mammalian cells giving high protein yield)122. The Adhiron library has two 
randomised loops of 9 residues which are suitable for molecular recognition and are 
expected to adapt to form appropriate molecular contacts with a wide range of targets 
including protein pockets, protein surfaces, peptides and small molecules122. 
 
Four panning rounds were carried out, and an ELISA was used to select those clones 
to be sequenced (Figure 48). Nine clones were sent for sequencing (5, 11, 12, 24, 34, 
36, 37, 41 and 43; see Figure 48) with four independent sequences present (Table 
22). Three Adhirons were taken forward: Ad24, Ad34 and Ad41 (note that Ad41 is 







































































Each of the three adhirons expressed in a high yield, although gel filtration did show 
a tendency for the adhirons to form higher oligomeric states (example Figure 49). It 
is difficult to confidently state that the major peak in each case is monomeric 
Adhiron as each of the major peaks elutes at a slightly different volume, this may 
indicate that the adhirons are interacting in someway with the column. As p300 is a 
hydrophobic protein hydrophobic molecules will be attracted to it, therefore the 
phage display may have selected for greasy Adhirons more prone to oligomerisation. 
The major peak in each case was taken forward for further studies. 
 Loop 1 Loop 2 
Ad41 AMHPTKNMD DWGWIDEAY 
Ad11 AMHPTKNMD DWGWIDEAY 
Ad12 AMHPTKNMD DWGWIDEAY 
Ad36 AMHPTKNMD DWGWIDEAY 
Ad5 AMHPTKNMD DWGWIDEAY 
Ad37 AMHPTKNMD DWGWIDEAY 
Ad43 PRISGDWEY HGLYWLPKI 
Ad24 PPDLSYYLF MKSFPHAND 




Figure 49 – Expression and purification of Adhrions (Ad 24 as an example), showing size 
exclusion chromatography trace and SDS PAGE of Ni column  washes and elute and minor 
and major peaks  from size exclusion chromatography. 
 
To assess that each adhiron was folded and thermostable the major peak of each 
Adhrion was assessed by circular dichrosim. Each of the adhirons showed a classical 
β sheet spectrum134, with a minima at 220 nM, as would be expected from the 
published Adhiron crystal structure122. The thermal melt data shows that all of the 





Figure 50 – CD analysis of Ad34. A) spectra run at 20 °C showing a classical β sheet trace. 
B) thermal melt 
 
 The affinity of the Adhirons for p300 was initially tested using BLitzTM (ForteBio), 
BLitzTM is a dip and read system which enables the real time (kinetic) quantification 
of molecular interactions in solution. The highest affinity Adhiron was Ad34 with an 
estimated Kd of 89 nM (Table 23). Therefore this Adhiron was taken forward to 
confirm binding by SPR, where an affinity of 157 nM (Chi2 0.114) was measured for 





Figure 51 – SPR sensogram of Ad34 binding to biotin-p300 
 
 
The affinity of the phage display-derived Adhiron, Ad34, for p300 is higher than the 
phage display-derived peptides and the shorter native peptide sequences and is in the 
same range as the HIF-1α786-826, which has an affinity of 16.11± 0.06 nM. However, 
Ad34 might be anticipated to bind at a more localised site than HIF-1α786-826. Each of 
the Adhirons was assessed for their ability to inhibit the HIF-1α/p300 interaction 
using the fluorescence anisotropy competition assay. All 3 Adhirons had an IC50 of 
1-5 µM (Table 23, Figure 52). This is significantly better than the fragments of 
native HIF-1α, or the phage peptides described previously (which were unable to 
disrupt the interaction). However, the binding site of the Adhiron on p300 is not yet 
defined, and unfortunately excessive peak broadening in HSQC spectra on addition 
of Adhirons precludes interpretation of the resulting NMR shifts. These Adhiron 
sequences do not appear in a selection of Adhirons raised against a variety of other 




























Table 23 - Phage display derived Adhiron binding data, Kd measured by BLITZ and IC50 


















To further characterise Ad34 it was crystallised from 0.8 M di-sodium succinate pH 7; 
crystals were then supplemented with 20% glycerol for cryo-cooling and X-ray 
diffraction data collection. Data were solved to 2.8 Å. Crystallographic data is 
summarised  
Table 24. 
Adhiron Kd (nM) IC50 (µM) 
Ad41 105 1.98 ± 0.32 
Ad34 89 4.78 ± 2.12 
Ad24 140 2.96 ± 0.46 
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There were two adhiron molecules in the asymmetric unit. Each of these adhirons 
forms a dimer to an adhiron in the adjacent asymmetric unit. This dimerization 
appears to be mediated predominantly via one loop binding to a β sheet of the 
adjacent adhiron by hydrogen bonding. This dimerization could be a crystallography 
Data set Adhiron Ad34 
Wavelength (Å) 0.91741 
Space group I 21 21 21 
Cell parameters (Å,º) a = 69.29 
b = 72.64 
c = 107.93 
α= 90 
b = 90 
γ = 90 
Total reflections 87,748 
Unique reflections 7,134 
Resolution shells(Å)   
Total (High) 36.73 – 2.73 (2.80 – 2.73) 
Rmerge (%) * 0.148 (1.644) 
Rpim (%) *** 0.045 (0.477) 
Completeness (%) 99.8 (100) 
Multiplicity 12.6 (13.8) 
I/s(I) 12.3 (1.7) 
VM (Å3/Da) 3.67 
Mol. per AU 2 
Reflections working set 6,761 
Free R-value set (No. of reflections) 373 
Rcryst (%) *** 0.2388 
Rfree (%) ** 0.2781 
RMSD bond lengths (Å) 0.0106 
RMSD bond angles (º) 1.725 
No. of atoms used in refinement  
Non-hydrogen atoms 1,574 
Water molecules 48 
Mean B value (Å2)  
Total 70.371 
Water molecules 82.341 
Ramachandran plot statistics (%)  
Preferred region 82.97 
Allowed region 11.54 
Outliers 5.49 
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artefact, however the gel filtration showed a potential for oligermisation, therefore 
there is a strong potential that Ad34 will be able to form dimers when free in solution 
and in crystals. Also, the size of the contacts is larger than would be expected for 
crystal contacts and is more in line with the size expected for dimerisation. The 
likelihood of Ad34 being a dimer could be further explored using analytical 
ultracentrifugation and native SDS PAGE. The scaffold could be further optimised to 
prevent the dimerization. The insertion of charged residues in to the β sheet near the 




Figure 53 - Dimerisation of Ad34, one molecule per assymetric unit, hydrogen bonding 
illustrated by dotted lines   
 
The binding mode of the Adhiron was then investigated by in silico docking. Ad34 
was docked (by George Burlsem, University of Leeds) against the NMR structure of 
p300 (PDB 1L8C)182 using HADDOCK (High Ambiguity Driven protein−protein 
Docking)181. The docking results for the highest scored and most frequently 
predicted complex suggested that both variable loops are involved in binding, with 
both of the loops buried in hydrophobic areas of p300 (Figure 54).  Neither loop 
docked in the HIF-1α helix 3 region, suggesting that Ad34 may bind to a different 
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region from the highest affinity phage display derived peptide (PDDP1) and the 
highest affinity native helix (HIF-1α816-826) (Figure 54). The modelling suggests the 
two Adhiron loops bind in different crevices on p300; these pocket-like structures are 
in mutual proximity to each over. Given the proximity of the two sites identified, 
fragment-based approaches may be appropriate to link small molecules that target 
each site, although further experimental work is required to validate the binding site. 
The ability of the Adhirons to disrupt the interaction means that the pharmacophore 
of the adhiron could be modelled in a small molecule compound for the development 
of small molecule inhibitors. As it is suspected that the Adhiron binding, and 
therefore inhibitor potency, is mediated predominantly through the variable loop 





Figure 54 - Adhiron structure and potential binding model to p300. a) Crystal structure of  
Ad34, variable loops shown in cyan. b) Adhiron Ad34 (magenta) docked to the NMR 
structure of p300 (green) using HADDOCK; key binding residues are shown in cyan.  c) 
NMR structure of HIF-1α (blue) bound to p300 (green) in the same orientation as the docked 
Adhiron (shown in b). d) Overlay of the docked Ad34 (magenta) and HIF-1α (blue) bound 
p300 (green), highlighting Ad34 may not dock in a helix binding pocket. 
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3.4.3.3 Summary of phage display. 
 
This study has shown, like the native binding study, that it is difficult to obtain high 
affinity binding of small peptides to p300. The Adhirons were measured as the 
highest affinity binders, although the interaction may be mediated through 2 sites. 
That being said each loop is only 9 amino acids therefore the overall binding is 
mediated through a relatively small area, compared to the native HIF-1α. The 
Adhirons have a higher affinity for p300 than the native peptides containing 
individual helices, therefore the pharmacophore properties of the loops may be a 
better model for small molecule design than the native sequence. Certainly if a small 
molecule is able to span the two sites, in which the adhiron loops bind, potentially by 
fragment bridging or merging, an exciting new strategy to disrupt the HIF-1α/p300 
PPI could be employed. However much further validation of the docking model is 
required before any such work could be carried out.  
 
The peptide phage display experiment has again suggested the region of p300 where 
the helix 3 of HIF-1α binds as key for binding. This is supportive of the conclusion 
drawn from the native sequence analysis. Therefore from all the studies conducted 
the single highest affinity hot-spot is in the region of HIF-1α helix 3 binding. This 
also supports the conclusions drawn by Cho et at.,  that the C terminus of HIF-1α is 
important for binding220, although the area highlighted has been decreased (in terms 


















3.4.4 Structural characterization by crystallography  
 
A high resolution crystal structure of p300 or the HIF-1α/p300 complex would 
further characterise the binding interface as a higher resolution image will give more 
information regarding which residues interact. For crystallisation the protein must be 
a pure, homogenous sample, this was obtained for p300 as outlined in the p300 
cloning and expression section (3.3.2.). The initial crystallisation trials for p300 were 
conducted at 10 mg/mL in the buffer 10 mM Tris pH 7.5, 150 mM sodium chloride 
and 5 % glycerol. Using commercially available sparse matrix screens, which were 
designed to sample a wide range of precipitants, salts, buffers, pH, polymers and 
organic molecules, in a high- throughput 96-well format, and were biased towards 
previously successful crystallisation conditions for macromolecules. The screens 
were set up in sitting-drops with various protein:mother liquor ratios across all 
conditions and at a range of temperatures. No crystals grew and very little protein 
precipitation was seen, indicating that a condition needed to be changed. To grow 
protein crystals, an undersaturated solution of protein and precipitant must be 
concentrated to supersaturation, i.e. beyond the concentration where the protein is 
soluble in the defined mixture of other solutes (the solubility line), but not allowed to 
reach the point of precipitation (disordered aggregation). The concentration of 
precipitant changes the position of the solubility line at a given protein concentration. 
Figure 55 shows a solubility phase diagram, illustrating the relationship between 
protein and precipitant concentrations – which varies depending on the specific 
protein and precipitant. Spontaneous nucleation (ordered aggregation) of crystals 
occurs in the labile zone, which reduces the protein concentration and moves the 
phase back into the metastable zone, where sustained crystal growth can occur. 
Crystals will continue to grow in the metastable zone until either the protein is 
depleted, or until impurities are incorporated into the lattice at the surfaces of the 
growing crystal285. The most common method used, and the method used in this 
case, for crystal growth is vapour-diffusion: The evaporation of water from a 
protein:crystallant drop as it approaches equilibrium with a reservoir of crystallant 
(in a closed system), concentrates both protein and crystallant to the point where 
nucleation and crystal growth can occur. Crystallant solutions (or ‘mother liquor’) 
typically contain combinations of precipitants (organic polyalcohols e.g. 
polyethylene glycol (PEG)), salts (e.g. ammonium sulphate or sodium chloride), 
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additives (e.g. detergents, metal ions, reducing agents etc.) and buffers. 
Protein:crystallant drops are either sat on platforms over a reservoir (sitting drop) or 
suspended below a coverslip over a reservoir (hanging drop) and sealed. As 
concentrations of free protein and precipitant increase, the phase moves from 
undersaturated to supersaturated. The supersaturated labile zone, where spontaneous 
nucleation occurs, is followed by the metastable zone, which supports sustained 




Figure 55 - The solubility phage diagram 
 
As no crystals grew and very little protein precipitation occurred p300 was deemed 
to be in an undersatured state. To push p300 towards the labile zone the 
concentration of protein was increased. The sparse matrix screens were repeated at 
numerous concentrations up to 50 mg/mL, however even at this high concentration 
of protein very little protein precipitation was seen and no protein crystal grew. 
Therefore different buffers were investigated to try and alter the stability of the 
protein. Such buffers included ammonium acetate, Hepes and Tris at various pH, 
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ranging from pH 6 –pH 9. The sparse matrix screens were repeated at each of these 
buffers, still very little protein precipitation occurred. 
Another attempt to try and change protein stability was to conduct the sparse matrix 
screens under oil286, 287. The use of oil is adventitious as all components are directly 
combined into a single, supersaturated protein solution, which is then left 
undisturbed as oil prevents evaporation of the sample287, therefore the equilibration 
process is slowed down by the insertion of an oil barrier over the reservoir288, 289. A 
further advantage to setting up crystal trials under oil is that the oil protects the 
airborne sample from airborne contamination. In order for nucleation to occur one 
must work with very clean solutions; when working under oil, the samples are never 
exposed to air therefore heterogeneous nucleation is controlled290, 291. In addition it is 
generally believed that external disturbances such as vibration can cause excess 
nucleation and lead to the formation of smaller crystals or to crystal imperfections289. 
Trials under oil are preserved from physical shock since the nuclei and the forming 
crystals are buoyed and cushioned by the viscous oil making trials less susceptible to 
vibration290. 
1536 cocktails were tested under oil (at the Hautpman-Woodward medical research 
institute, University of Buffalo). The stability of the protein appeared to change with 
a higher percentage of drops displaying protein precipitation. However no drops 
displaying protein crystals were observed.  One of the many possible reasons that 
p300 was recalcitrant to forming crystals is the high flexibility of the protein (which 
will be discussed further in the SAXS section (3.4.4.1). 
 
The complex HIF-1α/p300 may be less flexible than p300, therefore crystallisation 
trials were also conducted for the HIF-1α/p300 complex. HIF-1α was added to p300 
at a molar ratio of 1.5:1, to ensure all p300 was bound, and the mixture was 
incubated for 30 minutes before co-purification by size exclusion chromatography.  
This co-purification should remove all unbound HIF-1α from the sample, leaving a 
homogeneous HIF-1α/p300 complex. A decrease in elution volume (from p300) 
signified complex formation. Again commercially available sparse matrix screens 
were run to find initial crystal hits. In much the same way as with p300 very little 
protein precipitation occurred and no protein crystals grew at the initial concentration 
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of 10 mg/mL. Again numerous concentrations, buffer conditions and temperatures 
were tested with little success. For crystallisation to occur the protein must be a 
homogenous sample, one of the limitations of co-purification is that the resolution of 
the gel filtration column allows for the potential of unbound protein to be present. To 
limit this possibility a HIF-1α/p300 fusion construct was produced.  
 
A protein which consisted of p300 at the N terminus and HIF-1α at the C terminus, 
joined with a linker that includes a TEV protease site was produced by PCR.  
Multiple rounds of PCR were required, firstly to attach the N terminus of the linker 
region to the C terminus of p300 and the C terminus of the linker region to the N 
terminus of HIF-1α, and then to link these two fragments together (Figure 56). This 
fused p300/HIF-1α protein was then ligated into pGex-6p-2 plasmid and BL-21 
PLysD DE3 Gold expression strain was transformed with the plasmid. The HIF-
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Figure 56 – Fused p300/HIF-1α. HIF-1α (blue), p300 (green) and TEV linker region (red). 
The amino acid sequence is shown, colour coded as above (ribbons Pymol). 
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As the linker region may have a detrimental effect on the fold and stability of the 
protein CD was used to check the integrity of the protein (Figure 57).  The spectrum 
indicated that the HIF-1α/p300 fusion construct had an α-helical secondary 
structure134. The thermal melt did not give a sigmoidal curve, this may indicate that 
there is more than one species present in the sample or non-cooperative infolding. To 
investigate this further and to assess the flexibility and homogeneity of the HIF-
1α/p300 fusion construct, as well as p300 and co-purified HIF-1α/p300, small angle 
X-ray scattering was used. The SAXS experiment should indicate which construct 











































































































3.4.4.1 SAXS analysis 
3.4.4.1.1 Sample Quality 
 
Before studying the conformations of p300, co-purified HIF-1α/p300 and HIF-
1α/p300 fusion construct in solution the quality of the sample was assessed by 
collecting SAXS data for each protein over a concentration series (Table 25 and 
Figure 58). A persistent increase or decrease in the radius of gyration (Rg) or 
maximum particle dimension (Dmax) as the concentration of the sample increased 
would indicate protein aggregation or repulsion respectively. As Rg or Dmax remain 
consistent, within error, throughout the concentration range tested, the protein 
samples were deemed to be monodisperse and monomeric in solution. Data was 
analysed using Primus.      
 
 
Table 25 – SAXS derived size parameters for p300, co-purified HIF-1α/p300 and HIF-
1α/p300 fusion construct determined by Primus 
Protein Concentration (µM) Rg Dmax 
P300 
 108 15.8 ± 1.7 51.8 
167 16.2 ±  0.9 55.6 
217 16.6 ± 1.4 55.6 
271 16.9 ± 1.0 55.5 
334 17.7 ± 1.3 56.7 
381 16.9 ± 2.4 56.6 
434 16.9 ± 0.8 58.0 
HIF-1α/p300 fusion construct 
 115 17.8 ± 0.6 58.2 
177 17.6 ± 1.4 60.4 
230 17.6 ± 1.0 61.5 
288 18.9 ± 1.0 61.9 
354 17.8 ± 1.1 62.3 
404 17.6 ± 1.6 59.1 
460 17.9 ± 1.4 61.3 
Co-purified HIF-1α/p300  
 95 16.8 ± 2.0 56.2 
146 17.2 ± 0.6 56.5 
190 17.2 ± 1.2 54.9 
238 16.6 ± 1.2 54.4 
292 16.8 ± 1.5 55.0 
333 16.7 ± 1.3 55.9 









The lack of aggregation and repulsion of each protein can be further confirmed by 
consistency in their Guinier plots across the concentration range. A positive 
inflection within the Guinier region (qXRg<1.3) indicates aggregation of the sample 
whereas a negative infection within the Guinier region indicated repulsion. As the 
Guinier region remains linear at the highest concentration of each protein; p300 
Figure 58 - SAXS intensity profiles (logarithmic) for 7 concentrations of each protein 
sample. A) p300. B) HIF-1α/p300 fusion construct. C) co-purified p300/HIF-1α. 
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(Figure 59A), HIF-1α/p300 fusion construct (Figure 59B) and co-purified HIF-
1α/p300  (Figure 59C) the samples can be assumed to be resistant to aggregation and 





























Figure 59 - Linearity of Guinier plots with manual selection of Guinier region. a) Guinier 







The pair wise distribution function (P(R)) (Figure 60), which reflects inter-atomic 
difference distributions292, was consistent across the concentration range for each 
protein sample. This, taken together with the gel filtration elution profile, the Guinier 
plots and Rg and Dmax values indicates a monodisperse and monomeric solution of 





Figure 60 - Normalised pair distribution function P(R) calculated automatically by GNOM . 





3.4.4.1.2 Size and shape comparison of p300, co-purified p300/HIF-1α  and HIF-
1α/p300 fusion construct 
 
As there was no suggestion of aggregation or repulsion in the samples and no 
conformational change over concentration range was observed, indicated by 
consistency in Rg and Dmax (Table 25); further analysis was conducted using the 
data from the most concentrated sample of each protein due to the greater signal to 
noise ratio.   
 
The radius of gyration is largest for the HIF-1α/p300 fusion construct indicating that 
the HIF-1α/p300 fusion construct is the least compact of the three samples whereas 
p300 has the smallest radius of gyration (Table 25) indicative of a more compact 
structure. The Dmax supports this, with the HIF-1α/p300 fusion construct having the 
largest Dmax and p300 having the smallest. This difference in size and shape is 
illustrated by the slight differences in the shape of the pair distribution curves (Figure 
61A). These results align with what would be predicted for the size and shape of the 
samples from the known NMR structure (1L8C)182, molecular weights and gel 
filtration elution profile.  
 
Kratky plots describe the conformational heterogeneity of a protein, a relatively rigid 
protein will have a folded profile of a bell shape curve which returns to 0, whereas an 
unfolded protein with extreme conformational heterogeneity will not have a peak but 
will plateau at high q values, and flexible proteins with partial conformational 
heterogeneity will lie somewhere in between.  Each of the Kratky plots show the 
characteristic globular peak of a folded protein for each sample (Figure 61B). 
However, differences between the p300, HIF-1α/p300 fusion construct and co-
purified HIF-1α/p300 peaks illustrate a difference in conformational heterogeneity 
between all three of the samples. This difference was expected between p300 and the 
complexes (fusion and co-purified). The difference in Kratky plots between the HIF-
1α/p300 fusion construct and co-purified p300/HIF-1α revealed that under the 
conditions tested there is a difference in conformational heterogeneity of the 
complex dependent on whether the complex is co-purified or fused. This difference 
in conformational heterogeneity is supported by the difference in Rg and Dmax. To 
investigate this difference further the SAXS data for each protein can be compared to 






Figure 61 - Comparison of p300, co-purified p300/HIF-1α and HIF-1α/p300 fusion 
construct (concatomer). A) Comparison of the normalised pair distribution functions P(R) 






Theoretical SAXS data can be generated from the known NMR structure (1L8C)182 
of the HIF-α/p300 complex (the model)293. The p300 experimental SAXS data did 
not match well to this model (Figure 62a). However when a model was generated 
containing only p300 theoretical SAXS data from the NMR structure of the HIF-
1α/p300 complex (HIF-1α removed) the fit to p300 was improved (Figure 62b). The 
fit to this model would not be expected to match exactly as it is likely that p300 
would exhibit some conformational changes upon binding, which can not be 
accounted for in this model.  
A B 
3.4.4.1.3 Comparison with NMR structure  
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Figure 62 - Fit of the theoretical scattering profile for the rigid body model (blue line) with 
the experimental p300 SAXS data293. A) model generated from p300/HIF-1α  complex 




The co-purified p300/HIF-1α data did not fit to the HIF-1α/p300 complex model 
(Figure 63a) or the p300 model (Figure 63b). This indicates that under the conditions 
tested the p300 and HIF-1α does not appear to remain completely as a complex. As 
the data does not fit well to either model it is suspected that the sample was a mixture 
of apo proteins and complex; further analysis is required to assess how much of the 
solution is of complex and how much is of apo protein.  
 
 
Figure 63 - Fit of the theoretical scattering profile for the rigid body model (blue line) with 
the experimental co-purified SAXS data293. A) model generated from HIF-α/p300 complex 
NMR182. B) model generated from p300 NMR data (HIF-1α data removed from complex 
model) 
 
The HIF-1/p300 fusion construct α fit well to the HIF-1α/p300 model and poorly to 




folded and forms a complex in a similar way to the p300 and HIF-1α complex in the 
solution NMR structure182. This can be seen visually by generating an envelope from 
the HIF-1/p300 fusion construct and comparing it to the NMR structure of HIF-
1α/p300 (Figure 64C). The envelope was generated using the P(R) function in 





Figure 64 - Fit of the theoretical scattering profile for the rigid body model (blue line) with 
the experimental co-purified SAXS data293. A) model generated from HIF-1α/p300 complex 
NMR182. B) model generated from p300 NMR data (HIF-1α data removed from complex 
model). C) Average molecular envelope for the HIF-1α/p300 fusion construct 294 overlaid 




This SAXS experiment indicates that the HIF-1α/p300 fusion construct protein is a 
valid crystallisation target. The HIF-1α/p300 fusion construct has been shown to be 
resistant to oligomerisation (under the conditions tested), as have p300 and co-





greater homogeneity than when co-purified. As the complex will give additional 
information regarding binding and will therefore inform drug design; the fused form 




3.4.4.2 HIF-1α/p300 fusion construct crystallisation  
 
Crystallisation trials of HIF-1α/p300 fusion construct were conducted, again using 
commercially available sparse matrix screens. Unfortunately no proteins crystals 
grew in these factorial screens. The factorials were also performed under oil with no 
success. To try and change the stability of the protein, trypsin was added to cut any 
flexible regions that may be limiting crystallisation, this technique has been used to 
aid crystallisation with some success295, 296. Initially an experiment was performed to 
assess the behaviour of the HIF-1α/p300 fusion construct in the presence of trypsin. 
A 10 µL stock of trypsin was prepared in the buffer 10 mM Tris pH 7.5, 1 mM CaCl2 
and was added to 10 mg/mL of HIF-1α/p300 fusion construct (10 mM Tris pH 7.5, 
100 mM Nacl, 1 mM DTT and glycerol) to a final concentration of 1 nM, 250 nM 
and 500 nM. Each reaction was incubated at room temperature with samples at time 
points: 5 minutes, 10 minutes, 30 minutes one hour, two hours and four and a half 
hours.  
   
SAS PAGE analysis showed that the HIF-1α/p300 fusion construct was cut to a 
stable fragment (in terms of no further significant degradation) over the time course 
tested. This product remained the minority protein after the addition of 1 nM trypsin, 
however for the 250 nM and 500 nM reaction this was the majority protein after 1 
hour (Figure 65). The product was subject to mass spectrometry analysis and a mass 
of 12.48 kDa was measured for the product.  Trypsin cuts at lysines and arginines 
preferentially, when looking at the structure there is an arginine present near the N 
terminus of HIF-1α; p300, the linker region and the remaining N terminus of HIF-α 








Figure 65 – Trypsin digest analysis. A)SDS PAGE analysis of HIF-1α/p300 fusion construct   
cut with 250 nM trypsin over a time course. 0=before addition of trypsin, 1= 5 minutes, 2=10 
minutes, 3=30 minutes, 4=1 hour, 5 =2 hours and 6=4.5 hours. B) Full fused HIF-1α/p300 
with R785 highlighted (magenta), where trypsin potentially cuts (pymol, cartoon). C) Potential 
product of the after fused HIF-1α/p300 was treated with trypsin. (pymol cartoon). 
 
Crystal trials were set up using Morpheus screen (one of the sparse matrix screens). 
The HIF-1α/p300 fusion construct was incubated with 2 nM and 250 nM trypsin for 
45 minutes (as well as a sample which was not incubated with trypsin) before the 
plates were set up. The plate was more promising, with a slightly larger percentage 
of drops displaying protein precipitation than when no trypsin was present. Further 
work could consist of trying different trypsin concentrations and incubations times as 
well as trying the full complement of commercially available screens. It may also be 
worth testing the use of trypsin in a different way, trypsin can be added to the mother 
liquor as opposed to protein sample.  
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Unfortunately despite a great number of factorial screens conducted from many 
protein concentrations, buffer conditions and temperatures none of the three 
constructs (p300, co-purified HIF-1α/p300 and the HIF-1α/p300 fusion construct) 
yielded protein crystals. In total for the three constructs over 30,000 crystallisation 
conditions were tested. Further work can be conducted to trial further conditions and 
constructs, particularly the HIF-1α/p300 fusion construct which was highlighted as 
the better crystal target by SAXS. There are almost boundless possibilities for 
crystallisation conditions with very little predictability as to which condition a 




































3.5 HIF-1α/p300 chapter summary and further work 
 
 
As has been previously discussed HIF-1α/p300 is a protein-protein interaction which 
is up-regulated in many solid tumours. The challenge of disruption of the HIF-
1α/p300 interaction come as HIF-1α wraps around p300, with multiple potential sites 
for small molecule modulation, however which of these sites to target is unclear 
(Figure 17). Work conducted on this target involved biophysical and structural 
characterisation for the elucidation of the binding interface to try and locate binding 
hotspots, which could subsequently be used in the rational drug design progress. This 
was done by two approaches; firstly by analysis of the binding of shorter HIF-1α 
peptide fragments, this piece of work highlighted HIF-1α helix 3 as a key binding 
region. The second approach used phage display for unbiased exploration of the 
p300 surface. Two phage display technologies were used; a peptide phage library 
and an Adhiron (Affimer) phage display library.  
 
The peptide phage display library experiment yielded a peptide which bound with a 
higher affinity than any of the short native fragments, NMR and mutations in p300 
indicated that this peptide was binding in or around the helix 3 binding pocket. 
Oligoamide α-helix mimetics were designed against the helix 3 binding pocket, 
which disrupted the interaction with an IC50 = 9  µM. The Adhiron phage display 
experiment generated Adhirons around 100 nM, which disrupt the interaction IC50 = 
1-5 µM. The crystal structure of the Adhiron docked to the NMR structure of p300 
suggested that the interaction was mediated through the two variable loops. 
Therefore potentially two sites are required for potent inhibition of the interaction. 
 
This study demonstrated that HIF-1α/p300 is a high affinity interaction, which is 
difficult to inhibit; no short peptide region was able to disrupt the interaction. 
However, despite such challenges, inhibitors that do disrupt the interaction were 
designed. These compounds have been designed by mimicking the helix 3 region of 
HIF-1α using the Wilson group oligoamide scaffold96, 98. This work could be 
furthered by testing of these compounds in a cell-based assay, to give information 
about cytotoxicity and cellular potency. Other oligoamides, which have been 
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designed against different targets7, 96, 98, 246, 297-299, have been shown to be active in 
cells299.  
Structure affinity relationship studies have been conducted for the oligoamide 
compounds244, however further improvements to the compounds could be made to 
improve their properties. Attempts have been make to improve the solubility of 
scaffold246, 297, 300, as this is a limiting factor for some biophysical (ITC) and 
structural (NMR and crystallography) techniques. An N-alkylated oligoamide as 
opposed to the O-alkylated scaffold Figure 66 used to disrupt the HIF-1α/p300 have 
been synthesized117, 246, as have compounds which replace the central monomer 
which a natural amino acid300 Figure 66. Both of these adaptations have reported to 
improve the solubility of the scaffold. Such adaptations have shown to be tolerated 
on other PPI targets246, but suitably functionalized scaffolds did not inhibit the HIF-
1α/p300 interaction.  
 
 
Figure 66 – Structures of helix mimetic scaffolds. A) O-linked oligoamide. B) N-linked 
oligoamide. C) Hybrid scaffold replacing the central monomer with a natural amino acid. 
 
A B C 
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The phage display derived peptide binds to p300 with a higher affinity than any 
fragment of the native HIF-1α peptide of the same length, further studies to assess 
the binding confirmation of this peptide will allow for this peptide to be mimicked. 
As the phage peptide binds with a higher affinity than helix 3 it would be hoped that 
a mimetic would also be more potent. As the peptide may not be α-helical other 
small molecules may be able to mimic the peptide using a different scaffold. The 
ideal way to assess the binding conformation would be X-ray crystallography. 
However with a 20 µM binding affinity co-crystallisation might be difficult, and as 
p300 has proven difficult to crystallise the task may be more challenging. The NMR 
structure of the complex could be solved using multidimensional NMR studies, this 
would allow the complex to be visualised not just the binding region highlighted as 
in this study.  
 
The Adhiron phage display experiment generated nanomolar affinity binders of 
p300, a higher affinity than both the fragments of native HIF-1α peptide and the 
phage display derived peptide. Unlike the fragments and the phage display derived 
peptide the Adhirons were able to disrupt the HIF-1α/p300 interaction. There are 
many possible reasons as to why the Adhirons perform better, two of which are; the 
constraints on the peptide loops decrease the entropic cost of binding, and more than 
one binding site is required to disrupt the interaction, which is achieved by the two 
loops. If the binding is mediated through the two variable loops; a larger interaction 
area is being reached. As was previously discussed further validation of the binding 
mode is required to verify the binding mode of the Adhirons. However, if the 
Adhiron is binding in the predicted way there may be a potential to exploit fragment 
based drug design to target the HIF-1α/p300 interaction.  
The FBDD approach could be used in different ways to exploit the two sites 
identified by the two loops of the adhiron. If one fragment is identified which binds 
in one of the sites then this fragment could be optimized by fragment growth, with 
the fragment growing out to reach the second site.  For this to be successful the sites 
need to be in relative close proximity and the initial fragment must act as an 
“anchor” and not change its binding mode during its growth301. Another method of 
exploiting the two sites is by fragment linking, which is possible if two fragments, 
one binding at each site, are identified.  Such fragments could be linked directly 
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(although the two sites are likely to be too distant) or by a suitable linker. This may 
be challenging, as the linker must allow both fragments to maintain their original 
binding modes while combined in the new hybrid ligand301.  
Having structural data benefits the FBDD process greatly302. A soakable crystal 
system would not only allow for the discovery of binders but also give information 
regarding the binding mode of the fragment. Allowing for informed decisions 
regarding optimisation strategy. Therefore the lack of a crystallisable p300 construct 
may be a limiting factor. However the recent success of fragment based approaches 
and the indication that inhibition of HIF-1α/p300 is more likely through the targeting 
of multiple sites FBDD is an exciting prospect for inhibitor development of the HIF-
1α/p300 interaction.  
The Adhirons have been reported to be monomeric and stable122, however the 
Adhirons which bind to p300 have demonstrated a tendency towards aggregation. 
The gel filtration trace displayed oligomerisation peaks and the crystals structure 
indicated dimerization. Analysis of the dimer revealed hydrogen bonding from the 
loop region to the β sheet of the second adhiron (Figure 53). This tendency for 
dimerisation (and even the formation of higher order oligomers) may mean that the 
concentration of active protein is lower than that measured, therefore the Adhiron is 
more active than reported. Polar and charged residues could be introduced to the 
scaffold, at the base of the loop regions, to obstruct the dimerisation.  
As can be seen there is much more work that can be completed to further the project. 
However the characterisation of the interaction thus far has allowed for the 
development of small molecules, which disrupt the interaction. Therefore the 










As discussed briefly in the introduction, there was a second PPI target in this project 
eIF4E/eIF4G, which is also a potential cancer therapeutic target. This chapter will 
discuss the relevance and importance of this target and the biophysical and structural 
characterisation of the interaction with a view to informing inhibitor design. 
 
4.1.1 Eukaryotic translation 
 
The control of mRNA translation is important for cell growth, proliferation and 
differentiation152, and is one way in which protein levels may be selectively regulated167. 
Translation requires an initiation step where the Cap (m7GpppN) at the 5’ end of an 
mRNA binds to a ribosome.  This initiation is mediated by many eukaryotic initiation 
factors (eIFs)167; a key initiation factor is eIF4E. eIF4E is the Cap binding protein 
involved in directing the ribosome to Capped mRNA303. The Cap is located at the 5’ 
end of all cellular eukaryotic mRNAs. eIF4E binds the Cap when in complex with 
eIF4A (the RNA helicase) and eIF4G (the multidomain adaptor), this complex is known 
as eIF4F ( 
Figure 67A). eIF4E is described as the master switch that controls eukaryotic 
translation, as it is rate limiting for eIF4F complex formation. The interaction of eIF4E 
with eIF4G to form eIF4F is tightly and negatively regulated by eIF4E-binding proteins 
(4E-BPs), a family of inhibitory proteins that sequester eIF4E by occupying the same 
binding site as eIF4G304, 305, therefore the availability of eIF4E to bind to eIF4G relies 
on release from 4E-BP169 ( 






Figure 67 - Control of cap dependant translation. A) Formation of the eIF4F complex of 
eIF4E, eIF4A and eIF4G, allows the binding of the cap of mRNA which subsequently 
recruits the ribosome. B) 4E-BP bindings at the same site as eIF4G, blocking eIF4G binding 
which stops the formation of the eIF4F complex. 
 
The eIF4E/4E-BP binding event is controlled by phosphorylation, 
hypophosphorylated 4E-BPs bind strongly to eIF4E (therefore less eIF4E is available 
for binding to eIF4G), resulting in little or no formation of the eIF4F complex, 
whereas the hyperphosphorylated forms bind weakly152, 306, allowing eIF4G to 
compete for the binding of eIF4E and realise eIF4F assembly. Phosphorylation is 
mediated by many extracellular stimuli including growth factors, hormones, 
mitogens, amino acids, cytokines and G-protein-coupled receptor agonists152, 306.  
 
To become translated, mRNAs must interact with eIF4E within fully assembled 
eIF4F complex; those mRNAs with a short, unstructured, 5'UTR interact more 
readily than mRNA with highly structured 5'UTRs which are therefore translated less 
efficiently152. Consequently overexpression of eIF4E, which occurs in approximately 
30 % of all cancers, results in increased translation of mRNAs containing highly 
structured 5'UTRs, which include mRNAs encoding cancer-related proteins304 that 
control cell proliferation and viability307 and growth-promoting gene products such 
as cyclin D1, c-myc and VEGF152, 308-310. It is this increased translation of growth-
promoting gene products and cancer related proteins that may be a trigger for cancer 
development. eIF4E is a recognized oncogene as it is up-regulated in up to 30 % of 
human tumors, including breast, prostate and lung cancers  as well as in many 
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leukemias and lymphomas303. The connection between overexpression of eIF4E and 
tumour development has been validated in cell culture and in animal models as the 
up-regulation led to oncogenic transformation (in cells) and tumor formation (in the 
animal models)303.   
 
4.1.2 Inhibition of cap dependent eukaryotic translation  
 
There are multiple points on the Cap dependent translation pathway that are potential 
targets for modulation to decrease the up-regulated translation of cancer-related 
proteins and growth promoting gene products. Areas that offer the opportunity for 
modulation include; the release of eIF4E from 4E-BP which increases the 
availability of eIF4E to form the eIF4F complex, the formation of the eIF4F complex 
and the binding of the mRNA Cap to eIF4E.  
 
4.1.2.1 Phosphorylation state of 4E-BP 
The binding of eIF4E to 4E-BP is controlled via the phosphorylation state of 4E-BP. 
When hypophosphorylated (little or no phosphorylation) 4E-BP binds to eIF4E with 
a greater affinity than when hyperphosphorylated. This affect is due to the fold of 
4E-BP. Recent work has shown that in the hyperphosphylated state 4E-BP forms a 
highly structured β sheet fold. There is a key binding motif YXXXXLΦ (where X is 
any amino acid and Φ is hydrophobic) of 4E-BP (also present in eIF4G) which is 
required to be α-helical for binding, therefore when hyperphosorylated and in the β 
sheet fold no binding occurs169. When hypophosphylated 4E-BP is intrinsically 
disordered, the YXXXXLΦ motif is able to become α-helical and therefore 4E-BP is 
able to bind to eIF4E311. As 4E-BP and eIF4G compete for the same binding site of 
eIF4E312, the higher the affinity of the interaction between 4E-BP and eIF4E the less 
eIF4E is available to interact with eIF4G; therefore the formation of the eIF4F 
complex is limited and Cap dependent translation is decreased. Controlling the 
phosphorylation of 4E-BP is therefore a potential way of controlling the formation of 
the eIF4F complex. If the phosphorylation of 4E-BP were inhibited then more eIF4E 
would be bound to 4E-BP (and therefore less in the eIF4F complex). However the 
phosphorylation of 4E-BP is complex and specific inhibition of phosphorylation is 
extremely challenging.  
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The natural product Rapamycin313 (Figure 68) and its analogues, have been shown to 
inhibit 4E-BP phosphorylation by blockade of the mechanistic target of Rapamycin 
(mTOR) pathway314, 315. mTOR is a serine/threonine kinase, part of the 
phosphatidylinositol 3-kinase-related kinase family, and is regulated through the 











Figure 68 – Structure of Rapamycin (chem draw image drawn from pubchem, pubchem ID: 
5284616). 
 
The pharmacokinetic properties of Rapamycin are poor due to its lipophilicity317; 
therefore three analogues (Figure 69) that differ by their formulation and 
bioavailability but not by the mechanism of action have been developed. 
Temsirolimus (Wyeth/Pfizer), which has been FDA approved, Deforolimus or 
Ridaforolimus (Merck/Ariad) and Everolimus (Novartis)315.  This is one example 
where the phosphorylation of 4E-BP has been inhibited resulting in an anti-cancer 
agent. It is likely that there are many more opportunities for modulation in the 
mTOR and indeed other pathways to regulate the phosphorylation of 4E-BP, 
however the network of multiple pathways is complex therefore the likelihood of 
generating a specific ligand maybe problematic.     
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Figure 69 – Structures of Temsirolimus (pubchem ID:6918289), Deforolimus (pubcehm 
ID:11520894) and Everolimus (pubchem ID:6442177) 
       
4.1.2.2. eIF4E/mRNA Cap interaction     
Inhibition of the binding of the mRNA Cap to eIF4E is another potential point for 
inhibition of Cap dependent translation. For eIF4E to exert its role as an initiation 
factor it must bind to the methyl-7 guanosine (m7G) Cap structure on the 5’ end of 
mRNAs318. A guanosine ribonucleoside analogue, 1-β-D-ribofuranosyl-1,2,4-
triazole-3-carboxamide (Ribavirin), a drug which has been used for the treatment of 
infections including Lassa fever virus, respiratory syncytial virus, hepatitis C virus 
(HCV), and severe acute respiratory syndrome coronavirus319, has been shown to 
also disrupt the eIF4E/Cap interaction320. Initially it was shown that Ribavirin was 
misincorporated into mRNA by viral RNA-dependent RNA polymerases321, 322 due 
to its chemical similarity to guanosine, leading to lethal mutagenesis of polio and 
HCV genomes. More recently direct binding of Ribavirin to eIF4E (in the m7G 
mRNA Cap binding site) has been observed both in vitro and in cells; again most 
likely due to its similarity to guanosine320. Therefore Ribavirin inhibits eIF4E from 
promoting mRNA translation of eIF4E-sensitive transcripts, many of which are 
involved in cancer development320.  
 
Another inhibitor of the mRNA Cap/eIF4E interaction is a guanine-derived inhibitor 
(Kd (for eIF4E) = 95 nM, IC50 = 2.5 µM), discovered using structure guided drug 
design323. A crystal structure revealed that this compound bound by the same binding 
mode as Cap (Figure 70). This inhibitor was also shown to be selective, with no 
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Figure 70 – Structure of guanine-derived inhibitor (magenta) of the  mRNA Cap/eIF4E 
interaction bound in Cap binding sire of eIF4E (cyan). 
 
4.1.2.3 eIF4F complex  
The disruption of the eIF4F complex is another way to decrease cap dependent 
translation of cancer-related proteins and growth promoting gene products. 
Disruption of the eIF4E/eIF4G interaction would subsequently disrupt the eIF4F 
complex. There has been some success disrupting this interaction using small 
molecules. A high throughput approach was used to identify the small molecule 
4EGI-1324, 325 which disrupted the interaction with an IC50 = 16 ± 6 µM, this 
compound also inhibited cap-dependent translation in vitro in Renilla luciferase 
reporter assay system and similar affects were seen in mammalian cancer cell 
lines326. Structural studies have shown that this inhibitor acts through an allosteric 
mechanism. 4EGI-1 bindings to eIF4E at a site distinct from the eIF4G binding site, 
binding in a hydrophobic pocket which causes localized conformational changes, 
which causes an α-helical rearrangement, which is turn appears to stop the binding of 
eIF4G327. Another small molecule, 4E1R-Cat, was identified by library screening, 
this molecule inhibited eIF4E/eIF4G with an IC50 of 4 µM. Crucially 4E1R-Cat is 
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capable of reversing tumor chemoresistance in a genetically engineered Eµ−Myc 






Figure 71 – Structures of 4EIR-Cat (MDL number:MFCD01931282) and 4EGI-1 (CAS 
number:315706-13-9) 
 
Another approach used successfully to disrupt the eIF4E/eIF4G interaction is a 
stapled peptide approach. To staple the peptide, a hydrocarbon linker between turns 
of an α-helix was introduced; in theory this should stabilize the secondary 
structure329. This stabilisation should allow higher affinity binding due to the 
reduction of the entropic cost of binding. Proteolytic stability should also be 
improved, increasing the in vivo half life330. However, the introduction of a staple 
does decrease the conformational freedom of the peptide, therefore the location of 
the staple is important.  A stapled variant of the eIF4G peptide has previously been 
produced168. The location of the staple as well as mutations in the native binding 
sequence were explored when designing the stapled version of the eIF4G peptide. 
Initially mutations (made outside the key binding motif YXXXXLΦ) were made to 
stabilize the helix168, the mutations consisted of the inclusion of 1-
aminocyclopentane carboxylic acid; this non-natural amino acid was chosen as it is 
thought to force the peptide in a conformation more similar to that observed in the 
peptide-protein complex and thus reduces the entropic cost of binding168. The second 
mutation, an α-carbon methylation of the peptide backbone was chosen as it was 
thought it would rigidify the peptide further. The location of each of the mutations 
was decided by sequential mutagenesis studies. The mutations were reported to cause 
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a 15 fold increase in affinity168. Phage display was then used to further improve the 
potency of the peptide, from this experiment the peptide 1SLHYSRDQLVAL12 was 
selected. This peptide maintained the characteristic binding motif (Y624, L629 and the 
hydrophobic position at 630) seen in the eIF4G peptide, although the rest of the 
peptide is different (1KKRYDREFLLGF12). This phage display derived peptide was 
insoluble and highly intractable therefore the N-terminal SLH sequence was changed 
to KKR, to match the native eIF4G peptide sequence. This modified peptide had an 
improved solubility and a 6-fold higher affinity for eIF4E than eIF4G. To investigate 
where this additional affinity was coming from, peptides were synthesized which 
introduced each residue from the modified peptide in to eIF4G individually. This 
study highlighted two key substitutions that improved the affinity of the eIF4G 
peptide, a D to S substitution at position 5 (4.6 fold improvement) and a G to A 
substitution at position 11 (2.3 fold improvement)331. This peptide was then 
constrained to further improve potency. Table 26 demonstrates that the location of 
the staple has a large effect on affinity (sTIP-01 compared to sTIP-02) The helicity 
of the stapled peptides were shown to be greater than that of the unstapled variant332, 
and the stapled peptide which with the greatest helicity also had the greatest affinity. 
Competition fluorescence polarisation experiments showed the ability of stapled 
peptides to disrupt the eIF4E/eIF4G interaction, with the highest affinity analogue 
having an apparent Kd of 3 nM332.  
 
Table 26 – Peptide sequences, affinity and helicity of eIF4G peptide (including mutation 
D5S) and stapled variants.  The symbol (*) signifies positions that are linked by the 
hydrocarbon staple. 
Name Sequence Kd SPR/FP (nM) Helicity (%) 
eIF4GD5S KKRYSREFLLGF 99.9 ± 6.2 /195.2 ± 12.1 0 
sTIP-01 KKRYSR*FLL*F NA /558.0 ± 59.5 24 
sTIP-02 KKRYSRE*LLG* 109.6 ± 4.6 /146.7 ± 1.7 18 







4.1.3 Structural characterization of eIF4E/eIF4G 
 
The more structural and biophysical information available the more informed the 
rational design process. The crystal structure of eIF4G bound to eIF4E has 
previously been solved (PDB: 2W97)174 (Figure 72). Mutagenesis studies have 
highlighted key binding residues of eIF4G (Y624, L629, Leu630, F628 and F632). 
Although not in the helix Y624 makes a significant contribution to binding by 




Figure 72: Crystal structure of eIF4G (red) binding eIF4E (cyan). Key binding residues of 
eIF4G are highlighted in green. 
 
Complications in designing compounds may arise as not all the key binding residues 
are on the same face as the helix. Traditional α-helix mimetics have focused on 
designing scaffolds which mimic one face of the helix, although it should certainly 
be possible to design a small molecule scaffold which mimics side chain projections 
from more than one helical face. This chapter will discuss the work conducted to 
characterise the eIF4E/eIF4G interaction to inform rational drug design. 
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4.2 eIF4E/eIF4G Aims 
 
 
The aims of this part of the project were to structurally and biophysically 
characterise the eIF4E/eIF4G interaction for the rational design of small molecule 
modulators able to disrupt the interaction.  
 
4.3 Protein production  
 
 
As with the work conducted for the distribution of the HIF-1α/p300 interaction the 
first step was to clone and express the protein. PCR was used to clone eIF4E into 
pET-SUMO, pET-GFP-28b-PreScission; and pGEX-6p-2. Expression trials for each 
of these constructs transformed into expression strains E.coli BL21 (DE3) pLysS 
Gold, Star and Rosetta 2 were conducted. Initial trials of small-scale cultures (10 
mL) were produced and all were initially induced with 0.4 mM IPTG at 18 °C for 18 
hours. SUMO-eIF4E (35 kDa), GST-eIF4E (48 kDa) and GFP-eIF4E (53 kDa) were 
all overexpressed, however all the protein appeared to be largely insoluble Figure 73.  
Further trials were conducted, investigating IPTG concentration, incubation 



















Figure 73 - SDS PAGE analysis of GST-eIF4E as part of the initial expression trials. MW = 
molecular weight marker, I = insoluble fraction. S = soluble fraction UI = uninduced  
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Autoinduction was used to try to obtain soluble protein. Autoinduction is generally 
considered to be a more sensitive approach to protein expression than IPTG 
induction236, therefore it was hoped that a larger percentage of protein would remain 
soluble. The greatest expression by autoinduction was observed for the SUMO-
eIF4E construct expressed from Star cells with a yield of approximately 33 mg 
SUMO-eIF4E from 400 mL growth culture. SUMO-eIF4E was purified by size 
exclusion chromatography and the major peak was collected (Figure 74), both SDS 
PAGE and mass spectrometry confirmed the size of the expressed protein (within the 






Figure 74 - Size exclusion chromatography trace for SUMO-eIF4E, the major peak was 
collected and the fractions run on an SDS PAGE gel (inset). 
 
The SUMO was cleaved from eIF4E using SUMO protease by incubation for 
approximately 18 hours. Imidazole was removed by dialysis. The mixture was then 
applied to a second Ni2+ column, the eIF4E was eluted in the flow through, initial 
wash (0 % imidazole) and 50 mM imidazole wash. eIF4E was further purified by 
size exclusion chromatography. 
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The EIF4G peptides (RYDREFLLGFQ) both with and without a fluorescein tag 
were synthesised by solid phase synthesis by George Burslem (University of Leeds). 
The helicity of the eIF4G peptides was investigated by CD (Figure 75). In phosphate 
buffer (40 mM sodium phosphate pH 7.5, 200 mM sodium phosphate, 1 mM DTT 
and 5 % glycerol) both peptides adopted an irregular structure, however when 
solubilized in trifluoroethanol (TFE) both peptides appeared to contain an α helical 
component134, although this spectra is not a classical α helical spectra.  
 
Figure 75 - CD analysis of the eIF4G peptide, both FITC labelled and unlabelled and in 



































eIF4G in TFE 
FITC-eIF4G in TFE 
eIF4G in buffer 
FITC-eIF4G in buffer 
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4.4 eIF4E binding studies 
 
The first binding study conducted was a fluorescence anisotropy direct binding 
assay. SUMO-eIF4E was titrated against 40 nM FITC-eIF4G, in buffer (40 mM 
sodium phosphate pH7.5, 200 mM sodium phosphate, 1 mm DTT and 5 % glycerol). 
A Kd of 1480 ± 730 nM was measured. To ensure that eIF4G was binding to eIF4E 
and not to SUMO the fluorescence anisotropy assay was conducted for eIF4E, a Kd = 
710 ± 110 nM was measured (Figure 76). The control of a SUMO titration was also 
conducted to ensure that the binding was specific. No binding of FITC-eIF4G to 
SUMO was seen within the concentration range measured. Larger proteins should 
give greater changes in anisotropy; hence SUMO-eIF4E was used for further 
fluorescence anisotropy binding and competition assays (for a better signal to noise 




Figure 76 - Fluorescence anisotropy assay measuring the binding of SUMO-eIF4E (black) 
and eIF4E (red) binding to FITC-eIF4G. 
 
The robustness of the assay was assessed by checking the variation at different time 
points ( 
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Figure 77A) and temperatures ( 
Figure 77B). No change in affinity measured was observed between a 30 minute 
incubation and a 5 hour incubation (Kd after 30 minutes 1848 ± 252 nM and after 5 
hours = 1754 ± 98 nM) ( 
Figure 77A). The next time tested was 18 hours, the data collected at this time point 
was poor. A change in anisotropy was seen in a temperature dependent manor, this 
change is most likely due to an increase of kinetic energy in the system at higher 
temperatures, resulting in a faster overall tumbling rate of both the unbound and 
bound fluorophores. Despite the change in anisotropy no temperature dependent affect 
on affinity was observed within the temperature range tested (Kd 21 °C = 1800 ± 300 
nM, Kd 25 °C = 4100 Kd 30 °C = 3700 ± 400 and Kd 35 °C) ( 




Figure 77 –Testing the robustness of the fluorescence anisotropy assay. A) testing the 
change in affinity of the eIF4E/eIF4G interaction over a 5 hour period,  30 minutes (black) 
and 5 hours (red). B) the change in affinity of the eIF4E/eIF4G interaction over a 
temperature range, 21 °C (black), 25 °C (red), 30 °C (purple) and 35 °C (blue). 
 
 165 
It has been shown that the presence of eIF4G increases the affinity of Cap for eIF4E 
(approximately a 7-fold increase), although Cap does not bind to eIF4G itself333. A 
study to assess if the binding of Cap affects the affinity of eIF4G for eIF4E had 
previously been conducted. SPR was used to measure the Kd of the interaction in the 
presence and absence of Cap (m7GpppG). The results showed that eIF4G binds 
eIF4E and eIF4E·m7GpppG with the same affinity, although the authors recognised 
that this is contradictory to some previous studies334, 335. Due to this contradiction the 
effect of both Cap and Cap analogue (Figure 78) was tested in the fluorescence 
anisotropy assay (Figure 78). In this assay the presence of Cap and Cap analogue had 
no effect on the affinity of the eIF4E/eIF4G interaction (Kd with no additive =7740 ± 
1400 nM, Kd + Cap analogue = 4810 ± 52 nM and Kd + Cap analogue = 7780 ± 1300 
nM, due to the poorer quality data these data were fitted with a logistic fit rather than 





Figure 78 – Structures of Cap and Cap analogue, which have been tested in the fluorescence  











































Figure 79 – Fluorescence anisotropy analysis of the effect of Cap (blue) and Cap analogue 
(red) on the binding of eIF4E (black) to eIF4G. 
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4.5 eIF4E/eIF4G inhibitor development  
 
A fluorescence anisotropy competition assay was developed as a screen for potential 
inhibitors. To develop this assay the initial ligand used for disruption of the 
eIF4E/eIF4G interaction was unlabelled eIF4G. This ligand was able to disrupt the 
eIF4E/FITC-eIF4G interaction (1 µM eIF4E and 40 nM FITC-eIF4G) with an IC50 = 





Figure 80 - Fluorescence anisotropy competition assay testing the inhibitor Capability of 




Initially, known inhibitors were selected and tested. The inhibitor 4E1RCat was 
measured to have an IC50 = 7.75 ± 0.41 µM, (Figure 81) this is similar to the 
published IC50 (≈ 4 µM328).  The published inhibitor 4EGI-1 was also tested, 
however the inherent fluorescence of the compound disrupted the fluorescence 




Figure 81 – Fluorescence anisotropy competition assay testing the inhibitor 4E1RCat 
 
A rational design approach was employed to design small molecules to disrupt the 
eIF4E/eIF4G interaction. Initially the O-linked oligoamide helix mimetic scaffold96 
was used. Traditionally, as with the HIF-1α mimetics, this scaffold has been used to 
project 3 key side chains in the same spatial orientation as would be projected by the 
i, i+4 and i+7 side chains of an α-helix. A potential limitation of using this scaffold 
to disrupt this interaction is that the key side chains (Tyr624, Phe628, Leu629, Leu630 and 
Phe623; highlighted as key binding residues by mutagenesis studies168) of eIF4G are 
not presented on one face of the helix. Two oligoamide scaffolds were tested (which 
had been previously tested against the HIF-1α/p300 interaction; synthesised by 
George Burselm, University of Leeds), one which included three phenylalanine side 
chains (oligoamide 6) and the second which was designed to mimic HIF-1α, 
mimicking two leucine and a valine side chain (oligoamide 1). Neither of these 





As neither of the oligoamides disrupted the interaction with notable affinity a 
different scaffold was developed. It was hoped that this scaffold would project side 
chains Tyr, Phe and Leu, in a similar spatial orientation (from multiple helix faces) as 
the eIF4G helix. However this compound (eIF 1) did not disrupt the interaction with 
an IC50<1mM (Figure 83), therefore inhibitor development for this target was not 





Figure 82 - Fluorescence anisotropy competition  assay testing the alpha helix mimetics 






Figure 83 - Fluorescence anisotropy competition assay testing the designed eIF4G mimetic 





















4.6 Phage display 
 
As with the HIF-1α/p300 study a peptide phage display experiment was performed to 
try and generate higher affinity peptides for eIF4E. As no inhibitors have been 
rationally designed, the discovery of a different pharmacophore would be a new 
starting point for the design process. It has been demonstrated, by solving the crystal 
structures of both 4E-BP (1EJ4) and eIF4G (1EJH) bound eIF4E that the two peptide 
binding regions are molecular mimics of each312. Both 4E-BP and eIF4G have the 
motif YXXXXLΦ, which becomes α-helical in the presence of eIF4E and is required 
for binding312. Phage display may identify a different binding motif or may show a 
preference for one of the central residues (X in the motif).  
 
Initially eIF4E was biotinylated using the commercially available Sulfo-NHS-LC-
biotin (Thermo Scientific), the activity was shown to be comparable to unlabelled 
eIF4G in the fluorescence anisotropy competition assay. The phage display libraries 
selected for use were the NEB 7mer and 12mer libraries. As with the p300 phage 
display experiment two buffer conditions were used (high and low salt) and the 
elution strategy used was competition with eIF4G peptide (500 µM). Three panning 
rounds were completed, the unpanned libraries, the first and third panning round 
clones were then sent for sequencing using the Illumina platform (sequencing results 
are summarised in (Table 27). An ELISA was conducted to assess the enrichment of 
the phage display libraries through the panning rounds. This ELISA measured the 
percent of binders in the eluted pool of each panning round. A general trend of 
enrichment was seen, however sequential enrichment through each round was not 
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12mer library 0.5 M NaCl  
Figure 84 – Enrichment ELISA for each condition of the eIF4E phage display 
experiment, showing an enrichment from the unpanned library to the third panning 
round. 
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Condition Unpanned sequence and frequency Round 1  sequence and frequency Round 3 sequence and frequency 


































































































































The sequencing result did not clearly show one peptide which had been 
systematically enriched through the rounds of panning and no one peptide appeared 
in the elutes of multiple conditions. This indicated that the enrichment was poor.  
However two 12mer sequences were selected 1AADKVRPESWRM12 (eIF PDDP1) 
and 1HSKAFPVLYPLR12 (eIF PDDP2).  Neither of these peptides showed the 
conserved motif of eIF4G and 4E-BP, although some comparisons can be made. The 
C terminal residue M12 of eIF PDDP1 is hydrophobic (in the same way as the 
hyrdrophobic residue 630 of eIF4G and 4E-BP. eIF PDDP2 contains a Tyr (position 
9) and a Leu (in position 11), which is similar to the biding motif, however this 
peptide has a hydrophilic C terminus. These peptides were purchased with an N 
terminal fluorescein and tested for binding affinity using the fluorescence anisotropy 
assay (Figure 85). Neither of the phage display peptides bound with an affinity 
higher than 500 µM, which is lower affinity than the native eIF4G peptide, therefore 




Figure 85 - Fluorescence anisotropy assay testing the binding of the peptides (eIF PDDP1, 
black and eIF PDDP 2 red) generated by phage display to eIF4E.  
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The low affinity of the peptide may be due to the high entropic cost of binding, the 
helical prediction software, Agadir255, predicted each peptide to be only 2 % helical 
in isolation. The ability of the peptides to form a helix may therefore be poor. CD 
studies, as were conducted for the native eIF4G peptide, would confirm if the 
peptides were able to form helices when induced. Structural studies would confirm if 
the peptides bind in a helical confirmation. 
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4.7 eIF4E Crystallography  
 
There have been several crystal structures published of eIF4E, both apo 
(PDB:3TF2336, 2W97174) and in various complexes; bound to eIF4G (PDB:2W79174), 
4E-BP (PDB:4UED337, 3U7X336, 3HX1338, 1EJ4312 and 1WKW339) and inhibitors 
(PDB:4TPW327, 4BEA(stapled peptide)332 and 4DT6323). However, none of these 
structures show eIF4E to be in a soakable form or indeed to bound to an eIF4G 
orthosteric inhibitor. To further the development of inhibitors a soakable crystal form 
that could be utilised for obtaining small molecule inhibitor bound structures would 
be immensely useful.  
 
A pure and homogeneous sample of eIF4E was produced and screened at 8-10 
mg/mL for initial crystallisation conditions using commercially available sparse 
matrix screens. The screens were set up in sitting-drops with various protein:mother 
liquor ratios across all conditions and at a range of temperatures. In parallel the 
literature condition, 20 % PEG 3350, 0.2 M diammonium citrate, 16 °C, from which 
apo_eIF4e crystals grew336 was set up. Crystals grew in this condition and in one 
condition from the factorial screens, 20 % PEG 4000, 0.1 M sodium citrate pH 5.5 
and 10 % 2-propanol (v/v). From this initial factorial hit and literature condition, 
optimization screens varying protein concentration, percent PEG 4000, pH, percent 
isopropanol and ratio of protein to mother liquor were set up. Microcrystals appeared 
in many of these conditions; the most promising condition was 17.5% PEG 4000, 0.2 
M ammonium citrate, 25 °C; therefore an additive screen was conducted around this 
condition to improve crystal quality and size. A commercially available Additive 
Screen (Hampton Research) was used in 96-well sitting-drop format. This is a screen 
consisting of small molecules known to affect crystallisation by altering protein 
solubility, manipulating protein-solvent interactions, or perturbing the structure that 
water molecules form around the target protein. Several additives appeared to 
visually improve crystal quality, including sodium fluoride, gly-gly-gly, spermadine, 
trehalose and ethyl acetate. Multiple crystals were picked from each additive 





Many crystals diffracted, three additive conditions (sodium fluoride, gly-gly-gly and 
spermidine) diffracted to 2.7Å, the highest resolution data came from the condition 
17.5% PEG 4000, 0.2 M ammonium citrate, 25 °C with the additive trehalose and 
diffracted to 2.45 Å, the crystal structure was solved by molecular replacement Table 
28. 
Table 28 - Crystallographic data and refinement statistics for apo_eIF4E 
Data set eIF4E-apo 
Wavelength (Å) 0.97949 
Space group P21 
Cell parameters (Å,º) a = 39.263 
b = 110.333 
c = 81.118 
α= 90.00 
β = 101.77 
γ = 90.00 
Total reflections 65,872 (9,483) 
Unique reflections 22,265 (3,253) 
Resolution shells(Å)   
Low 39.79-8.03 
High 2.68-2.54 
Rmerge (%)  9.1 (41.3) 
Rfree (%)  27.89 
Rpim (%) 6.9 (33.3) 
Rcryst (%)  24.88 
Completeness (%) 99.3 (99.7) 
Redundancy 3.0 (2.9) 
I/s(I) 6.9 (2.3) 
VM (Å3/Da) 1.71 
Mol. per AU 4 
Reflections working set 21152 
Free R-value set (No. of reflections) 5.0% (1113) 
RMSD bond lengths (Å) 0.0048 
RMSD bond angles (º) 0.916 
No. of atoms used in refinement  
Non-hydrogen atoms 5,788 
Water molecules 0 
Mean B value (Å2)  
Total 49.752 
Water molecules N/A 
Ramachandran plot statistics (%)  
Preferred region 96.3 




It was initially hoped that the eIF4E would form a soakable crystal system, as 
a soakable crystal form maybe used for the hit discovery and optimisation. 
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However the eIF4G binding site appears to be enclosed within the crystal form 
and is not exposed to solvent channels (Figure 86). Therefore the apo-eIF4e 
crystals are unlikely to be a soakable system. Consequently, co-crystals 
structures of eIF4E with inhibitor bound will need to be made via co-
purification of eIF4e and inhibitor, unless an alternative crystal condition is 




Figure 86 - Crystal structure of apo-eIF4e. Each of the 4 molecules in the asymmetric unit is 
coloured separately with the eIF4G binding site coloured orange. The squares highlight the 
non-solvent accessible binding site. 
 
Attempts have been made to co-purify eIF4E and the inhibitor 4E1RCat, however 
the solubility limit of 4E1RCat has restricted the co-purification as the complex is 
not stable to gel filtration. Analogous compounds, which were hoped to be more 
soluble, were purchased and co-crystallisation was attempted, however all crystals 
that grew were in the apo form. None of these crystals differed in form to those 
structures previously solved therefore no further optimisations were made. 
Unfortunately as none of the ligands rationally designed in this study disrupted the 
interaction with a sufficient potency, co-crystal trials with these ligands were not 
possible. eIF4E appears to crystallise readily in many different conditions, as seen 
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from the number of crystal structures in the literature and the number of crystals 
obtained during this study, therefore a soakable crystal form may still be achievable. 
Many more crystals may be required to be screened; with the advances in high 
throughput crystallography this should be feasible. 
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4.8 eIF4E/eIF4G Summary and Further Work 
 
In this project eIF4E was cloned, expressed and biophysically characterised for 
eIF4G binding. The disruption of the eIF4E/eIF4G interaction is a therapeutically 
relevant anticancer target, as the prevention of the binding of eIF4E to eIF4G would 
limit the formation of the eIF4F complex, resulting in a decrease in the cap 
dependent translation of proteins associated with cancer development and 
progression. This project has cloned and expressed the eIF4E protein and 
biophysically assessed its ability to form a complex with eIF4G in the presence and 
absence of mRNA cap. A robust assay has been established for the testing of 
potential inhibitors.  
 
As the first generation ligands and phage display peptides did not bind to eIF4E or 
disrupt the eIF4e/eIF4G with notable affinity, much of the emphasis of the overall 
project focused on the HIF-1α/p300. However the robust biophysical assays for the 
testing of potential inhibitors has left a strong platform to build upon. Further work 
may consist of the development of a helix mimetic scaffold able to mimic more than 
one helical face. The Hamilton group have recently described a variation of the 
teryphlyl scaffold that mimics an additional residue in the i + 5 position (therefore 
projecting side chains off multiple faces) by incorporating an indane ring in the 
central position340, although no inhibition of PPIs has been described as yet. The 
peptides generated by the phage display experiment may be a good starting point for 
the generation high affinity peptide binders, previous phage display experiments for 
eIF4E yielded peptides which required much optimization before the nM ligand was 
produced168, 331. Mutagenesis or peptide constraints could be used to improve this 
peptide, however evidence that the peptide is binding in a helical confirmation (as 
with eIF4G) must be obtained first.  Phage display could also be used to develop a 
new pharmacophore, the peptide phage display did not yield high affinity binding 
peptides, however other phage display experiments using scaffolds such as the 
Adhiron scaffold122 may be more successful.    
 
 181 
Chapter 5 : Overall conclusion and discussion 
 
This project has focussed on increasing our understanding of two therapeutically 
relevant protein-protein interactions, HIF-1α/p300 and eIF4E/eIF4G, which have 
been highlighted as a targeted anticancer therapy. Using both biophysical and 
structural techniques with the overall aim of informing rational inhibitor design.  
 
Some of the difficulties in targeting these interactions can be attributed to the fact 
that they are protein-protein interactions.  PPIs, in contrast too more traditional drug 
targets such as enzymes, have larger interacting surfaces which lack clearly defined 
pockets. This makes potent and selective inhibition more challenging. Another 
reason that enzymes have been targeted more successfully is the availability of 
transition-state analogues, which can be used as a starting point for inhibitor design. 
Theses difficulties have limited the success of PPI inhibitor development9, 10, 341, 342. 
 
It was hypothesised that increasing our understanding of an interaction, both 
biophysically and structurally, we can increase the success rate of PPI inhibitor 
development by designing small molecules more rationally rather than using a high 
throughput library screening method343, 344.  During this project characterising the 
interaction successfully informed inhibitor design, particularly for the HIF-1α/p300 
interaction. The difficulty with disrupting the HIF-1α/p300 interaction is that due to 
the size of the interaction a conventional small molecule11 will not be able to cover 
the whole interacting area, as NMR studies182, 197 have shown HIF-1α to have three 
helical regions, which wrap around p300 (Figure 17). Therefore a detailed analysis to 
locate binding hot-spots would be an integral part of the drug design process. 
Previous analysis had highlighted the C-terminus of HIF-1α to be important for 
binding220, including helix 2 and helix 3. Residues of both of these helices have been 
shown by mutational studies to be key for binding (Cys800 and Asn803 (helix 2) and 
Leu818, Leu822 and Val825 (helix 3))216, 218, 219. 
 
In this study two approaches to probe the HIF-1α binding surface on p300 were used 
to refine our understanding of the most productive regions to target using designed 
small-molecules: first, by analysis of the binding of shorter HIF-1α peptide 
fragments; and second, by phage display experiments. Binding analysis of fragments 
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of the native peptide allows identification of the highest affinity region of the HIF-1α 
peptide, whereas phage display permits the unbiased exploration of the p300 CH1 
protein surface to discover high affinity binders. Two phage display technologies 
were used237: a peptide phage library (NEB238-240) and an Adhiron122 phage library.  
 
The binding analysis of fragments of the native HIF-1α peptide revealed HIF-1α 
helix 3 to have the highest affinity of any short region (< 15 residues) of the native 
HIF-1α sequence. This was supported by mutational studies; mutations in the HIF-1α 
helix 3 binding pocket of p300 reduced the binding affinity of the full length HIF-1α. 
The peptide phage display experiment also highlighted helix 3 to be a key binding 
area. A higher affinity peptide was generated and NMR studies indicated that it 
bound in or around the helix 3 pocket182, 197. This was again supported by mutation 
studies. The information that HIF-1α helix 3 is a high affinity binding area was used 
to inform inhibitor design. An α helix mimetic which projected the three key side 
chains of HIF-1α helix 3 was designed and synthesised244, and disrupted the 
interaction in with an IC50 in the low micromolar range244. Therefore the 
understanding of the location of a binding hot-spot the of the HIF-1α/p300 
interaction has lead directly to the design of a ligand which  is able to disrupt the 
interaction.  
 
The Adhiron phage display experiment yielded adhirons which bound to p300 with 
an affinity of approximately 100 nM and were able to disrupt the interaction with an 
IC50 = 1-5 µM. This is significantly better than fragments of native HIF-1α, or the 
phage peptides (which were unable to disrupt the interaction). After solving the 
crystal structure of the Adhiron, docking suggested that the Adhiron bound in a 
different location to helix 3 (Figure 54). The binding site of the Adhiron needs to be 
validated by structural studies as the location and binding mode of the adhirons will 
provide new information on suitable chemotypes for orthosteric small-molecule 
inhibitor development. As the Adhirons themselves inhibit the HIF-1α/p300 
interaction with a low micromolar IC50; mimicking the pharmacophore of the loops 
in a small molecule or using fragment based approaches has the potential to generate 




One potential limitation is that throughout the studies the recombinant protein used 
was expressed using a bacterial protein expression system (E. coli). This expression 
system is used extensively345, generally without problems with many proteins can 
now be produced routinely in secreted form with yields in the gram/litre scale346 this 
system was chosen for these studies due to the low cost and potential for high protein 
yields.  However, as a prokaryotic expression system, E. coli cannot perform post-
translational modifications, which can be required for protein folding and protein 
functionality345, 347, 348.  E. coli is not the only bacterial expression system, the soil 
bacterium B. subtilis can be used to produce recombinant protein and has several 
advantages, it does not produce lipopolysaccharide, a common byproduct of E. coli 
that can occasionally result in some degenerative disorders in humans and animals. 
Also, the bacterium can secrete some well-processed proteins directly into medium, 
facilitating further purification steps349. Furthermore, this cell type can grow to very 
high densities in relatively simple and cheap medium345.  However problems remain 
which include degradation by proteases and instability of plasmids.  
 
Eukaryotic expression systems such as yeast, filamentous fungus, insect/baculovirus 
systems and mammalian cells will overcome the limitation of the lack of post-
translational modifications. Each of these systems has its own advantages and 
drawbacks. Yeast, like E. coli, has the advantage of culture simplicity, rapid growth, 
and low cost, but in addition the enriched endomembrane system of yeasts allows 
some intracellularly synthesized proteins to be secreted into the extracellular 
environment. As a unicellular eukaryote, yeast can potentially produce soluble, 
correctly folded recombinant proteins that have undergone all the post-translational 
modifications that are essential for their functions345, 350.  Yeast is considered easier 
to culture and manipulate genetically than other eukaryotic expression systems and 
can be grown to higher cell densities345. Filamentous fungus has been used for 
protein expression, however the production of heterologous proteins is often 
limited345. One of the major advantages of baculovirus–insect expression systems is 
the eukaryotic protein processing capabilities of the host. Consequently, these 
systems are widely considered to be excellent tools for recombinant glycoprotein 
production. Although, the heterologous gene cannot be expressed continuously as the 
host cells infected by the nuclear polyhedrosis virus will eventually die. Also every 
round of synthesis of the protein of interest requires the infection of new insect cells, 
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therefore this system is limited in terms of high –throughput method. Finally 
mammalian cell expression systems have the distinct advantage that they promote 
signal synthesis, process, and can secrete and glycosylate proteins, particularly 
eukaryotic proteins. However this system has a relatively high cost and more 
complex due to the greater potential for contamination. A summary of the different 







































Phosphorylation Acetylation Acylation Gamma-
carboxylation 
E. coli Rapid Low High No No No No No No 
Yeast Rapid Low Low-High High mannose Yes Yes Yes Yes No 
Insect Slow High Low-High Simple Yes Yes Yes Yes Yes 
Mammalian Slow High Low-Moderate Yes Yes Yes Yes Yes Yes 
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Of course there is much additional work that would allow this project to be furthered 
to design a useable therapeutic. However the combination of a detailed biophysical 
analysis of the interaction between HIF-1α and p300, along with two orthogonal 
phage display techniques, has provided detailed information that could be used to 
inform design of highly potent compounds to disrupt an extremely challenging but 
pharmaceutically important protein-protein interaction. This work has helped to 
prove the principle that biophysical and structural studies can be used in combination 
to characterise complex protein-protein interactions, and the information obtained 
from such studies can be used to inform inhibitors which can be optimized to be used 
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